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The work in this thesis concerns the development of advanced mass spectrometric 
techniques to study model systems for drug discovery and accelerate the process of high-
throughput screening (HTS) in the field of inflammation. This has primarily been achieved 
using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry 
(MALDI-TOF-MS) to develop screening assays for anti-inflammatory compounds. MALDI-
TOF-MS utilises a laser to ablate and consequently ionise biomolecules that are co-
crystallised with a matrix. The absorbed laser energy enables the transfer of charge to the 
analyte molecule from the excited matrix molecules before acceleration into the TOF tube 
where analytes are then separated based on their mass to charge ratio (m/z) and detected 
to generate a mass spectrum. With the development of advanced mass spectrometers 
that have unmatched laser and digitiser speeds these instruments now rival established 
fluorescent based drug discovery assays. 
The first study presented in this thesis is the development of a HTS assay to identify 
inhibitors of salt inducible kinases (SIKs) in vitro. These kinases are an attractive drug 
target as they mediate the production and secretion of the cytokine interleukin 10 (IL-10) 
in immune cells. When secreted, IL-10 dampens the pro-inflammatory response in 
surrounding macrophages and suppresses a further inflammatory response. Using a 
peptide-based assay, a proof of concept screen generated a positive correlation with an 
established fluorescent based assay, thus validating MALDI-TOF-MS as a viable 
alternative for HTS. Interestingly, several compounds were identified as kinase activators. 
Inhibitors of SIKs could be particularly beneficial for patients with autoimmune diseases 
who require immunosuppressive drugs as they may increase the production of IL-10, thus 
preventing excessive inflammation and subsequent onset of pathogenesis.  
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MALDI-TOF-MS was then applied to the development of cellular based assays to screen 
compounds against cell types that transition into different phenotypes. Rigorous 
development of a technically reproducible sample preparation technique enabled robust 
phenotyping of different cell lines. This method was then successfully applied to study 
mouse embryonic stem cells (mESCs), which transition between naïve and pluripotent 
phenotypes under pharmacologically controlled conditions. Moreover, a cellular assay to 
identify inhibitors of inflammation in the presence of a bacterial ligand lipopolysaccharide 
(LPS) in monocytes was developed. Here, the BCR-ABL inhibitor nilotinib was identified 
as having anti-inflammatory properties. Interestingly, its first-generation counterpart 
imatinib was not identified as having this effect, suggesting novel off-target effects for 
nilotinib. Its anti-inflammatory properties were then validated by cell biology techniques 
that demonstrated the reduction of the pro-inflammatory cytokine TNF-α in nilotinib-
treated cells.  
Finally, I utilised advanced high-resolution mass spectrometry to undertake secretomic 
analysis of L929 fibroblasts, which are commonly used to generate supplemented media 
that aids the differentiation of bone marrow-derived macrophages (BMDMs). These cells 
are promising drug targets and the understanding of their differentiation state is 
paramount to potential drug screening campaigns. A detailed proteomic profile of L929 
supplemented media, as well an in-depth proteomic profile of BMDMs differentiated under 




Taken together the work of this thesis contributes valuable knowledge in the field of how 
mass spectrometry can be utilised to advance HTS campaigns as well as provide valuable 
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Chapter 1. Introduction 
1.1 Fundamentals of Mass Spectrometry 
1.1.1 Core mass spectrometry principles  
Mass spectrometry is an analytical technique that measures the mass to charge ratio (m/z) 
of ions to generate a mass spectrum that can in turn yield chemically relevant information 
such as empirical mass or structure about a particular analyte. In its simplest form a mass 
spectrometer consists of an ionisation source coupled to a mass analyser and detector. 
Modern mass spectrometry techniques were first described by Dempster and Aston in 
1918-19, respectively.1 Since then, mass spectrometry technology has advanced 
exponentially with the development of a vast array of ionisation techniques, mass 
analysers and hybrid instruments. In addition, ion traps and soft ionisation techniques 
such as electrospray and laser desorption technologies have gained international 
recognition after being awarded the Nobel prizes in 19892 and 20023, respectively, thus 
highlighting the importance of this technology across all scientific fields. For successful 
MS experiments analytes must reach the gaseous phase as ions, therefore they must 
carry a positive or negative charge. The charge of the ions is then exploited to enable 
filtering, storage, fragmentation or detection using electric and magnetic fields. Once 
detected, the signal is deconvoluted and translated into information that can provide an 
ion’s mass, abundance or chemical structure. The way in which analytes are now ionised, 
separated and detected have advanced significantly in the past century with respect to 
precision, resolution, mass accuracy and a more user-friendly interface. These advances 
have resulted in applications of mass spectrometry that are now wide ranging with use in 
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clinic, research and industrial settings. The diversity of mass spectrometry applications is 
vast and the work in this thesis will focus on two mass spectrometric techniques: MALDI-
TOF-MS and LC-ESI-MS/MS and their application to the analysis of biomolecules. 
1.1.2 Matrix-assisted laser desorption/ionisation (MALDI) 
Matrix-assisted laser desorption/ionisation, or MALDI, is a soft ionisation method that was 
first described in 1985 by Karas et al. who used ultraviolet laser irradiation to ionise and 
analyse intact organic molecules.4 This was particularly novel at the time as previously 
techniques such as electron bombardment were considered “hard” ionisation methods 
that utilised high energy electrons to generate ions. However, the process of electron 
bombardment or electron ionisation (EI) induced substantial fragmentation of the 
biomolecule, thus information regarding the intact analyte was lost. The soft ionisation 
success was taken further by the addition of a matrix to improve ionisation of large intact 
biomolecules, and in 1988 Tanaka et al. were able to detect analytes with an m/z of up to 
100,000 Da by applying a thin layer of ultra-fine cobalt powder dissolved in an organic 
solvent as a matrix. 5,6 These two studies were the first of their kind to show the power of 
MALDI to ionise intact biomolecules. The basic principles of MALDI sample preparation 
and ionisation are described in Figure 1-1, where a sample is first mixed with an excess 
of matrix solution and allowed to co-crystallise onto a target to produce a dried spot (Figure 
1-1.A). Ablation of the dried spot enables transfer of both matrix and analyte molecules 
into the gas phase. Matrix molecules readily absorb the laser irradiation and enter an 
excited state. This irradiation process enables transfer of protons between excited matrix 
ions and vaporised analyte molecules that generates analyte ions which are then 
accelerated by an electric field to enter the mass analyser. 
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Figure 1-1. Principles of MALDI-TOF-MS analysis. (A) Graphical representation of the 
mixing of matrix and sample mixture that is then deposited as spots onto a MALDI target. 
(B) The process of MALDI. Crystallised spots of matrix and analyte are ablated by a laser 
that first induces transfer into the gas phase followed by ionisation as charge is transferred 
between the matrix and the analyte to form ions. (C) The chemical structures of the three 
most common MALDI matrices: sinapinic acid (SA), 2-5-dihydroxybenzoic acid (DHB) and 
α-cyano-4-hydroxycinnamic acid (CHCA)  
Utilisation of a suitable matrix in MALDI analyses is imperative to ensure successful 
ionisation, however the transfer of charge between matrix and analyte is still theorised. 
There are several theories that postulate the MALDI process and how this soft ionisation 
method predominantly produces singly charged species as the dominant ion.7–9 The most 
accepted of these models was presented by Karas et al., a “lucky survivor” mechanism 
that describes the role of photoionisation and photochemical reactions that drive the 
ionisation process and the neutralisation that occurs within the gaseous plume.10 This 
generates charged positive and negative species of analyte and matrix ions that then 
25 
 
collide to induce charge neutralisation. This neutralisation is most effective for highly 
charged cluster ions, which in turn leads to the preferable formation of singly charged ions 
that survive the ionisation process to enter the mass analyser. More recently, compelling 
evidence was published that validates the lucky survivor model with gas phase 
protonation as the driving mechanism behind this ionisation process.11  
The matrix choice in most experimental designs is typically a low molecular weight 
aromatic organic acid with phenolic groups that has a strong optical absorption in the 
range of the laser wavelength used. In their original study, Karas et al. mixed samples 
with saturated nicotinic acid, which although effective for laser desorption of different 
peptide or protein samples, also produced unwanted adduct effects between analyte and 
matrix ions.6,12 The matrix composition varies according to the analyte of interest and the 
type of laser used. This therefore led to the development of a plethora of different matrices 
to suit a wide range of different potential biomolecules. The most commonly used matrices 
for biomolecule analysis are α-cyano-4-hydroxycinnamic acid (CHCA), sinapinic acid 
(SA), 2,5-dihydroxyacetophenone (DHAP), and 2,5-dihydroxybenzoic acid (DHB), which 
have been shown to be effective for the analysis of peptides, glycopeptides, proteins, 
glycans, and lipids respectively (Figure 1-1.C).12–14 
MALDI sources are now widely used in commercial instruments, as they are often user 
friendly and can be coupled to a variety of mass analysers such as orbitraps, fourier 
transform ion cyclotron resonance analysers (FT-ICR) and more recently, instruments that 
use ion mobility sectors. These allow a great variety of speeds and resolutions to be 
achieved, but the most common mass analyser coupled to a MALDI source is the time-of-




Time-of-flight tubes or TOFs are one of the oldest mass analysers described along with 
magnetic sector separation technology that dates back to 1950’s. This is due to their 
simple separation principle and the fact that the subsequent manufacturing of TOF 
instruments is relatively inexpensive when compared with other mass analysers. In brief, 
pulsed ions from a MALDI source are accelerated into a TOF tube that is under strong 
vacuum and are separated by their time of flight, which is dependent on their mass-to-
charge ratio (m/z) and the energy that is used to accelerate the ions into the TOF.5 The 
longer the flight path, the better the separation of ions as described by the equation 
below. The simplest mode of a TOF instrument is that extracted ions from a MALDI source 
enter the TOF tube and then pass through a field free zone along a linear flight path where 
the lighter ions travel fastest to a detector. This is described as linear geometry (Figure 1-
2.A) and is particularly suitable for large molecules such as intact proteins above 20 kDa. 
As the flight path is relatively short, individual ion packets are not well separated leading 




Figure 1-2. Principles of time of flight (TOF) mass spectrometry. (A) Linear operation 
of a MALDI time-of-flight mass spectrometer where ions are separated by their m/z and 
detected at the end of the TOF tube. (B) Reflectron operation of a MALDI time-of-flight 
mass spectrometer where ions at the end of the TOF enter a reflectron that normalises 
their kinetic energy and reflects ions back down the TOF tube to a detector. 
Theory dictates that all ions enter the TOF tube with the same kinetic energy, however in 
practice this is often not the case as not all ions are vaporised evenly by the laser pulse. 
This generates a small kinetic energy distribution for each discrete m/z; therefore, ions do 
not arrive at the detector at the same time as they possess different initial potential 
energies. This in turn results in a broadening of the peaks and a poorer resolution when 
operated in linear mode geometry.15 To correct for this, inclusion of a reflectron at the end 
of the field free region of the TOF tube was described by Mamyrin et al. to enhance 
MALDI-TOF-MS detection and resolution.16 A reflectron consists of stacking metal plates 
to which a gradient electric current is applied, thus creating an ion mirror. Ions penetrate 
the electric field to different extents before they are repelled out of the field in the opposite 
direction towards a detector, therefore greatly increasing the ion path. Ions of the same 
m/z are refocussed to correct for differences in the initial potential energy and generate 
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much tighter “ion packets”. These ions then reach the detector at the same time, as they 
are more spatially grouped, which results in significantly superior resolution over linear 
mode.17 Further to this, the reflectron is often displaced slightly to deflect ions back along 
the TOF tube (Figure 1-2.B), the flight path length can be almost doubled, thus enhancing 
instrument resolution and mass accuracy. This mode of operation is typically limited to 
smaller molecular weight biomolecules as larger molecular weight species experience 
decay and ion dissociation faster than smaller molecules as they take longer to travel 
through the drift free zone. Thus, application of a reflectron to correct for initial energy 
distributions of large molecular weight species leads to the loss of these ions. However, 
reflectron MALDI-TOF-MS is exceptionally powerful for analysis of peptides, lipids, 
carbohydrates and small organics as full isotopic resolution can be achieved up to 
approximately 15 kDa. 
Commercially available MALDI-TOF-MS technologies are now utilised as analytical 
methods for a broad range of biological and chemical questions. Potentially the most well-
known application is peptide mass fingerprinting (PMF), where proteolytic peptides can 
be analysed and sequenced to identify proteins.18 This technique is widely used for 
proteomic studies with mammalian and plant species, but has also proven particularly 
powerful for archaeological studies and detection of ancient proteins.19,20 As well as this, 
MALDI-TOF-MS is now widely applied as an imaging technique. Here, it has been 
possible to exploit the speed and sensitivity of MALDI-TOF-MS to rapidly profile the 
abundance of an analyte within a sample whilst also preserving the spatial information.21 
This technique is particularly versatile and can now be applied to assessing lipid, 
metabolite and drug distribution within a tissue. Finally, one of the most recent and rapidly 
growing uses for MALDI-TOF-MS is the clinical profiling and screening of micro-
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organisms. Here, tissue or biofluid samples can be rapidly analysed by MALDI-TOF-MS 
to identify unique signatures of bacteria genera, thus enabling the identification of a 
bacterial infection as well as accurate species determination.22 This approach enables 
sensitive whole cell analysis of micro-organisms and generates a unique protein mass 
fingerprint, mostly from bacterial ribosomal proteins. Consequently, this has led to robust 
phenotyping of bacteria taxonomy by spectral matching that allows classification of subtle 
differences in strains of infectious pathogens such as Mycobacterium tuberculosis. 
This demonstrates the diversity of MALDI-TOF-MS for a wide range of applications and 
the work of this thesis will seek to develop and optimise novel methodologies using state-
of-the-art MALDI-TOF-MS instruments 
1.1.4 Electrospray ionisation  
Similarly to MALDI, electrospray ionisation (ESI) is a soft ionisation technique that uses 
electrical energy to assist the transfer of ions from solution to the gas phase. The 
development of ESI first began in 1968 by Dole et al., who successfully introduced a 
polystyrene polymer into the gas phase as a charged species through electrospraying.23 
However, studies showing ESI coupled to mass spectrometry for large biomolecules were 
first presented by Yamashita and Fenn et al., who in 2002 were awarded the Nobel prize 
for their work.24,25. This technique works by flowing liquid phase analytes through a fine 
tipped metal capillary to which a high voltage (2-6 kV) is applied relative to the source-
sampling entry cone of the mass spectrometer.26 This generates a strong electric field that 
causes the dispersion of the sample aerosol into highly charged droplets in a process 




Figure 1-3. Principles of electrospray ionisation (ESI). Graphical description of the 
electrospray ionisation process where liquid phase analytes are nebulised under high 
voltage to generate an aerosol. These aerosol droplets then undergo a desolvation 
process, typically with a drying gas, to produce highly charged ions that then enter a mass 
analyser. 
Formation of charged ions from the aerosol mists requires rapid desolvation, thus the 
droplets are often vaporised under the flow of nitrogen and ion-pairing agents such as 
organic acids can also be added to increase conductivity. Ions are eventually formed as 
the ever-decreasing droplet reaches its Rayleigh limit upon which it undergoes a 
coulombic explosion or fission where the Coulomb repulsion becomes too large for the 
droplet surface tension and ions are expelled.27 During this process, there is a significant 
loss of mass and charge, but the surviving ions are now often multiply charged species 
and enter the mass analyser. The efficiency of ESI-MS is highly dependent on an analyte’s 
structure and the solvent used but it has been shown to be particularly versatile with 
respect to biomolecule diversity such as intact proteins, peptides and metabolites.28–30 
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1.1.5 The Orbitrap and ion trap mass analysers 
Ion trap mass analysers are trapping instruments that utilise both magnetic and electric 
fields to capture ions. Ion Traps are versatile mass analysers that can used to be as the 
primary mass analyser or integrated into hybrid instruments. The Orbitrap is an ion trap 
mass analyser that is based on an earlier ion storage device, the Kingdon trap.31 The 
Orbitrap was first described by Makarov in 1995 and is a mass analyser that consists of 
an outer barrel-like electrode and a coaxial inner spindle-like electrode that traps ions in 
an orbital motion around the spindle.32,33 The ions rotate around an electrode system with 
a harmonic oscillation path along the axis of rotation at a frequency characteristic of their 
m/z value. At close proximity, a current from the trapped ions is detected on receiver plates 
as a time-domain signal and deconvoluted to generate a mass spectrum using fourier 
transformation (FT) of the frequency signal.   
FT-based mass spectrometers, such as the Orbitrap and FT-ICR, provide high mass 
resolution and mass accuracy that enables the separation of ions with the same nominal 
mass, as well as confident assignment of empirical formulas for small molecules and 
lipids. This is particularly beneficial in the low mass range (<1000 Da) where background 
features such as matrix peaks and endogenous species can interfere with signal 
identification and intensity when analysing specific compounds or metabolites. However, 
the acquisition times of these instruments are typically much longer than lower resolution 
instrumentations, such as TOF’s and quadrupoles, therefore their use for studies that 
require throughput are limited. Many studies now utilise the high resolution Orbitrap 
instruments for analysis of small metabolites, lipids and drug compounds as well as large 
intact proteins and native mass spectrometry. However, to date the most successful 
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application of the Orbitrap has arguably been to the field of proteomics where these 
instruments are now at the forefront of mass spectrometry based proteome research. 
1.1.6 Proteomics 
The large-scale study of proteins and their function within an organism or system is termed 
proteomics and is complimentary to genomics and transcriptomic research. The proteome 
covers the entirety of proteins that are produced and/or modified by an organism or system 
that alters significantly in composition and function depending on cellular demands or 
perturbation by external stimuli. Proteomics itself is an interdisciplinary field that covers all 
research into protein function and behaviour, however, the large-scale study of complex 
cellular proteomes is typically achieved using mass spectrometry.34,35 This can be 
achieved by either a top down or bottom up approach depending on the experimental 
design.  
 
Figure 1-4. Overview of bottom up strategy of mass spectrometry based proteomic 
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workflow. (A) Proteins are first isolated from tissues or cells before (B) enzymatic 
digestion into peptides that are analysed by HPLC-MS/MS (C & D). Spectra are entered 
into a search engine to yield a list of proteins and their associated information depending 
on experimental design. 
Bottom up strategies are most common, and here proteins are first extracted from tissues 
or samples before being digested enzymatically into their component peptides, typically 
by trypsin, which is a specific endopeptidase (Figure 1-4).36 Peptides are then analysed 
by MS/MS, usually utilising online high-performance liquid chromatography (HPLC) 
separation to enhance peptide identification and deepen the proteome coverage. 
Combining fragmentation spectra, precursor m/z values and endopeptidase specificity 
allows specialist software to search protein databases obtained from genome sequencing. 
This software then utilises the amino acid sequencing of peptides to identify the digested 
protein, thus resulting in generation of a proteome. Currently, the most successful 
commercial instruments for proteomic studies use electrospray coupled orbitrap mass 
analysers. These instruments can perform fragmentation and MS scans with great 
resolution and can be coupled with ion traps and multipoles to generate hybrid instruments 
such as the Q Exactive or Fusion Lumos instruments that have multiple modes of action 
and are incredibly functional. 
The generation of total proteomes can now regularly exceed 10,000 protein identifications 
for an experiment, thus yielding huge datasets and information regarding a system.37 
Optimisation of methods for the isolation and purification of organelles such as 
mitochondria, phagosomes and cell secretomes has enabled the separation of these 
discrete proteomes. When combined with MS proteomic analysis, these methods have 
led to deep characterisation of sub cellular and extra cellular protein composition and in 
turn lead to ground breaking research into their function. Standard proteomic methods 
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may now be coupled to quantification techniques using isobaric labelling such as iTRAQ, 
TMT, and SILAC38, all of which enable the relative quantification of proteins within a 
system, thus generating more robust and accurate data sets. In more recent years, these 
technologies and methods have been exploited to perform more functional studies such 
as protein conformation changes, thermal cellular shift assays and subcellular spatial 
studies. Consequently, the combination of these strategies and advanced mass 
spectrometry instruments enables valuable insights into the composition and functional 
dynamics of a system’s proteome. 
1.1.7 Sample preparation methods and proteomic workflows  
There are now many published methods that describe the digestion of proteins into 
peptides for proteomic analysis that range from traditional in-solution digestion39 to in-gel 
digestion40, magnetic bead digestion41,42 and matrix trapping techniques.43–46 It is 
paramount that efficient enzymatic digestion is achieved; thus, proteins must be in a 
denatured conformation to allow proteolytic enzymes such as trypsin to reach peptide 
regions that would otherwise be conserved by the natural conformation of the protein 
(Figure 1-5.A). This is typically achieved by resuspending samples in either a strong 
detergent such as sodium dodecyl sulfate (SDS) or highly concentrated urea, before the 
addition of a reducing agent such as DTT or TCEP to reduce the sulfur of disulfide bridges 
from cysteine residues, which are strong intra-protein interactions that influence protein 
conformation. As these bonds can re-form under oxidising conditions, it is standard 
practice to use an alkylation reagent such as iodoacetamide or 4-vinyl pyridine to alkylate 
the sulfur groups and prevent reformation.47 From this step onwards, sample preparation 
protocols diverge depending on the method chosen. For in-solution digestion (Figure 1-
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5.A), samples are simply diluted to a working concentration that allows stable digestion 
by the addition of an endoproteinase such as trypsin, Lys-C or Lys-N and incubated 
overnight. After digestion, samples typically require clean-up as detergents and high salt 
concentrations are incompatible with mass spectrometry analysis. Previously, C18 clean 
up columns have been used for this purpose. However, recently, there has been 
development of matrix trapping protein digestion methods that dramatically reduce sample 
preparation time and can enable significantly faster sample throughput by integration of 
plate formats.  
 
Figure 1-5. Workflows for proteomic sample preparation methods. (A) Graphical 
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representation of reduction/alkylation where cysteine disulfide bonds are first reduced and 
alkylated to denature proteins. (B) Workflow for in-solution digestion where proteins are 
digested and the resulting peptides are cleaned-up using C18 spin columns to remove 
contaminants prior to LC-MS/MS. (C) S-trap workflow where proteins are aggregated onto 
a solid phase and contaminants removed through washing. Proteins are digested on-
phase before peptides are eluted and analysed by LC-MS/MS.  
Here, denatured and alkylated protein samples are first acidified and then loaded onto a 
spin column that contains a solid phase that non-specifically immobilises proteins. The 
driving force behind this is the induction of protein aggregates that enables the capture of 
proteins onto solid matrices or microspheres leading to very little flow through of sample 
during subsequent washing steps.48 Consequently, columns are then typically washed 
with buffers that contain high organic solvent concentrations to remove contaminants 
before a fast digestion for 2 hrs at an elevated temperature. Digested peptides can then 
be directly eluted, dried and resuspended for proteomic analysis. 
This technology is fast being adopted for previously complicated sample analysis such as 
tissue embedded in formalin, for which previous techniques would have been 
unfavourable. Matrix trapping protocols dramatically improved the proteomic profiles of 
these tissue samples, as nearly all sample contaminants including melted formalin can be 
removed by washing. This opens up new avenues of research that had previously been 
unexplored, such as archaeology or precious clinical samples where sample volume is 
limited. Furthermore, this trapping technology is now being supported for clinical 
applications, where robust sample digestion can be coupled to automated liquid handling 
robots and there is no need for sample clean up that can lead to unnecessary sample 
loss.49 From both these sample preparation methods, dried peptides can then be 
resuspended in a suitable buffer and injected into a mass spectrometer for analysis. 
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1.1.8 Protein identification and quantification 
After mass spectrometric analysis, precursor (MS) and fragment scans (MS/MS) can be 
combined to identify the digested peptide amino acid sequence and consequently protein 
identification. Endopeptidase specificity is particularly important here as it simplifies 
downstream analysis. Typically, trypsin is used in most workflows as it is highly specific 
for cleavage after arginine or lysine residues with the exception of missed cleavages 
where a proline residue resides directly after or within close proximity.50,51 Furthermore, 
this cleavage formation is particularly advantageous for mass spectrometry analysis as 
lysine or arginine side chains can be easily protonated by ESI or  MALDI techniques to 
generate peptides that can be multiply charged. Other endopeptidases such as elastase 
or proteinase K are relatively unspecific in their cleavage sites and are more frequently 
used for specific experimental designs such as membrane proteomics.52 Traditionally, 
proteomic analysis is conducted in data dependent acquisition (DDA), where the most 
abundant peptides are selected by the multipole as precursors for MS/MS analysis (Figure 
1-6.A). This technique results in good coverage and protein identification but can be 
biased towards highly abundant peptides. Therefore, data independent acquisition (DIA) 
can be more suitable in some cases (Figure 1-6.A).53 Here, rather than identifying specific 
precursors, narrow sequential m/z windows are scanned within the multipole and 
fragmented to result in fragmentation spectra of multiple species. This enables the 
unbiased identification of peptides and detection of low abundant proteins. However, this 
approach is more arduous as it relies on having a comprehensive spectral library for 
spectra matching as the fragmentation of several peptides results in complex MS/MS 
spectra. Therefore, this often necessitates prior DDA acquisition to generate sample 




Figure 1-6. Principles of peptide fragmentation strategies. (A) Comparison of DDA 
and DIA analysis showing peak selection and complexity of MS2 fragmentation spectra 
depending on acquisition mode. (B) Fragmentation of peptides to produce either b+y, a+x 
or c+z ion pairs. 
Once precursors are selected for MS/MS analysis, they are sent for fragmentation. The 
most common peptide fragmentation technique is collision induced dissociation (CID).54 
Here, an inert gas such as nitrogen or helium is used as a collision gas within a 
fragmentation cell and as the charged peptides collide with the inert atoms they are 
vibrationally activated, leading to the breakage of the weakest chemical bond. The 
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resulting product ions are characteristic for peptides as cleavage is favourable at the 
amide bond of the peptide back bone to generate b and y ions (Figure 1-6.B). The b and 
y ions are formed from the N- and C- terminus, respectively, and their sequencing allows 
for precursor peptide structures to be elucidated and in turn their parent proteins identified. 
Alternative fragmentation methods such as electron transfer dissociation (ETD) and 
photodissociation techniques induce the formation of a+z and c+x ions (Figure 1-6.B) that 
can be used for peptide structure identification and are particularly important for branched 
peptides and identification of post-translational modification sites.55,56 Once acquired, raw 
spectral data files can be processed by using available search engines such as 
MaxQuant57, Mascot58 or PEAKS59. Using the specificities described previously, proteins 
can be identified by de novo peptide sequencing algorithms, which match fragment 
spectra and their parent ion mass to in silico protein digest. An in silico database is a 
computationally generated model of the biological experiment. For proteomic 
experiments, each desired protein sequence and the specific proteolytic method is used 
to predict the potential proteolytic peptides for each protein within the model. Using the 
theoretical mass, charge states and sequences the signals detected in the mass spectrum 
and their MS/MS data can then be matched to theoretical peptides and identified. Not only 
can proteins be identified, but also the relative abundance of each protein can be 
determined if combined with isobaric tagging techniques. More recently, these search 
techniques are moving towards live identifications, where Wichmann et al. showed that it 
was possible to target more than 25,000 peptides in real time during a single LC-MS run.60 
Hybrid orbitrap mass spectrometers are still currently the most common instruments for 
proteomic analyses, however the development and optimisation of ion mobility (IM) mass 
analysers are showing promise in this field.61 Here, IM is being conjugated to lower 
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resolution TOFs to dramatically increase acquisition speeds, resolution and sensitivity.62 
This technology has been demonstrated to be very powerful for clinical applications and 
low sample volumes and more recently is expanding into the DIA space for broader 
application in MS based proteomics.63 However, despite this technology’s enhanced 
speed it lacks the resolution of orbitrap and FT technologies, which is paramount when 
utilising isobaric labelling techniques such as TMT 10, 11 and 16 plex.64 Overall, taken 
combined these advanced mass spectrometers enable the identification and 
quantification of diverse proteomes towards understanding biological function and are 
paramount for answering complex biological questions. 
1.2 Drug discovery 
1.2.1 The drug discovery pipeline 
The drug discovery and development pipeline is an interdisciplinary process that engages 
multiple phases of research to facilitate the production of effective therapies (Figure 1-7). 
The timeline itself is typically divided into two groups: drug discovery and drug 
development. The discovery phase entails the development of diverse compound 
libraries, target validation and high-throughput screening campaigns to identify hit 
compounds. The development process occurs after, where lead compounds undergo 
further optimisation such as pharmacokinetic and in vivo validation studies before moving 
forward into pre-clinical and clinical trials. The result of these combined stages is a  a long 
and arduous process to get FDA approval of compounds, often with high failure rates 
across all stages and taking up to a decade for successful therapies to reach the clinic.65 
Due to the time and capital investment needed during the development and clinical trial 
process, there is a growing need to develop more biologically relevant and diverse 
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screening assays to qualify hit compounds during the discovery phase. However, current 
assays are often biochemical, and although high-throughput, can result in false positive 
hits. Here, mass spectrometry and other more advanced technologies could aid the drug 
discovery process by identifying better quality lead compounds. 
Figure 1-7. Drug discovery pipeline highlighting the time taken for each stage of 
drug development. 
Knowledge of the molecular mechanisms underpinning diseases such as cancer, 
inflammation and neurodegenerative diseases has advanced significantly in the past 
decade and in turn has led to a demand for more personalised and precise medicine. 
Historically, small molecules have predominantly ruled the approved treatments for such 
diseases, but large biomolecules such as antibodies, liposomes and gene therapies have 
emerged as promising targeted treatments. However, design and validation of these 
therapies is significantly different to the development of small molecule inhibitors, 
therefore more specialised and advanced technologies must be integrated into the 
existing pipeline. Mass spectrometry is already well established as a sensitive and 
versatile technique in research for the analysis of large biomolecules and is a natural 
choice for the development of new therapies. 
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1.2.2 Use of mass spectrometry within drug development 
Mass spectrometry techniques are already widely used throughout the drug development 
pipeline from target identification and screening to clinical studies and quality control of 
FDA approved compounds (Table 1-1). At the initial stage of drug discovery, MS based 
exploratory techniques such as proteomics, metabolomics and analysis of clinical tissue 
samples are an important part of lead compound discovery to identify and validate 
therapeutic targets.  
Table 1-1. Mass spectrometric techniques and their associated application within the drug 
discovery and development pipeline. 
MS Technique Stage of drug discovery/ development Application 
MALDI-MS 
MALDI-TOF-MS • HTS 
• Lead Optimisation 
Peptide mass fingerprinting, bottom up 
shotgun proteomics, HTS, intact mass 
analysis 
MALDI-Imaging • Target validation 
• Lead optimisation 
Either FT-ICR or TOF; high resolution or 
speed. Clinical validation of tissue 
disease state as well as drug efficacy 
and localisation. 
MALDI-FT-ICR • Target validation 
• Lead optimisation 
High resolution for intact target 





• Lead optimisation 
• Pre-clinical and 
clinical trials 
Targeted assays for lead optimisation: 
SRM, MRM. Drug and antibody 
detection from biofluids in clinical 
studies. 
Q-Trap / Ion trap 
• Manufacturing QC 
• FDA QC 
• Library generation 
Large fragmentation data enables 
maximum structural information that can 
characterise compound libraries. 
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Orbitrap/Q-TOF • Target discovery 
and validation 
High resolution, large complex data sets: 
Metabolomics, proteomics. 
 
Despite mass spectrometry being a powerful tool within the drug development process, 
its application to the compound library screening has lagged behind, often due to a lack 
of throughput. However, advances and development of novel MS instruments and liquid 
handling system’s have, in principle, enabled MS based screening methods that rival 
conventional biochemical assays, especially with respect to large biomolecule screening. 
1.2.3 Mass spectrometry as a tool for high-throughput screening 
For high-throughput screening, MS-based readouts have been largely dominated by 
instruments containing SPE and ESI-MS, such as the RapidFireTM system.66 Here, as a 
conventional liquid chromatography module would not produce the sample processing 
speeds required for HTS, the LC-unit is replaced by a sample clean up cartridge that 
enables higher flow rates and faster sample processing within a 384 plate format.67 
Coupled with an automated microfluidic sample collection and purification system as well 
as high-speed robotics to directly aspirate fluidic samples directly from 96- or 384-well 
screening plates sample processing speeds of 4-8 seconds can be reached. This fully 
automated system can remove non-volatile assay components such as salts, buffers and 
detergents in an online fractionation step to deliver purified analytes to the mass 
spectrometer.66 In addition, the RapidFire source can be coupled to either a triple 
quadrupole or TOF mass analysers, thus enabling various modes of action such as intact 
mass or fragmentation methods as well as selected reaction monitoring (SRM). Hence, 
there has since been a plethora of HTS assays developed for RapidFire MS  for a variety 
of drug targets including acetyl-coenzyme A carboxylase,66 stearoyl-CoA desaturase,68  
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sphingosine kinases,69 histone lysine demethylase10 and phosphatidylserine 
decarboxylase.70 These assays demonstrate that ESI-MS is capable of achieving the 
robustness necessary for HTS, as well as the throughput of libraries >10,000 compounds. 
However, the speed of sample injection and analysis still does not yet rival conventional 
assays that can achieve a <1 second per sample throughput. To tackle this, Leveridge et 
al. proposed a simple multiplexing strategy using mass tagged substrates and JmjD2d as 
a model system to increase the throughput of RapidFire assays, thus making ESI-MS 
more viable as a HTS platform.71 Here, four H3 peptides from separate JmjD2d 
demethylation reactions  were pooled and simultaneously analysed by MRM, which in turn 
offered a four-fold increase in compound throughput over the standard RapidFire assay. 
This could be implemented to enable diverse screening where substrates differ in mass 
and transition, thus enabling screening of libraries against one or more drug target in 
parallel.  More recently, RapidFire BLAZE-mode was developed that retains the same 
quality and robustness as previous operating systems, but modification of the switch valve 
connections and operational pumps enabled rapid cycling times of 2.5 seconds per 
sample.72  This technology is the fastest commercially available ESI-MS instrument at this 
time and is very attractive for low-molecular mass or poor performance analytes that 
require more sensitive methods. However, it still does not reach the speeds of true ultra-
HTS assays that process samples in under a second, therefore exploring into alternative 
liquid dispensing techniques such as acoustic mist MS or open-port probe MS is 
growing.73–75  
Acoustic technology dispensing has been utilised widely within the drug discovery pipeline 
for preparation of screening microplate from compound stocks and dosing in cellular 
assays.76,77 Therefore, recent research has explored the use of acoustic mist ionisation 
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(AMI) as a technique to introduce liquid samples into a mass spectrometer to solve the 
current sampling throughput bottleneck in HTS mass spectrometry.78 Current 
advancements in the design of the AMI-MS instruments led to the development of 
technologies that can introduce samples at speeds of three samples a second that are 
robust throughout drug screening campaigns. Recently, AstraZeneca performed a 2 
million compound library screen to identify inhibitors of a human histone deacetylase and 
measure their half-maximal inhibitory concentration in under 7 weeks, totalling 2.75 million 
wells screened on a single AMI-MS instrument.79 However, although this technology 
shows great potential, it is currently limited by the high well-to-well variability as smaller 
mists are generally harder to control compared with nanolitre droplets and can lead to 
poorer assay quality and Z’ values.73 Further to this, AMI-MS is prone to matrix 
interference as it is more similar to direct injection ESI-MS where no clean up or separation 
can be performed, thus assays can lack sensitivity.80,81 
1.2.4 Rise of MALDI-TOF-MS within high-throughput screening 
The potential of MALDI-TOF-MS assay development for HTS is broad as the technology 
can be applied to potentially any reaction that involves a mass change or intensity shift.82 
These assays enable label-free quantitation, a gold standard for assays in the drug 
discovery field over conventional assays. This is particularly attractive to the 
pharmaceutical industry as the use of assays with fluorophore labelled substrates or 
secondary amplification assays can lead to false positive or negative hits with auto-
fluorescent compounds. Utilising MALDI-TOF-MS assays, a compound’s potency can be 
measured independently to any inherent luminescent properties, thus enable the 
screening of larger libraries. This has naturally led to the development of enzymatic 
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assays that measure the rate of post translational modification of either a protein or 
peptide substrate by a potential drug target enzyme. Many of these optimised assays 
match or exceed conventional assays in performance and speed, but assay development 
can be challenging. Direct translation of assay buffers to MALDI-TOF-MS assays has 
often been problematic, as mass spectrometry is sensitive to ion suppression from salts, 
glycerol and other common reagent buffers that are imperative for biologically relevant 
assays and to preserve protein function. This may in turn result in significantly different 
enzyme activity, conformation or compound interaction and it would be interesting to 
further understand whether these buffer substitutions influence compound hit profiles. To 
ease the process of assay development for non-experts in the field, Haslam et al. 
published a systematic study of buffers for small molecule analysis that are compatible 
with MALDI-TOF-MS.83 Combined with novel, user friendly software and a fully 
automated, integrated liquid handling platform, MALDI-TOF-MS has become a promising 
novel tool for future drug screening campaigns.84 
1.2.5 In vitro biochemical screening assays 
Development of in vitro MALDI-TOF-MS assays that were able to evaluate the IC50 of drug 
compounds was presented by Greis et al., who describe a kinase phosphorylation assay 
that probes inhibitor action.85 However, sample analysis speeds here were still relatively 
slow for HTS speeds with a 10 second per spot analysis required to acquire good spectra. 
The development of the RapifleX mass spectrometer overcame this and enabled a 1 
second sample analysis speed that rivalled the more conventional HTS assays and the 
field MALDI-TOF-MS assays expanded rapidly. 
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The first studies utilising the high speed of these new generation MALDI-TOF-MS 
instruments for drug discovery was the development of an assay to study deubiquitylases 
(DUBs) specificity and drugability by Ritorto et al.86 Ubiquitylation is a post-translational 
modification that involves a discrete set of ligases and conjugating enzymes to modify 
target proteins by conjugation of ubiquitin, a small 8.5 kDa protein.87 The cleavage of 
ubiquitin moieties from target proteins is catalysed by DUBs, whose primary role is to 
modulate the levels and types of ubiquitylation within a system. However, as ubiquitin 
itself can be conjugated to proteins through either of its seven lysine residues or n-
terminus, the system becomes inherently more complex and there is formation of complex 
chain linkage architecture. Therefore, it is known that DUBs must have a certain degree 
of specificity for different chain types so as to modulate the vast landscape of 
ubiquitylation. Aberrant or accumulation of certain chain linkage types by dysregulated 
DUB activity has since been linked to diseases such as Parkinson’s disease and cancer, 
therefore elucidating the DUB specificity and screening for potential inhibitors has become 
prominent in the drug discovery field.88 Previously, profiling DUB specificity required the 
use of activity based probes,89,90 or DUB activity to be profiled by conjugation of 
fluorogenic probes such as Rhodamine110.91 Neither of these assay types provided 
conclusive specificity and activity of DUBs in vitro, used label-free substrates or were not 
suitable for use on a high-throughput platform, therefore the development of a MADLI-
TOF-MS assay for screening DUB specificity and activity has revolutionised the field.86 In 
brief, DUBs were incubated with synthetic ubiquitin dimers of different linkage type and 
the amount of mono-ubiquitin resulting from dimer cleavage was quantified using an 
isotopically labelled internal standard. This set up was fast, label-free and enabled the 
determination of DUB specificity for different linkage types as well as drug specificity. This 
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assay was unique to the field as it could be expanded to a HTS platform and this lead to 
the development of an assay to screen for E3 ligase inhibitors by De Cesare et al.92 Here 
using the same technology and experimental set up, E2-E3 ligase pairs could be 
established by measuring conjugation of ubiquitin rather than cleavage of dimers, which 
also translated to screening of inhibitors of the auto-ubiquitylation process. Taken 
together, these two methods added significant value to the expanding tool box of mass 
spectrometric techniques for elucidating ubiquitylation signalling and has aided the 
discovery of several new DUB inhibitors.93–95 
The targeting of enzymes that catalyse the addition or cleavage of PTMs for MALDI-TOF 
assay development has grown from ubiquitylation to phosphorylation96,97,98, acetylation 
and methylation (Figure 1-8.B)99,100. Here, several assays were compared with existing 
biochemical assays and report good correlation of compound hits and IC50 values, as well 
as identifying potentially new compounds that could have previously been missed with 




Figure 1-8. MALDI-TOF-MS as a tool for enzymatic activity assays. (A) Graphical 
representation of enzymatic reaction that converts substrate to product has a mass 
change that can be measured by MALDI-TOF-MS. This reaction allows relative 
quantitation between substrate and product peaks and can be reversed with hit 
compounds that can be detected by MALDI-TOF-MS. (B) Timeline of the past 15 years 
showing the growth of published enzymatic MALDI-TOF-MS assays. 
Self-assembled monolayers (SAMs) can be coupled with MALDI to form another surface-
based MS technique: SAMDI-TOF. A similar method coined surface enhanced laser 
desorption ionisation (SELDI) affinity technology was developed in 1993. however, the 
binding of substrates to the surface was unspecific and poorly distributed and could result 
in diminished sensitivity.101,102 In the case of SAMDI, a single nano-scale monolayer, or 
SAM, is first formed on the surface that will capture substrates. The chemistry of the mono-
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layer molecules are carefully selected for substrate capture suitability as well as their 
ability to self-assemble into a crystalline upon the surface.103 These molecules have 
typically been alkanethiols as they form a strong disulphide bond with the surface and can 
be modified to have wide range of terminal functional groups for specific analyte 
capture.104 In the case of biochemical assays, a peptidic substrate would typically be 
immobilised and then individually treated with enzyme with or without the presence of 
inhibitors. The targets can then be treated with a matrix, similar to a traditional MALDI 
experiment, and upon irradiation with a laser the monolayers and substrate are desorbed 
from the surface through cleavage of the substrate-target bond and ionised. This 
technology was pioneered by the Mrksich lab and is well-suited for measuring a broad 
range of enzyme activities as SAMs can be customized to use a variety of immobilisation 
chemistries. As SAMDI benefits from the same instrumentation as MALDI, it is also a 
promising strategy for a HTS targeted approach with a potential throughput of >100,000 
compounds per day. A strength of this technology is that the bond between surface and 
bound molecule is strong enough to permit thorough washing to remove assay 
contaminants, yet weak enough to be analysed by MALDI-MS.105. To demonstrate drug 
discovery assay suitability, a study by Patel et al. utilised this technology and discovered 
a novel specific inhibitor of sirtuin 3 (SIRT3) from a label-free screen of 100,000 
compounds library using SAMDI-TOF.106 From this, SAMDI has also been used for in vitro 
screening of diverse enzyme classes such as phosphatases107, glycosyltransferases108, 
deacetylases109. More recently, VanderPorten et al. developed a new tool using SAMDI 
that allows screening and identification of non-covalent binding small molecules to target 
proteins.110 In this study, a proof of concept workflow demonstrated a novel screening 
format of a pooled compound mixture using affinity capture and purification followed by 
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SAMDI-MS. Here, binders with affinities below the micro-molar range were identified in a 
robust and reproducible manner that correlated well with biochemical assay potencies.110   
1.2.6 Cellular assays 
Whole cell analysis or cellular assays for evaluating compound efficacy at moderating or 
reversing a cellular phenotype presents an interesting challenge for MALDI-TOF-MS 
analysis as the system becomes inherently more complex. A well-established application 
for whole cell MALDI-TOF-MS is the classification of micro-organisms, also known as 
biotyping, which was first presented by Claydon et al. in 1996.111 Here, microbe 
classification is achieved by identifying protein biomarkers in a MALDI-TOF-MS spectrum 
to generate a signature spectral mass fingerprint. Typically, the m/z region selected is 2–
20 kDa as this reflects the unique ribosomal protein profiles of a bacterial species, which 
are highly abundant and reproducible.112,113 For classification, the specific spectral 
fingerprint is then either compared against a database of known bacteria genus spectra 
to identify an unknown species, or masses can be matched to a prokaryote proteome 
databases.114,115 This genus and sub-species specificity can be achieved as the bacterial 
genome is relatively simple compared with eukaryote proteomes, thus proteins can be 
matched to identified m/z values confidently with the aim of generating a comprehensive 
database.116–118 Throughout the past decade this has led to sensitive and robust 
phenotyping of micro-organisms in clinical microbiology for the diagnosis of infectious 
diseases as the technology is fast, inexpensive and can be automated.119,120 More 
recently, MALDI-TOF-MS has also been used to accurately identify Mycobacterium 
tuberculosis (TB) sub species, which is particularly important with the rapid progression 
of TB infections worldwide. Therefore, this technology could be important for detecting 
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subtle changings in bacterial ribosomal proteome that may indicate a mutation or 
adaptation towards treatment or environmental exposure. This approach has already 
been applied in the field of antibiotic resistance, where MALDI-TOF-MS can be used to 
evaluate whether antibiotics are efficient or detect biomarkers of antimicrobial 
resistance.121–123 
Application of whole cell MALDI-TOF-MS methodologies to mammalian cells has not yet 
reached the heights of microbial biotyping but is rising as a promising technology for 
phenotypic screening and the development of drug discovery assays. Similarly to bacterial 
biotyping, fingerprinting of mammalian cell protein biomarkers has been successfully 
applied to phenotype different cancer cell lines124, classify immune cells125 as well as 
monitor early stress or apoptosis signals in cell lines.126 The classification of cell lines from 
primary tissues can be complicated by cell heterogeneity, but MALDI-TOF-MS has proven 
to be sensitive and robust at distinguishing tissue derived cell mixtures127 as well as 
classifying differentiated cells from primary blood monocytes.128 Typically, these 
strategies utilise multivariate analysis and detection of unique features for classification 
that, when combined with flow cytometry, microscopy or known biomarker analysis result 
in robust MALDI-TOF-MS methodologies. However, as mammalian cell PMFs can be 
complex and difficult to deconvolute, several strategies have been developed to quantify 
and identify sub-categories of cells. These include dual-biomarker approaches that uses 
a ratiometric quantification between common features of co-cultured cells129, as well 
classifying cell secretion such as extracellular vesicles to sensitively identify 
chemoresistance in cancer cells.130 This in turn could be a less invasive way of 
characterising a patient’s response to cancer treatment.  
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Complimentary to cell proteomes, mammalian cells exhibit dynamic lipid profiles that are 
often indicative of cell phenotype or a diseased state such as liver or heart disease.131–133 
Imaging mass spectrometry has already demonstrated that MALDI-MS is well suited for 
lipid analysis of cells, and therefore research has expanded into cellular classification 
using lipid analysis.134 Typically, this has been performed using high resolution MALDI-
FT-ICR instruments, as lipids can be identified empirically from spectra, which is often 
needed as the generated data are more complex than protein marker data and many 
hundreds of lipids are identified. This in turn has led to single cell lipid profiling, which 
enabled the classification of astrocytes and neurons by Neumann et al., who were also 
able to show that this was robust across 30,000 individual rodent cerebellar cells.135,136 
However, these methods are not as fast nor suitable for high-throughput drug discovery 
as MALDI-TOF-MS, therefore Weigt et al. combined the power of both MALDI-FT-ICR 
and MALDI-TOF-MS instruments to develop a cellular drug discovery assay.137 In this 
study, a proof-of-concept assay demonstrated that inhibitors of fatty acid synthase 
(FASN), which are key for cancer proliferation can be identified by MALDI-MS. Using 
MALDI FT-ICR, lipids were first empirically identified before transferred to a MALDI-TOF-
MS platform that rapidly profiled compounds and showed good IC50 correlation of hits with 
a biochemical assay.137 Combined with automated liquid handling and sample 
preparation, this study demonstrates that lipid analysis of whole mammalian cells by 
MALDI-TOF-MS is suitable for the development of drug discovery assays to identify 
inhibitors of lipid metabolism.138 
Taken together, these studies demonstrate the compatibility of cellular analysis with high-
throughput MALDI-TOF-MS technology. Here, biomolecules such as proteins and lipids 
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can be identified from whole cells and used to classify cell types as well as evaluate a 
compound’s activity in-cell.  
1.3 Inflammation and the innate immune response  
The innate immune system is a host’s first line of defence against invading pathogens or 
injury. This response is evolutionarily conserved and tightly regulated by a host’s immune 
cells such as monocytes, macrophages, neutrophils and other myeloid cells, whereas 
lymphoid cells like T-cells and B-cells propagate the adaptive immune response. Unlike 
the adaptive immune response, the innate mechanism is a rapid response that is initiated 
within hours of initial infection and involves the recruitment of immune cells to the site of 
infection and development of a physical barrier between pathogens and the host. Both 
these systems are important for host protection and resolving infection and are key targets 
for drug discovery as sustained inflammation is linked to a plethora of diseases.  
1.3.1 Macrophages in the innate immune response 
Macrophages play an important role in the innate immune response but are also highly 





Figure 1-9. Polarisation of macrophages. Activation states of M1 and M2 macrophages 
and their activity in response to specific triggers. 
A simplified model of macrophage activation describes two macrophage states that are 
coined classically activated (M1) or alternatively activated (M2). While M1 is a 
proinflammatory state import for infection and inflammation, M2 is important for 
maintaining homeostasis within an organism (Figure 1-9).139,140 The M1 state is the better 
described macrophage phenotype, however, understanding the M2 phenotype is 
becoming more necessary as these macrophages can modulate M1 phenotype and help 
maintain homeostasis.141 Alternatively activated M2 macrophages and their signalling 
cascades are poorly understood, but they have particularly important roles in tissue 
regeneration and wound healing.142,143  In nature, these macrophages are often polarised 
by the presence of apoptotic cells or debris, presence of fungi or host secreted immune 
complexes but can also be polarised by cytokines such as IL4 and IL10.141 Furthermore, 
M2 macrophages have a distinctly different chemokine profile to M1 macrophages. During 
anti-inflammatory polarisation, macrophages induce Th2 cytokine secretion including 
IL10, TGF-β and IL1-ra that can signal for tissue remodelling in surrounding cells.144,145 
Consequently, the functional study of these macrophages is paramount to understanding 
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the complexities of inflammation, wound healing and immune cell activation within an 
organism.  
Unlike alternatively activated macrophages, M1 classically activated macrophages have 
a well described proinflammatory phenotype.146  
 
Figure 1-10. Classical activation of M1 macrophages. Stimulation induces the 
secretion of pro-inflammatory cytokines, phagocytosis of invading pathogens and links the 
innate and adaptive immune response through antigen presentation. 
During pathogenic inflection, M1 macrophages are particularly important as they are often 
the first responders to danger. Here, they can perform a multitude of functions as shown 
in Figure 1-10 to eliminate pathogens and induce a protective inflammatory response. 
This primarily involves the engulfment of pathogens through phagocytosis, which results 
in the degradation and processing of the biological material and subsequent antigen 
presentation.147 Unique markers or antigens of the pathogen are retained and presented 
on the surface of the M1 macrophages or dendritic cells to engage T cells. Consequently, 
this ties in the innate with the adaptive immune response and induces the production of T 
cells and antibodies specific for a particular bacterial or viral species to prevent 
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subsequent infection.148 As well as this, biological markers such as pathogen-associated 
or danger associated molecular patterns (PAMPs & DAMPs) help propagate the innate 
immune response through a host cell’s pattern recognition receptors (PRRs).149 These 
PRRs include c-type lectin receptors (CLRs) or NOD-like receptors (NLRs), but perhaps 
the most common and well described receptors are Toll-like receptors (TLRs).150 Typical 
PAMPs signal through TLRs and include exo- or endotoxins such as lipopeptides 
expressed by bacteria that when recognised induce a pathogenic infection immune 
response (Figure 1-10).151,152 Conversely, DAMPs such as heat shock proteins or free 
DNA are released by host cells and perpetuate an inflammatory response independent of 
pathogenic infection.153 Transmission of PAMPs or DAMPs signalling by receptors results 
in the production of pro-inflammatory cytokines such as TNF-α, IL-6 and IFN-β that can 
propagate the inflammatory response to other cells within the environment. At a tissue 
level, this results in swelling, pain and redness that is indicative of a localised immune 
response coordinated by immune cells to isolate the injury. 
Inflammation can progress from acute to persistent to chronic inflammation if dysregulated 
and therefore the inflammatory response must be suppressed to prevent tissue 
pathogenesis.154 Under normal conditions, resolution of inflammation is well managed by 
the production of mediators to prevent further recruitment of immune cells to site-specific 
inflammation as well as macrophage remodelling. Here, macrophages can undergo 
transformation from classically to alternatively activated cells that initiate wound healing 
and prevent the tissue infiltration of further immune cells such as neutrophils.155 Chronic 
or severely acute inflammation occurs when anti-inflammatory mechanisms fail to resolve 
inflammatory signalling that can lead to tissue injury and in some cases to diseases, such 
as cardiovascular diseases, cancers and diabetes. Therefore, macrophages themselves 
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are key drug targets as their phenotype can be manipulated to prevent systemic 
inflammation and enable the discovery and development of targeted therapies. 
1.3.2 Macrophages as drug targets for dysregulated inflammation 
Macrophages themselves and consequently dysregulated inflammation are implicated in 
variety of diseases ranging from lifestyle disorders such as obesity and diabetes, to the 
some of the most common diseases including cancer, arthritis and heart disease.156 
Therefore, they  are considered key drug targets and the focus of anti-inflammatory drug 
discovery. Macrophages are distributed throughout tissues in the human body and 
contribute to clearing pathogenic infection but also tissue homeostasis and repair. As all 
tissues and organs comprise of specialised cells depending on the function, specialised 
macrophages with variable functions are often found integrated into tissues. For murine 
studies, macrophages are distinguished within tissue by morphology or expression of 
surface proteins such as F4-80 or CD11b that can be detected by histology staining and 
flow cytometry, which in turn allows monitoring of macrophage progression within tissue 






Figure 1-11. Graphical representation of the specialism of macrophages within the 
human body. Specific roles of macrophages in maintaining tissue homeostasis alongside 
descriptions of the function of a particular macrophage specialism as well as their role in 
disease when inflammation is dysregulated. 
The diversity of these macrophage populations is highlighted by their functions described 
in Figure 1-11. For example, the resident macrophages within the gastrointestinal tract 
are localised to specific regions associated with digestion, nutrition and maintaining 
homeostatic balance in the gut. Interestingly, they can utilise their phagocytic abilities to 
modulate the microbial flora activity within the gut, thus developing a symbiotic relationship 
between bacteria and macrophage.159,160 This process is essential for maintaining gut 
health and if dysregulated can result in inflammatory bowel disorders. On the other hand, 
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microglia are localised to the brain or spinal tissues and are extremely sensitive to subtle 
changes in tissue.161 The speed at which these macrophages engage invading pathogens 
in brain tissue is unmatched when compared with other tissue resident macrophages as 
the damage incurred could potentially be fatal. Microglia are highly adept at killing bacteria 
unlike intestinal macrophages that sense and modulate bacteria populations. However, 
they are now linked to chronic neurodegenerative disorders such as Parkinson’s and 
Alzheimer’s and the knowledge surrounding the mechanism of these macrophages is 
limited.162 Therefore, there is a strong drive to develop new therapies that can combine or 
replace existing treatments to increase efficacy and improve prognosis.163  
One such area that has grown significantly in recent years is the relationship between 
inflammation and cancer, thus resulting in the targeting of tumour associated 
macrophages or TAMs for targeted therapies.164 These macrophages are key drivers of 
tumour promoting inflammation and can dampen anti-tumour therapies by promoting an 
environment that is preferable for tumour growth in the presence of anti-cancer 
compounds.165,166 This has resulted in the on-going clinical trials of over 30 compounds 
that target TAMs, with many of these manipulating the macrophage behaviour such as 
inhibiting recruitment or re-programming.167 Some of the current therapies in clinical 
research include antibodies against CD47, a “don’t eat me signal”,  inhibiting 
phagocytosis.168,169 Some tumour cells exhibit high expression of CD47, that in turn 
prevents them from being efficiently phagocytosed and enable proliferation and 
metastasis.   
Taken together, this vast biological landscape of inflammation highlights that a 
comprehensive knowledge of immune signalling is necessary for effective drug discovery. 
The complex signalling and mechanisms that surrounds the immune response presents 
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an interesting challenge for the field. The selection of the correct model for the specific 
disease is therefore critical. The model can vary significantly from in vitro models such as 
cellular or enzymatic assays to a myriad of in vivo models including zebrafish, mice, rats 
and primates.170,171 These layers of complexity make the discovery of novel anti-
inflammatory compounds difficult. Interestingly, there has recently been a drive to assess 
whether existing therapies could be repurposed for treating chronic inflammation which 





Chapter 2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
All solvents were HPLC grade unless otherwise stated. Ethanol (EtOH), methanol 
(MeOH), dichloromethane (DCM), isopropanol, hexane, chloroform, acetonitrile (ACN), 
water (H2O), dimethyl sulfoxide (DMSO) were purchased from Merck (Darmstadt, GER).  
Trifluoroacetic acid (TFA), phosphoric acid, formic acid (FA) ammonium hydroxide were 
purchased from Sigma Aldrich (St. Louis, MO, USA). Sinapinic acid (SA), 2-5-
dihydroxybenzoic acid (DHB), 2-5-dihydroxacetophenone (DHAP), α-cyano-4-hydroxy-
cinnamic acid (CHCA) were kindly provided by Bruker Daltonics (Bremen, GER). Peptide 
calibration standard (II), protein calibration standard (I), protein calibration standard (II) 
were provided by Bruker Daltonics used for calibration purposes (Tables 2-1, 2-2 and 2-
3).  
Table 2-1 Peptide calibration standard (II) 
Peptide [M+H]+ Monoisotopic [M+H]+ Average 
Bradykinin 1-7 757.3992 757.86 
Angiotensin II 1046.5418 1047.19 
Angiotensin I 1296.6848 1297.49 
Substance P 1347.7354 1348.64 
Bombesin 1619.8223 1620.86 
ACTH clip 1-17 2093.0862 2094.43 
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ACTH clip 18-39 2465.1983 2466.68 
Somatostatin 28 3147.4710 3149.57 
 
Table 2-2 Protein calibration standard (I) 
 
Table 2-3 Protein calibration standard (II) 
Protein Charge state Average m/z 
Insulin [M+H]+ 5734.51 
Ubiquitin I [M+H]+ 8565.76 
Cytochrome C [M+H]+ 12360.97 
Myoglobin [M+H]+ 16952.30 
Cytochrome C [M+H]2+ 6180.99 
Myoglobin [M+H]2+ 8476.65 
Protein Charge state Average m/z 
Trypsinogen [M+H]+ 23982 
Protein A [M+H]+ 44613 
Albumin-bovine (BSA) [M+H]+ ~ 66.5 kDa 




2.1.2 Toll-like receptor agonists and cytokines 
Salmonella lipopolysaccharide (LPS) and phorbol 12-myristate 13-acetate (PMA) were 
supplied by Sigma Aldrich (St. Louis, MO, USA). PAM2CSK4, PAM3CSK4, Poly(I:C), 
Poly(A:U) were from Invitrogen. Macrophage inhibitory factor (MIF) and Macrophage 
colony stimulating factor (M-CSF) were purchased from Invitrogen (Carlsbad, CA, USA). 
2.1.3 Inhibitors 
Staurosporine, HG-9-91-01, MRT199665, MRT67307, KIN112, NG-25, BI2536 were 
provided by the Division of Signal Transduction Therapy (DSTT) Dundee, UK. The 2648 
kinase inhibitor panel was kindly provided by Dundee Drug Discovery Unit (DDU), 
Dundee, UK. The 78 select macrophage compound panel, Nilotinib and Imatinib were 
kindly provided by LifeArc (Stevenage, UK).  
2.1.4 Cells & cell culture reagents 
L929, THP-1, MCF7, HEK293, U2OS and BMA cell lines were all purchased from the 
American Type Culture Collection (ATCC, Manassas, VA, USA). Bone marrow derived 
macrophages (BMDM’s) were isolated from 3 month old WT female C57BL/6 mice femurs 
and tibiae that were kindly provided by the Institute for Aging, Newcastle University. 
Dulbecco´s modified eagle medium (DMEM), Roswell Park Memorial Institute medium 
(RPMI), Iscove's Modified Dulbecco's Medium (IMDM), Opti-MEM, phosphate buffered 
solution (PBS), fetal bovine serum (FBS) and β-mercaptoethanol (cell culture grade) and 
sterile DMSO were purchased from Gibco, Life Technologies (Darmstadt, Germany).L-
glutamine, penicillin & streptomycin (Pen/strep) were purchased from Lonza (Basel, 
Albumin-bovine (BSA) [M+H]2+ ~ 33.3 kDa 
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Switzerland). Trypsin-EDTA solution and 37% paraformaldehyde solution (PFA) were 
purchased from Sigma Aldrich (St. Louis, MO, USA). 
Table 2-4 Buffer compositions 
 
2.2 Methods 
2.2.1 Cell culture & treatments 
Adherent cell lines U2OS, MCF7 and HEK293 were lifted from 10 cm culture plates by 
addition of trypsin-EDTA solution. All cell lines were incubated in a controlled atmosphere 
at 5% CO2 and 37°C. Cells were harvested and centrifuged at 300 xg for 3 minutes before 




375 mM Tris/HCl (pH 8.5), 0.1% SDS (w/v) and 8-12% (w/v) 
acrylamide. 0.1% (w/v) ammonium persulfate (APS) and 
0.1% (v/v) TEMED were used to polymerise the gels. 
6% Stacking gels 
250 mM Tris/HCl (pH 6.6), 0.1% SDS (w/v) and 4% 
acrylamide (w/v). 0.1% (w/v) ammonium persulfate (APS) 




25 mM Tris base, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3 
SIK Assay buffer 




a concentration 1 × 106 into 1.5 mL microtubes and centrifuged at 1000 xg, 4 °C for 10 
minutes. 
2.2.1.1 Mammalian immortalized cell-line culture 
All procedures were carried out under aseptic conditions meeting biological safety 
requirements.  
2.2.1.2 Adherent cells lines. 
BMA, HEK293, MCF7, L929 and U2OS cell lines were cultured in 10 or 15 cm cell culture 
treated dishes. HEK293, L929 and U2OS cells were maintained in Dulbecco´s modified 
eagle medium (DMEM), 10 % (v/v) foetal bovine serum (FBS), 1 mM L-Glutamine, 100 
U/ml penicillin, 100 µg/ml streptomycin, whereas BMA and  MCF7 cell lines maintained in 
Roswell Park Memorial Institute medium (RPMI-1640), 10 % (v/v) foetal bovine serum 
(FBS), 1 mM L-Glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin. Cells were 
maintained in this media under 5% CO2 at 37°C in a water-saturated incubator. 
2.2.1.3 Suspension cell lines 
THP-1 cells were cultured in tissue culture treated flasks (25 - 225cm2 surface area) and 
maintained in Roswell Park Memorial Institute medium (RPMI-1640), 10 % (v/v) foetal 
bovine serum (FBS), 1 mM L-Glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 
55 µM β-mercaptoethanol. Cells were maintained in this media under 5% CO2 at 37°C in 
a water-saturated incubator. 
2.2.1.4 Harvesting of cell pellets 
Adherent cell lines U2OS, HEK293 and MCF7 were lifted from 10 cm culture plates by 
addition of trypsin-EDTA solution. All cell lines were incubated in a controlled atmosphere 
at 5% CO2 and 37°C. Cells were harvested and centrifuged at 300 xg for 3 minutes before 
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resuspension in PBS and counted using a haemocytometer. Cells were then aliquoted at 
a concentration 1 × 106 into 1.5 mL microtubes and centrifuged at 300 xg, 4 °C for 10 
minutes. 
2.2.1.5 Mouse Embryonic Stem Cell (mESC) Culture. (Anna Segarra-Fas) 
CGR8 mESCs were cultured in 0.1% gelatine [w/v] coated plates in N2B27 medium 
(DMEM/F12‐Neurobasal (1:1), 0.5% N2, 1% B27 (ThermoFisher Scientific, Waltham, MA, 
USA), 1% L‐glutamine, 100 μM β‐mercaptoethanol) containing “2i”, 3 μM CHIR99021 
(Axon Medchem, Groningen, Netherlands) and 1 μM PD0325901, in a controlled 
atmosphere at 5% CO2 and 37°C. To induce multi-lineage differentiation, cells were plated 
at 4 × 104 cells/cm2 in N2B27 medium without CHIR99021 and PD0325901 and incubated 
for 48h at 5% CO2 and 37°C. 
Total RNA extraction was performed by a column-based system (Omega Bio-tek, 
Norcross, GA, USA) and then subjected to reverse transcription using iScript reverse 
transcriptase (Bio-Rad) according to the manufacturer’s guidelines. qPCR reactions were 
carried out using SYBR® Premix Ex Taq™ II Supermix (Takara Bio, Shiga, Japan) in a 
CFX384 real-time PCR system (Bio-Rad, Hercules, CA, USA). Samples were analysed 
for gene expression in 2i release conditions relative to 2i medium culture using the ΔΔCt 
method, and GAPDH expression was analysed as a loading control. Data from three 
independent biological replicates, with two technical replicates for each, were analysed in 
Excel software (Microsoft) and plotted in GraphPad Prism v.6.00 software (GraphPad). 
Primers used are listed in Table 2-5.  
 
Table 2-5 List of primers for RT-qPCR analysis 
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Gene Forward (5' to 3') Reverse (5' to 3') 





Oct4 AGCTGCTGAAGCAGAAGAGG AGATGGTGGTCTGGCTGAAC 
Fgf5  GCTGTGTCTCAGGGGATTGT CACTCTCGGCCTGTCTTTTC 
Dnmt3b CTGGCACCCTCTTCTTCATT ATCCATAGTGCCTTGGGACC 
Gapdh CTCGTCCCGTAGACAAAA TGAATTTGCCGTGAGTGG 
 
2.2.1.6 Cell passaging 
Adherent cell lines were grown to 80-90% confluency in a 10 or 15 cm cell culture dish. 
Cells were washed twice with warm PBS before addition of trypsin-EDTA (0.25%) solution 
and incubation at 37°C. After approximately 5-10 minutes cells were dissociated from the 
plate and the trypsin was quenched by addition of complete RPMI or DMEM media and 
the cells were centrifuged down at 1300 rpm for 3 minutes. Medium was aspirated and 
cells were resuspended in fresh media. Cell suspension of 1-2×106 were transferred to 
seed in new tissue culture dishes. 
THP-1 monocytes were maintained at a confluency between 2.5x105 – 1.0x106 per 
millilitre of media. Every two days cells were centrifuged down at 1300 rpm for 3 minutes. 




2.2.1.7 Thawing of cells 
For thawing, cryogenic vials were placed into 37°C water bath and then transferred into 
tube with pre-warmed media. Cells were pelleted and resuspended in pre-warmed growth 
media and transferred into a cell culture dish or flask.  
2.2.1.8 Production of L929 supernatant 
L929 cells were grown for three passages from cryogenic storage before seeding for 
secretion collection. Cells were seeded in 50 mL of complete DMEM at a density of ~6500 
cells per cm2 of available surface area. Media was carefully removed after seven days of 
culture and replaced with 50 mL of fresh DMEM media for a subsequent seven days. The 
two supernatant collections were then combined and sterile filtered before aliquoting into 
50 mL falcon tubes and stored at -20°C. 
2.2.1.9 Culture of bone marrow derived macrophages (BMDMs) 
BMDMs were isolated from femurs and tibiae of WT C57BL/6 mice. The cells were treated 
with red blood cell lysis buffer (155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA) and 
suspended in 2 mL of un-supplemented IMDM media. Here, BMDMs were transferred into 
one of three different culture conditions: L929, M-CSF or M-CSF + MIF. One mL of the 
suspension was added to tissue culture treated 10 cm dishes containing 9 mL of IMDM 
supplemented with 10% FBS, 1% L-glutamine, 1% pen/strep and either (1) 20% L929 
conditioned supplement, (2) 10 ng/mL of M-CSF or (3) 10 ng/mL of M-CSF and 10 ng/mL 
of MIF. After 24 hours, cells in suspension were transferred to 10 cm petri dishes and 
seeded at 5.0 – 7.5×105 cells per dish. Differentiation occurred over 7 days with an 
additional 2 mL of media being added at 2, 4 and 6 days.  
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2.2.1.10 Collection of supernatant for proteomic analysis 
L929 cells were seeded in a six well plate for secretomic analysis with cell density and 
media volume consistent with the protocol described in 1.3.1.8. For secretome collection, 
cells were first washed 2x with warm PBS and 1x with Opti-MEM 1 mM L-Glutamine, 100 
U/ml penicillin, and 100 µg/ml streptomycin. One millilitre of Opti-MEM media was added 
to each well for a maximum of 3hrs before being carefully removed to avoid disturbing 
adherent cells. Supernatants were centrifuged at 2000xg, 4°C for 10 minutes to pellet cell 
debris. The supernatant was then carefully removed and stored in 1.5 mL lo-bind tubes at 
-80°C. 
2.2.1.11 Pro-inflammatory stimulation of THP-1 monocytes 
THP-1 cells were treated with one of six pro-inflammatory stimuli: LPS, Pam2CSK4, 
Pam3CSK4, IFN-γ, Poly(A:U) and Poly (I:C). Assay concentration was maintained at 1 
µg/mL of each treatment, or 100 U/mL of IFN-γ for 24 hrs.  
2.2.1.12 Treatment of cells with inhibitors 
For all cellular treatments with inhibitors cells were incubated with compounds for 1hr prior 
to further stimulation. Compounds were stored in DMSO at 10 mM stocks, however DMSO 
concentration never exceeded 2% in-culture. For single point inhibition measurements, a 
concentration of 5 µM was used. For IC50 titrations compound concentrations ranged from 
30 µM – 0.0001 µM. 
2.2.2 Biochemistry Techniques 
2.2.2.1 Cell microscopy and diameter measurements 
The four cell lines were measured for number, viability and cell diameter by light 
microscopy using an Evos XL Core Cell Imaging System (Invitrogen). To assess 
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permeability, cell pellets were resuspended in PBS before mixing 1:1 with trypan blue. 
Trypan blue positive cells were then automatically counted using the same microscope to 
calculate cell viability. For mESC phenotype visualization, brightfield light microscopy was 
used in a Leica DM IL LED microscope at 10X magnification. 
2.2.2.2 BCA protein quantitation  
For whole cell MALDI-TOF-MS quantitation were titrated from 300,000 to 9,000 in a 96 
well plate format. For proteomic and secretomic quantification samples were quantified at 
two different concentrations that were typically 1% SDS and 0.1% SDS. BCA reagent 
(Pierce, Thermo Fisher Scientific, Waltham, MA, USA) was then prepared to the 
manufacturer’s instruction by mixing Reagent A and Reagent B at a ratio of 50:1, 
respectively. 20 µL of the mixed reagent was added to 180 µL of sample and incubated 
at 37°C for 30 minutes. The plate was then read on a plate reader measuring absorbance 
at 562 nm and protein concentration calculated from these values. 
2.2.2.3 Protein precipitation 
In 5 mL lobind tubes (Eppendorf) 960 µL of ice cold methanol was added to ~1 mL of 
protein supernatants and vortexed briefly before subsequent addition of 160 µL of ice cold 
chloroform and thorough mixing. 2.5 mL of ice cold water was then added to each tube, 
vortexed and centrifuged at 4000×g, 4°C for 30 minutes. A protein layer could then be 
observed at the interface of the organic and aqueous phases and the top layer was 
carefully removed to prevent disruption of the protein layer. A further 500 µL of ice cold 
methanol was then added and the solution vortexed thoroughly before transfer to a 1.5 
mL lobind tube (Eppendorf) followed by centrifugation 20,000×g, 4 °C for 30 minutes. The 
supernatant was then carefully aspirated and the pellet ambient dried. 
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2.2.2.4 Separation of proteins by SDS-PAGE  
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) allows proteins 
to be separated according to their molecular weight. Protein samples are denatured and 
reduced by treatment with SDS, an anionic surfactant, and the reducing agent β-
mercaptoethanol boiled before loading. 
A resolving gel was first prepared according to the recipe described in Table 2-4. A 
stacking gel of different pH and acrylamide percentage (Table 2-4) was then layered on 
top, which acts to concentrate proteins into one tight band before entering the resolving 
gel, thus enhancing gel resolution. The gels were run in Tris-glycine SDS running buffer 
(Table 2-4) at 60 V initially through the stacking gel, and this was voltage was then 
increased to 120 V through the resolving gel. The voltage applied to the gel promotes 
migration of negatively charged proteins away from the cathode to the anode. Commercial 
pre-cast gels (4-12% Bis-Tris, NuPAGE) were used for precious samples. Commercial 
gels were run in MOPS buffer (NuPAGE) or MES (NuPAGE) buffer at a constant 120 V.  
2.2.2.5 Protein staining of SDS/PAGE and PVDF membranes 
After SDS/PAGE gels were washed in deionised water and incubated in 10 ml of 
InstantBlue (Expedeon, Cambridge, UK) on a rocking platform for 1-24h. Following this, 
the gel was washed repeatedly in deionised water to de-stain.  
2.2.2.6 Measurement of cytokines by enzyme-linked immunosorbent assay (ELISA) 
For experiments pertaining to BMDM differentiation, mouse TNF‐α, IL‐6, IFN-γ and IFN-β 
DuoKits were used (R&D Systems, Minneapolis, MN, USA). BMDMs cultured in either M-
CSF, M-CSF + MIF or L929 supernatant were seeded in six well plates and treated with 
100 ng/mL of LPS. The supernatant was collected at 6 hrs and centrifuged at 10,000 xg 
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for 10 minutes to remove cell debris. The supernatant was transferred to a new tube and 
ELISAs were performed according to the manufacturer's instructions. 
For THP-1 experiments, a human TNF- α DuoKit was used (R&D Systems, Minneapolis, 
MN, USA). Cell supernatants were collected after 24 hr LPS stimulation centrifuged at 
10,000 xg for 10 minutes to remove cell debris. The supernatant was transferred to a new 
tube and ELISAs were performed according to the manufacturer's instructions. 
2.2.2.7 Antibody labelling for flow cytometry (FACS) analysis 
BMDMs cultured in either M-CSF, M-CSF + MIF or L929 supernatant were collected at 1 
× 106 cell per tube in 1.5 mL microtubes tubes (Corning Incorporated, New York, NY, 
USA). Cells were transferred to a 96 conical well plate and were washed twice in FACS 
buffer (1% FBS in PBS, pH 7.2) by centrifugation at 1,200 xg for 3 min and resuspended 
in 300 µl FACs buffer. Cells were then incubated with alexa fluor 488-conjugated 
antibodies against CD11c and F4/80 (Invitrogen) or allophycoyanin (APC)-conjugated 
CD11b (eBioscience, San Diego, CA, USA) antibody at 1:1000 dilution in FACS buffer for 
20 min in the dark for 4°C. The reaction was quenched by addition of more FACS buffer. 
After washing for three times in PBS/FBS, cells were analysed by flow cytometry.  
2.2.3 In vitro assays 
2.2.3.1 Preparation of plates for SIK screening 
For single-concentration screening, 15 nL (MALDI TOF assay) or 24 nL (ADP Hunter 
assay) of 10 mM compound solution in DMSO was transferred into 384-well HiBase, non-
binding microtiter plates (Greiner, Stonehouse, UK), using an Echo 550 acoustic 
dispenser (Labcyte, USA), to give a final screening concentration of 30 µM. Staurosporine 
at 10 µM was used as a positive control in column 24, with column 23 containing only 
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DMSO as the negative control. The Dundee Drug Discovery Unit (DDU) small molecule 
kinase library contains 2648 commercially available ATP mimetics describing a diverse 
region of kinase pharmacophore space. 
2.2.3.2 MALDI-TOF-MS SIK assay 
In this assay the synthetic peptide CHKtide (KKKVSRSGLYRSPSMPENLNRPR) and 
NUAK peptide (ALNRTSSDSALHRRR) were used as a substrate for SIKs. Both CHKtide 
and the NUAK peptide are phosphorylated at the third serine residue  
(KKKVSRSGLYRSPSMPENLNRPR) and (ALNRTSSDSALHRRR) to give 
phosphorylated products. Both these peptides and their products were measured by 
MALDI-TOF-MS at m/z 2700.47 (CHKtide), m/z and m/z 2780.37 (CHKtide + Phosphoryl) 
as a read out for SIK activity. Screening assays were performed with an XRD-384 
Automated Reagent Dispenser (FluidX) by dispensing 3 μL of freshly prepared SIK assay 
buffer 1 μL of 15 nM SIK2 prepared in SIK assay buffer onto prepared compound plates 
followed by 30 minutes incubation at 30˚C. The reaction was then initiated by addition of 
1 μL substrate solution containing a mixture of CHKtide and ATP, to a final concentration 
of 1 μM and 100 μM respectively. Plates were then returned to incubation at 30˚C for 30 
minutes before being quenched by addition of 1.2 μL of 10% TFA to a final concentration 
of 2%.SIK ADP Hunter assay (Anthony Hope & Lesley Pearson, Drug discovery unit, 
University of Dundee) 
The ADP Hunter technology (DiscoverX, UK) is a coupled enzyme assay that detects the 
production of the resorufin fluorophore as a downstream consequence of the conversion 
of ATP to ADP. It therefore provides a generic high throughput assay for the measurement 
of kinase enzyme activity. Screening of full length GST-tagged human SIK2 was 
performed using CHKtide as a substrate peptide. Compounds were stamped into 384-
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well, low volume, black wall, assay plates (Greiner Bio-one, UK) as described above. The 
assay window was defined by addition of DMSO in the presence (no effect) or absence 
of enzyme (maximum effect), to defined control wells. Using a Wellmate liquid dispenser 
(Thermo Scientific, UK), 4 μL of a 2x enzyme solution (ADP Hunter Plus assay buffer, 
1mM DTT, enzyme) was dispensed into all wells and pre-incubated for 20 minutes at room 
temperature. The assay enzyme reaction was initiated by the addition of a 4 μL of a 2x 
substrate solution (ADP Hunter Plus assay buffer, 100 μM CHKtide, 200 μM ATP Gold) 
such that the final assay concentration of SIK2 was 10 nM. Assay plates were incubated 
for 30 minutes at room temperature after which the reaction was stopped by the addition 
of 4 μL ADP Hunter Plus Reagent A and 8 μL ADP Hunter Plus Reagent B. Following a 
further incubation for 30 minutes at room temperature, resorufin elicited fluorescence was 
measured (ex 550 nm; em 595 nm) using a PHERAstar FS (BMG Labtech, UK).  
2.2.3.3 Whole cell MALDI-TOF-MS assay for U2OS, HEK293, THP1, HEK293 cell lines 
and mESCs 
After initial harvesting, cell pellets were processed in one of three ways: 
(1) Direct analysis where cell pellets were washed twice with PBS and centrifuged at 
1000×g, 4°C for 5 minutes. Cell pellets were then resuspended in 0.1% TFA before 
subsequent spotting. 
(2) Cell pellets were snap frozen on dry ice and stored at -80°C until required. Thawed 
cell pellets were centrifuged at 1000 xg, 4°C for 10 minutes before either being washed 
1x with PBS or fixed in 4% paraformaldehyde solution or methanol on ice. For the 
methanol fixing method, cells were allowed to fix for 10 minutes on ice. Cell suspensions 
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were then centrifuged at 1000×g, 4°C for 10 minutes before being resuspended in 0.1% 
TFA. 
(3) Cell pellets were washed twice with PBS and centrifuged at 1000×g, 4°C for 10 
minutes. Cell pellets were then either washed 1x with PBS or fixed in 4% 
paraformaldehyde solution or methanol on ice. For the methanol fixing method, cells were 
allowed to fix for 10 minutes on ice. Cell suspensions were then centrifuged at 1000×g, 
4°C for 10 minutes before being resuspended in 0.1% TFA, snap frozen on dry ice and 
stored at -80°C until required. 
Resuspended cell samples were mixed 1:1 with matrix and spotted either manually or 
using the Mosquito HTS in accordance with the dried droplet method. 
2.2.3.4 MALDI-TOF-MS THP-1 cellular assay  
THP-1 monocytes were seeded at 1×106 cells per mL in either a 6, 12 or 24 well plate at 
1, 0.5, 0.2 mL respectively. For stimulus titrations, cells were treated with either LPS, 
PAM2CSK4, PAM3CSK4, Poly (IC) or IFN-γ from 100 pg – 10 µg/mL for 24 hours. For 
inhibitor studies, cells were incubated with either NG-25, BI2536, MRT67337, Nilotinib or 
Imatinib at 5 µM for one hour before addition of pro-inflammatory stimuli. IC50 curves were 
generated by incubating cells in a 24 well plates with compound concentrations ranging 
from 30 -0.0001 µM for one hour before addition of LPS for 24 hrs. 
For the 78 compound screen, THP-1 monocytes were aliquoted at a density of 1×106 per 
mL into a 6 well plate and incubated with each compound at 5 µM for one hour in technical 
triplicate with a final concentration of DMSO at 0.5%. LPS was then added to a final 
concentration of 1 µg/mL for 24 hours. Compounds were staggered into 8 sets of 10 
compounds, each with individual positive and negative controls to enable maximum 
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relative peak area calculations. This screening process was repeated three times with 
cells at different passage numbers.  
Cells were harvested by manual scraping, pelleted at 1000 xg, frozen and stored at -80°C 
until required. Thawed cell pellets were washed with 200 µL Tris buffer (100 mM Tris, pH 
7.5) and centrifuged at 1000 xg, 4 °C for 10 minutes. Cell pellets were then resuspended 
in Tris buffer at a concentration of 5000 cells/µL. 
Cell suspensions were spotted with CHCA that was prepared in 50% ACN, 0.1% TFA at 
10 mg/mL. For manual deposition cell suspensions were mixed at a 1:1 ratio with matrix 
solution and 1 µL spotted onto a ground steel MALDI target before ambient drying. 
2.2.4 MALDI-TOF Mass spectrometry 
2.2.4.1 Preparation of DHAP matrix solution 
Ammonium citrate dibasic was resuspended in water (MS grade) to a final concentration 
of 12 mg/mL. 7.6 mg of 2,5-DHAP was resuspended in 375 µL of ethanol and vortexed 
briefly before addition of 125 µL of the ammonium citrate dibasic solution. The microtube 
was then sealed with parafilm and mixed vigorously for 1 hour. The resulting suspension 
was then centrifuged 5000 xg for 1 minute and the supernatant carefully removed into a 
separate tube for use.  
2.2.4.2 Preparation of CHCA, DHB and SA matrix solutions 
Sinapinic acid (SA), α-cyano-4-hydroxycinnamic acid (CHCA) and 2,5-dihydroxybenzoic 
acid (DHB) were all resuspended in acetonitrile/TFA buffers to various concentrations and 
ratios. Solutions were prepared ranging from 2.5 mg/mL to saturated concentration 
depending intended use. TFA concentration was varied from 0.1 – 5% and the acetonitrile 
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component from 30 – 70%. For all preparations, matrix suspensions were mixed 
vigorously for 30 mins and centrifuged 5000 xg for 1 minute prior to use. 
2.2.4.3 Cleaning of MALDI targets 
All target types were first sonicated in HPLC grade isopropanol for 5 minutes, followed by 
further sonication in 30% acetonitrile, 0.1% TFA for 5 minutes. AnchorChip targets (1536, 
384) were then allowed to airdry. 
Ground steel or polished steel targets (384 or no geometry, Bruker Daltonics) were often 
used for cellular analysis and required more rigorous cleaning. Targets were washed first 
with protocol described above but were then sonicated with 1% ammonium hydroxide, 
follow by HPLC grade methanol and any residual spots were wiped with a KIMTECH 
science wipe before a final rinse with methanol. Targets were then dried thoroughly under 
a stream of nitrogen gas.  
2.2.4.4 MALDI-TOF-MS Spotting 
Spotting of targets for MALDI-TOF-MS can be achieved through various techniques. 
Within this thesis, I have utilised two techniques: the dried droplet method or sandwich 
spot. Both these methods utilise liquid deposition of sample and matrix to spot sample 
arrays onto a MALDI target. For the dried droplet method, sample and matrix are mixed 
prior to deposition onto the target. The sandwich method deposits aliquots sample and 
matrix sequentially onto the target, with each layer drying before the next to produce 
MALDI spot arrays. This technique allows deposition of multiple layers of either matrix or 
sample. For all automated target spotting a Mosquito liquid handling robot (TTP Labech) 
was used for both dried droplet and sandwich spotting.  
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For the SIK in vitro screening assay spotting a dried droplet technique was used and all 
spotting was performed with the Mosquito. First 1200 nL of matrix solution was mixed with 
1200 nL of sample before subsequent deposition of 200 nL of the matrix: sample mixture 
an AnchorChip MALDI. The target was allowed to ambient dry before MALDI-TOF-MS 
analysis. 
Manual spotting of targets for cell based studies were performed using the dried droplet 
technique. Automated target spotting was achieved by the sandwich method. First, 200 
nL of cell suspension was deposited onto a 1536 AnchorChip MALDI Target (Bruker 
Daltonics, Bremen, GER) and allowed to dry before subsequent deposition of 200 nL of 
the matrix solution. The target was allowed to ambient dry before MALDI-TOF-MS 
analysis. 
2.2.4.5 MALDI-TOF-MS Parameters for SIK assay 
A RapifleX MALDI-TOF/TOF mass spectrometer (Bruker Daltonics, Bremen, GER) 
equipped with a smartbeamTM 3D laser was used in positive-ion mode with Compass 2.0 
control for all data acquisition. Samples were run in automatic mode (AutoXecute, Bruker 
Daltonics) acquiring 5000 shots at 10 kHz frequency per spot in a random walk on spot 
laser ablation pattern and M5 smartbeamTM parameter at a 25 μm x 25 μm scan range. 
Ionization was achieved using a fixed laser power of 70% (laser attenuator offset 7%, 
range 30%) and detected by the FlashDetector at a detector gain of ×2 in the m/z range 
of 2500 –2800. Samples were analyzed in Reflector mode with optimized voltages for 
reflector-1 (20.82 kV), reflector-2 (1.085 kV) and reflector-3 (8.8 kV), Ion sources, (Ion 
Source 1 20 kV, PIE 2.66 kV), Lens (11.3 kV) and a pulsed ion extraction of 200 ns. A 
novel 10-bit digitizer was used at a sampling rate of 5.00 GS/s. 
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Spectra were accumulated with FlexControl software (v4.0) and processed using 
FlexAnalysis software (v4.0) (Bruker Daltonics). Peaks were centroid detected with a 
signal-to-noise threshold of 6.00 with a Snap2 algorithm to detect only the intense peaks 
before being processed with a Savitzky-Golay smoothing algorithm (m/z width of 0.05, 1 
cycle) and ‘TopHat’ baseline subtraction. External calibration was performed before each 
new target in Cubic Enhanced mode with Pepmix II calibrant (Bruker). 
The laser parameters were set up as follows: Global Attenuator Offset 0%, Attenuator 
Offset 42%, Attenuator Range 30%, Focus Offset 0%, Focus Range 100%, Focus Position 
19%, smartbeamTM index 1. 
2.2.4.6 MALDI-TOF-MS Parameters for whole cell analysis 
A RapifleX PharmaPulse MALDI-TOF/TOF mass spectrometer (Bruker Daltonics) 
equipped with a smartbeamTM 3D laser was used in positive ion mode with Compass 2.0 
control for all data acquisition. Samples were acquired in automatic mode (AutoXecute; 
Bruker Daltonics), totalling 10,000 shots at a 10-kHz frequency per spot. A random walk 
pattern (complete sample) on spot laser ablation pattern was used with a M5 Smart beam 
Parameter at a 45-µm × 45-µm scan range. Spot diameter was limited to 2000 µm and a 
random walk pattern movement enabled at 1000 shots per raster position. Ionization was 
achieved using a variable laser power between 50-85% (laser attenuator offset 14%, 
range 30%) with a detector gain of ×6.8 in the m/z range of 2000 to 20,000 with a 
suppression up to m/z 1600. Samples were analysed in a linear geometry with optimized 
voltages for ion sources (ion source 1, 20 kV, PIE 1.3 kV), lens (8.6 kV), and a pulsed ion 
extraction of 180 ns. A novel 10-bit digitizer was used at a sampling rate of 1.25 GS/s. 
Raw data were processed first by a TopHat baseline subtraction followed by smoothing 
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with a Savitzky-Golay algorithm. Calibration of the instrument was performed prior to each 
experiment using protein calibrant I. 
The laser parameters were set up as follows: Global Attenuator Offset 0%, Attenuator 
Offset 42%, Attenuator Range 30%, Focus Offset 0%, Focus Range 100%, Focus Position 
19%, smartbeamTM index 1. 
MALDI TOF data processed by the FlexAnalysis 4.0 software where a peak picking 
threshold of 3 S/N with a centroid algorithm was set before being exported as a .csv file 
using FlexAnalysis Batch Process (Compass 2.0) and further processed in Microsoft 
Excel and/or Perseus.174 Spectra based PCA plots were generated using ClinPro Tools 
(Bruker Daltonics). Data was then formatted using both GraphPad Prism 7.0 and Adobe 
Illustrator. 
2.2.5 Proteomics 
2.2.5.1 Protein extraction, reduction and alkylation 
Biological replicates were lysed in either 8M Urea, 50 mM TEAB pH 8.5 (in solution) or 
5% SDS, 50 mM TEAB pH 7.55 (S-Trap), sonicated and protein quantification was 
determined using the BCA Protein Assay Kit (Pierce Protein) as described in 1.3.2.2. Each 
sample was reduced by addition of TCEP to a final concentration of 10 mM for 30 min at 
room temperature followed by alkylation with 10 mM iodoacetamide for 30 min at room 
temperature in the dark.  
2.2.5.2 In-solution protein digestion  
Samples were diluted to 1M Urea and digested overnight at 37°C by adding porcine 
trypsin (1:50, w/w) (Pierce). Peptides were then acidified, desalted and concentrated 
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using C18 SPE Macro Spin Columns (Harvard Apparatus). Peptides were then dried 
under vacuum. 
2.2.5.3 S-Trap protein digestion 
Samples were acidified by addition of 2.5 µL of 12% phosphoric acid and diluted with 165 
µL of S-trap binding buffer; 90% MeOH, 100 mM TEAB, pH 7.1. The acidified samples 
were then loaded onto the S-trap spin column (ProtiFi, USA) and centrifuged for 1 minute 
at 4000 xg. Columns were washed five times with S-trap binding buffer before addition of 
porcine trypsin (1:20) (Pierce) in 25 µL of 50 mM TEAB to the column. Samples were 
incubated at 47°C for 2 hours. Peptides were eluted by washing the column with firstly 50 
mM TEAB, pH 8.0 (40 µL), followed by 0.2% FA (40 µL) and finally 0.2% FA, 50% ACN 
(40 µL). Peptides were then dried under vacuum. 
2.2.5.4 TMT 10-plex labelling  
Isobaric labelling of phosphorylated peptides was performed using the 10‐plex tandem 
mass tag (TMT) reagents (Thermo Fisher). TMT reagents (0.8 mg) were resuspended in 
41 μL of acetonitrile, and 10 μL added to the corresponding samples that were previously 
resuspended in 50 μL of 50 mM TEAB, pH 8.5. After 1 hour incubation at room 
temperature the reaction was quenched by addition of 4 μL of 5% hydroxylamine. Labelled 
peptides were then combined and acidified with 200 μL of 1% TFA (pH ~ 2) and 
concentrated using C18 SPE on Sep‐Pak cartridges (Waters). Mixing ratios of each 
channel and labelling efficiency was tested by injection of a small pool of each channel on 
a Fusion Lumos Tribid mass spectrometer. Each TMT‐labelled sample was quantified by 
a MaxQuant with a labelling efficiency >95%. 
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2.2.5.5 Offline high-pH reversed-phase (HPRP) liquid chromatography fractionation 
The combined TMT‐labelled peptides were fractioned by offline HPRP. Labelled peptides 
were solubilized in 20 mM ammonium formate (pH 8.0) and separated on a Gemini C18 
column (250 × 3 mm, 3 μm C18 110 Å pore size; Phenomenex). Using a DGP‐3600BM 
pump system equipped with a SRD‐3600 degasser (Thermo Fisher), a 40 min gradient 
from 1 to 90% acetonitrile (flow rate of 0.25 ml/min) separated the peptide mixtures into a 
total of 40 fractions. The 40 fractions were merged into 10 samples, dried under vacuum 
centrifugation and resuspended in 0.1% (v/v) TFA for LC‐MS/MS analysis. 
2.2.5.6 Q-Exactive HF mass spectrometer parameters 
2.2.5.6.1 L929 Secretome acquisition 
Peptide samples were separated on an Ultimate 3000 RSLC system (Thermo Scientific) 
with a C18 PepMap, serving as a trapping column (2 cm x 100 µm ID, PepMap C18, 5 µm 
particles, 100 Å pore size) followed by a 50 cm EASY-Spray column (50 cm x 75 µm ID, 
PepMap C18, 2 µm particles, 100 Å pore size) (Thermo Scientific). Buffer A contained 
0.1% FA and Buffer B 80% ACN, 0.1% FA. Peptides were separated with a linear gradient 
of 1-35% (Buffer B) over 120 minutes followed by a step from 35-90% ACN, 0.1% FA in 
0.5 minutes at 300 nL/min and held at 90% for 4 minutes. The gradient was then 
decreased to 1% Buffer B in 0.5 minutes at 300 nL/min for 10 minutes. Mass spectrometric 
identification was performed on an Orbitrap QE HF mass spectrometer (Thermo Scientific) 
operated “Top Speed” data dependant mode in positive ion mode. FullScan spectra were 
acquired in an m/z range of 400 to 1500, at a resolution of 120 000 (at m/z 200), with an 
automated gain control (AGC) of 1,000,000 and a maximum injection time of 50 ms. 
Charge state screening is enabled to exclude precursors with a charge state of 1. For 
MS/MS fragmentation, the minimum AGC was set to 5000 and the most intense precursor 
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ions were isolated with a quadrupole mass filter width of m/z 1.6 and an offset of m/z 0.5. 
Precursors were subjected to CID fragmentation that was performed in one-step collision 
energy of 25%. MS/MS fragments ions were analysed in the Orbitrap mass analyser with 
a 15 000 resolution at m/z 200.  
2.2.5.7 Fusion Lumos Tribrid mass spectrometer parameters 
2.2.5.7.1 BMDM TMT total proteome acquisition 
Peptide samples were separated on an Ultimate 3000 RSLC system (Thermo Scientific) 
with a C18 PepMap, serving as a trapping column (2 cm × 100 µm ID, PepMap C18, 5 µm 
particles, 100 Å pore size) followed by a 50 cm EASY-Spray column with a linear gradient 
consisting of (2.4–28% ACN, 0.1% FA) over 180 min at 300 nl min−1. Mass spectrometric 
identification and quantification was performed on an Orbitrap Fusion LUMOS Tribrid 
mass spectrometer (Thermo-Fisher Scientific) operated in data dependent, positive ion 
mode. FullScan spectra were acquired in the m/z range of 400 - 1,500 with a resolution of 
120,000, an automated gain control (AGC) of 300,000 ions and a maximum injection time 
of 50 ms. The 12 most intense precursor ions were isolated with a quadrupole mass filter 
width of m/z 1.6  and CID fragmentation was performed in one-step collision energy of 
35% and 0.25 activation Q. Detection of MS/MS fragments was acquired in the linear ion 
trap in a rapid mode with an AGC target of 10,000 ions and a maximum injection time of 
40 ms. Quantitative analysis of TMT-tagged peptides was performed using FTMS3 
acquisition in the Orbitrap mass analyser operated at 60,000 resolution, with an AGC 
target of 100,000 ions and maximum injection time of 120 ms. Higher-energy C-trap 
dissociation (HCD fragmentation) on MS/MS fragments was performed in one-step 
collision energy of 55% to ensure maximal TMT reporter ion yield and synchronous-
85 
 
precursor-selection (SPS) was enabled to include 10 MS/MS fragment ions in the FTMS3 
scan. 
2.2.5.7.2 THP-1 total proteomes 
Peptide samples were separated on an Ultimate 3000 RSLC system (Thermo Scientific) 
with a C18 PepMap, serving as a trapping column (2 cm × 100 µm ID, PepMap C18, 5 µm 
particles, 100 Å pore size) followed by a 50 cm EASY-Spray column with a linear gradient 
consisting of (2.4–28% ACN, 0.1% FA) over 240 min at 250 nLmin−1. Mass spectrometric 
identification and quantification was performed on an Orbitrap Fusion LUMOS Tribrid 
mass spectrometer (Thermo-Fisher Scientific) operated in data dependent, positive ion 
mode. FullScan spectra were acquired in the m/z range of 400 - 1500, at a resolution of 
120,000, with an automated gain control (AGC) of 300,000 ions and a maximum injection 
time of 50 ms. The 12 most intense precursor ions were isolated with a quadrupole mass 
filter width of m/z 1.6  and CID fragmentation was performed in one-step collision energy 
of 35% and 0.25 activation Q. Detection of MS/MS fragments was acquired in the linear 
ion trap in a rapid mode with an AGC target of 10,000 ions and a maximum injection time 
of 40 ms. 
2.2.6 Data analysis 
2.2.6.1 In vitro SIK assay data analysis 
For enzyme characterization, initial rates in both technologies were determined using 
time-course experiments under conditions of either excess ATP or CHKtide. The rates 
were plotted against variable substrate concentration and subjected to standard 
Michaelis-Menten analysis to derive Km and Vmax values. IC50 curves were fitted with 
GraphPad Prism (V7, USA) using a four parameter non-linear regression curve fitting 
algorithm to generate mid-point IC50 values for the inhibitors.  
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Values were normalised for volume and protein concentration across the two technologies 
for comparative purposes. SIK2 activity was measured by the percent phosphorylation 
(%P) of the CHKtide substrate by the following equation: 
�
(𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑎𝑎𝑃𝑃𝑃𝑃 𝑝𝑝ℎ𝑜𝑜𝑜𝑜𝑝𝑝ℎ𝑜𝑜𝑎𝑎𝑜𝑜𝑜𝑜𝑃𝑃𝑜𝑜𝑃𝑃𝑜𝑜 𝑝𝑝𝑎𝑎𝑜𝑜𝑜𝑜𝑝𝑝𝑝𝑝𝑜𝑜)
(𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑎𝑎𝑃𝑃𝑃𝑃 𝑝𝑝ℎ𝑜𝑜𝑜𝑜 𝑝𝑝𝑎𝑎𝑜𝑜𝑜𝑜𝑝𝑝𝑝𝑝𝑜𝑜) + (𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑎𝑎𝑃𝑃𝑃𝑃 𝑜𝑜𝑝𝑝𝑠𝑠𝑜𝑜𝑜𝑜𝑎𝑎𝑃𝑃𝑜𝑜𝑃𝑃)�  × 100 
Peak areas were determined using a SNAP II algorithm incorporated into the FlexAnalysis 
post acquisition software (Bruker Daltonics, Bremen, GER). 
Raw data from the ADP Hunter assay (relative fluorescence units [RFU]) were also 
exported as a comma delimited (.csv) file. All subsequent primary single-point screening 
data processing and analysis for both assays were conducted within Activity Base version 
8.1.2.12 using Activity Base XE Runner version 8.1.1 (IDBS, Guilford, UK). Data were 
normalised and expressed as a percentage effect (PE) value for each test compound as 
follows:  
MALDI-TOF-MS: 
𝑃𝑃𝑃𝑃 =  �
%𝑃𝑃𝑃𝑃𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 − %𝑃𝑃𝑃𝑃ℎ𝑖𝑖𝑖𝑖ℎ
%𝑃𝑃𝑃𝑃𝑙𝑙𝑙𝑙𝑙𝑙 − %𝑃𝑃𝑃𝑃ℎ𝑖𝑖𝑖𝑖ℎ
 × 100� 
ADP Hunter:  
𝑃𝑃𝑃𝑃 =  �
𝑅𝑅𝑅𝑅𝑅𝑅𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 − 𝑅𝑅𝑅𝑅𝑅𝑅ℎ𝑖𝑖𝑖𝑖ℎ
𝑅𝑅𝑅𝑅𝑅𝑅𝑙𝑙𝑙𝑙𝑙𝑙 − 𝑅𝑅𝑅𝑅𝑅𝑅ℎ𝑖𝑖𝑖𝑖ℎ
 × 100� 
Where PE or RFU test is the signal associated with the test compound, high is the median 
of the no-effect signal (reaction in presence of enzyme only), and low is the median of 
maximum effect control signal (reaction in absence of enzyme [biochemical] or presence 
of staurosporine [MALDI TOF]). The performance of the assay on each screening plate 
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was evaluated using internal controls to determine robust signal-to-background (s:b) and 
robust Z′ values, which were calculated as follows:  
𝑜𝑜:𝑠𝑠 =  
ℎ𝑖𝑖𝑖𝑖ℎ
𝑜𝑜𝑜𝑜𝑙𝑙  
𝑍𝑍′ = 1 − �
�3 × 𝑜𝑜𝑠𝑠𝑠𝑠𝑠𝑠ℎ𝑖𝑖𝑖𝑖ℎ� + (3 × 𝑜𝑜𝑠𝑠𝑠𝑠𝑠𝑠𝑙𝑙𝑙𝑙𝑙𝑙)
(ℎ𝑖𝑖𝑖𝑖ℎ − 𝑜𝑜𝑜𝑜𝑙𝑙) � 
High refers to either RFUhigh or %Phigh and low corresponds to either RFUlow or %Plow, as 
appropriate for each assay. sMADhigh is 1.4826 × median absolute deviation of signal 
associated with the no-effect control, and sMADlow is the 1.4826 × median absolute 
deviation of signal calculated for the maximum effect control. All database querying for 
global data analysis and report creation was undertaken using the Dotmatics Browser 
(version 4.9.623.45008-s) and Vortex analysis software (version 2015.12.46651.25; 
Dotmatics, Bishop Stortford, UK). 
2.2.6.2 MaxQuant parameters 
Protein identification and label free quantification was performed using MaxQuant Version 
1.5.8.3. Trypsin/P set as enzyme; stable modification carbamidomethyl (C); variable 
modifications Oxidation (M), Acetyl (Protein N-term), Deamidation (NQ), Gln & Glu to pyro-
Glu; maximum 8 modifications per peptide, and 2 missed cleavage. Searches were 
conducted using either a murine (downloaded March 2019, 17008 entries) or human 
(downloaded March 2019, 20416 entries) database depending on proteomic experiment 
plus common contaminants. Identifications were filtered at a 1% FDR at the peptide level, 
accepting a minimum peptide length of 5 amino acids. Quantification was performed using 
razor and unique peptides and required a minimum count of 2. “Re-quantify” and “match 
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between runs” were enabled. Label free quantification (LFQ) intensities were extracted for 
each protein/condition and used for downstream analyses. 
2.2.6.3 Statistical Analysis 
Statistical analyses were performed in Perseus (v1.6.0.7 - v1.6.6.0). Contaminants and 
reverse removed from the data sets prior to analyses. T-test-based statistics were applied 
to the LFQ protein ratios to extract the significant regulated proteins. Hierarchical 
clustering was performed in Perseus with Euclidian distancing on either Log2 fold changes 






Chapter 3. Identifying inhibitors of inflammation: a MALDI-
TOF-MS screening assay for Salt Inducible Kinases (SIKs)  
3.1 Introduction 
The variety of cells and signalling pathways that are involved in the process inflammation 
are incredibly complex and constantly evolving. In recent years, systemic inflammation 
has been linked to almost all acute and chronic diseases such as cancer, diabetes175, 
auto-immune diseases176, obesity177 and many more. This in turn has established a prolific 
platform for research to identify anti-inflammatory compounds, which is challenging but 
has revealed a wide range of potential new drug targets. These are often linked to key 
processes in macrophages, who are important players in the innate immune response 
and exhibit great plasticity in response to environmental stimuli. Macrophages that are 
polarised towards a pro-inflammatory state, or an M1 activation state, are important for 
sensing invading pathogens and responding to infection. However, prolonged activation 
can lead to sustained and systemic inflammation and, in severe cases such as Crohn’s 
disease and rheumatoid arthritis, pathogenesis and tissue damage.178 These effects can 
be countered by interleukin-10 (IL-10), a potent repressor of proinflammatory cytokine 
production, and key immunoregulator during infection and resolution of inflammation.179 
Treatment with recombinant IL-10 to reduce inflammation in patients with inflammatory 
bowel disease has been hypothesised and despite some success in mouse models 
clinical trials showed no clear therapeutic or clinical improvement.180,181 Furthermore, as 
large biomolecule therapies with recombinant cytokines and antibodies are very 
expensive and become an increasing burden for health systems, small molecule inhibitors 
to treat inflammatory disease are urgently needed.182 Therefore, innovative therapeutic 
90 
 
approaches to target these diseases could exploit this macrophage plasticity in an attempt 
to reduce the inflammatory response and alleviate patient symptoms.183 Current work in 
this field has highlighted that one or potentially all three isoforms of salt-inducible kinases 
(SIKs) play a major regulatory role in macrophage phenotype switching to an M1 activation 
state by negatively regulating the production of the anti-inflammatory cytokine IL-10 
(Figure 3-1).184–186 
 
Figure 3-1. SIK signalling pathway from TLR stimulation and EP2/4 stimulation. SIKs 
phosphorylate CRTC3 that then sequesters in the cytoplasm and is unable to initiate 
transcription of IL-10 with CREB, thus promoting the inflammatory phenotype. Inhibition 
of SIKs would lead to de-phosphorylated CRTC3 that can translocate to the nucleus and 
initiate transcription of IL-10. 
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SIKs belong to the serine/threonine protein kinase family and have been implicated in a 
wide range of biological processes such as insulin signal transduction and metabolic 
regulation, but their importance in the inflammatory response is best established.187,188 
Previously, it was shown that prostaglandins activate protein kinase A (PKA), which 
prevents SIKs from phosphorylating its substrates in cells. This leads to 
dephosphorylation of the SIK target CREB-related transcriptional coactivator 3 (CRTC3) 
at Ser62, Ser162, Ser329, and Ser370 subsequently its nuclear translocation promoting 
CREB dependent gene transcription and increased IL-10 production.186,189 Consequently, 
small-molecule inhibitors affecting SIKs have been shown to increase IL-10 production, 
thereby switching macrophages to an anti-inflammatory phenotype.190,191 This suggests 
that SIKs are attractive drug targets to combat chronic inflammatory diseases.192 
Kinases are a family of enzymes that catalyse the transfer of phosphate groups to specific 
substrates.193 Modification of protein substrates by phosphorylation is the most common 
post-translational modification in cells and plays a role in almost all biological and cellular 
process.193 Dysregulated phosphorylation of proteins disrupts complex intracellular 
signalling mechanisms and is now linked to a variety of different diseases such as 
Parkinson’s194, Alzheimer’s195 and systemic inflammation196.197 Consequently, kinases 
are considered excellent drug targets and development of small molecular inhibitors that 
are able to neutralise aberrant phosphorylation is at the forefront of drug discovery.198,199 
Methods for kinase profiling and screening are well established and have led to the 
discovery of kinase inhibitors involved in a variety of cellular processes,200–202 but also 
yielded a much better understanding of kinase catalytic activity and inhibitor selectivity.203 
However, these in vitro methods of kinase profiling are often indirect, measuring 
fluorescence of labelled non-physiological peptides or adenosine diphosphate (ADP), 
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and/or inclusion of coupling enzymes, or, if direct, require the incorporation of 33P through 
radio-labelled adenosine triphosphate (ATP). There is therefore a clear need to develop 
a complimentary screening assay that avoids the use of labelled reagents. 
MALDI-TOF-MS has been shown to be particularly powerful for monitoring post 
translational modifications on both protein86 and peptide substrates100, however these 
assays have not been directly compared to traditional methods. The phosphorylation of a 
substrate results in a mass shift of 79.96 Da, thus is a suitable reaction for MALDI-TOF-
MS assay development.  
3.2 Aims 
In this chapter I will describe the development of an in vitro MALDI-TOF-MS screening 
assay for the salt inducible kinases (SIKs). This body of work has been peer reviewed and 
published. 
Heap, R. et al. Inhibitors of Inflammation: A Novel High-Throughput MALDI-TOF 
Screening Assay for Salt-Inducible Kinases (SIKs). SLAS Discovery 10, 1192-1202 (2017) 
3.2.1 Sub-chapters 
1. Determining SIK isoform activity and substrate specificity for a MALDI-TOF-MS 
assay. 
2. Characterising the enzyme reaction kinetics of the MALDI-TOF-MS assay 
compared with ADP Hunter fluorescent assay. 
3. Determining IC50 values for known compounds and compare correlation between 
MALDI-TOF MS and ADP Hunter assay and cellular validation. 
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4. Proof of concept screen of 2648 compounds with both the MALDI-TOF-MS and 
ADP Hunter assays. 
3.3 Results 
3.3.1 Determining SIK isoform activity and substrate specificity for a MALDI-TOF-
MS assay. 
Salt-inducible kinases (SIKs) exist in the human genome as three isoforms: SIK1, 2 and 
3, all of which are responsible for regulating a wide range of cellular and biological 
processes. The SIK family structures are all relatively similar and share common features 
such as a ubiquitin associated domain (UB), an RK-rich region and a highly conserved 
kinase domain with T-loop activation.204  
 
Figure 3-2 The domain structure of SIK isoforms. Position of the LKB1 T loop 
phosphorylation sites of the three SIK isoforms. SIK1,2 and 3 all contain kinase domains 
(KD) a ubiquitin associated domain (UB) and an RK-rich region. Adapted from Taub.204 
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SIKs are expressed ubiquitously throughout tissue, with SIK1 expression being closely 
linked to external stimulation such as high salt intake and metabolic signalling.205 In 
contrast, SIK2/SIK3 are broadly expressed at all times in tissue, with SIK2 levels observed 
to be at their highest in adipose tissue and SIK3 in brain tissue.206 Therefore, there was a 
distinct possibility that despite their structural similarities, these three isoforms could 
exhibit variable activity with different substrates. I therefore chose to evaluate the activities 
of the three SIK isoforms with two readily available synthetic peptides as substrates: (1) 
NUAK peptide, which is derived from NUAK2, a stress-activated kinase from the LKB1 
signalling pathway, and (2) CHKtide, a peptide derived from the CHK1 protein kinase 
involved in the DNA repair pathway (Figure 3-3.A&B).207 The matrix α-cyano-4-
hydroxycinnamic acid was used for co-crystallisation as it is well known to be preferable 
for peptide analysis and crystallises homogenously. Both CHKtide and NUAK peptide 
ionised well by MALDI-TOF-MS and could be detected at 1 fmol when diluted with SIK 
assay buffer (50 mM Tris/HCl, 10 mM magnesium acetate, 2 mM DTT, pH 7.5) at m/z 
2700.47 and 1739.52 respectively. However, CHKtide exhibited much better ionisation 
sensitivity over NUAK peptide (Figure 3-3.B) as it was detected at a significantly higher 
signal to noise (S/N) at the lower concentrations and could be detected at ~100 amol, 10-
fold lower than NUAK peptide. This ionisation bias is likely due to differences gas-phase 
basicity between the peptides, which has been shown to dramatically effect ionisation 
efficiency.208 Peptides rich in the basic residues arginine- or lysine- tend to exhibit greater 
ionisation efficiency as these residues contain very basic side chains. CHKtide contains 
seven arg- and lys- residues (KKKVSRSGLYRSPSMPENLNRPR), whereas NUAK 
peptide contains only four arginine residues (ALNRTSSDSALHRRR). Theoretically, 
CHKtide should transfer more efficiently into the gas phase with a positive charge 
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associated with the guanidino group of these residues or the n-terminus as under acidic 
conditions as CHKtide possesses three more sites for potential protonation. This could 
explain why I observe CHKtide to have a greater ionisation efficiency as it is more readily 
protonated at one of its proton-acceptor sites. Interestingly, I also observed more sodium 
salt adduct formation [M+Na]+ with CHKtide peptide at m/z 2723.7, compared with NUAK 
peptide, which may be due to glutamic acid residue. However, this adduct formation never 
exceeded 5% of the total substrate peptide signal and did not interfere with subsequent 
quantitation. 
 
Figure 3-3. SIK assay activity and peptide sensitivity. (A) & (B) Amino acid sequence 
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of both NUAK peptide and CHKtide, respectively, with highlighted in green the 
phosphorylation site of a serine residue of both peptides. MALDI-TOF-MS spectra 
sensitivity of both peptides from 100 – 1 fmol showing that CHKtide can be detected at a 
lower limit of detection (LOD). (C) activity of SIK1, 2, 3 with both NUAK peptide and 
CHKtide at 5 µM concentration in-assay. All error bars are given as ± SD over three 
technical replicates. 
To test enzyme activity all three SIKs were incubated at 5ng/µL final concentration with 
both NUAK peptide and CHKtide (5 µM) and the phosphorylated product was measured 
at m/z 1819.82 and 2779.48 respectively (Figure 3-4) and the reaction was quenched at 
regular intervals over one hour. The percentage phosphorylation was calculated by the 
following equation: 
% 𝑝𝑝ℎ𝑜𝑜𝑜𝑜𝑝𝑝ℎ𝑜𝑜𝑎𝑎𝑜𝑜𝑜𝑜𝑃𝑃𝑜𝑜𝑖𝑖𝑜𝑜𝑟𝑟 =  � (𝑝𝑝𝑡𝑡𝑝𝑝𝑝𝑝 𝑝𝑝𝑎𝑎𝑡𝑡𝑝𝑝 𝑝𝑝𝑎𝑎𝑙𝑙𝑝𝑝𝑝𝑝𝑝𝑝𝑡𝑡)
(𝑝𝑝𝑡𝑡𝑝𝑝𝑝𝑝 𝑝𝑝𝑎𝑎𝑡𝑡𝑝𝑝 𝑝𝑝𝑎𝑎𝑙𝑙𝑝𝑝𝑝𝑝𝑝𝑝𝑡𝑡 + 𝑝𝑝𝑡𝑡𝑝𝑝𝑝𝑝 𝑝𝑝𝑎𝑎𝑡𝑡𝑝𝑝 𝑡𝑡𝑝𝑝𝑠𝑠𝑡𝑡𝑡𝑡𝑎𝑎𝑝𝑝𝑡𝑡𝑡𝑡)
� × 100 
 
Overall, I observed significantly less activity of all the SIKs with NUAK peptide versus 
CHKtide (Figure 3-3.C) and therefore all further experiments and optimisation was 
performed with CHKtide as the substrate. Interestingly, for both the NUAK peptide and 
CHKtide I observed multiple other mass features in the phosphorylated spectra. For both 
peptides, the neutral loss of phosphate (m/z 94.97) from the phosphorylated peptide 
product is observed as a well resolved peak at either m/z 1723.85 or 2684.4 for NUAK 
peptide and CHKtide respectively. This can sometimes be observed for phosphorylated 
peptides where they experience post source decay that results in the neutral loss of the 
phosphate ion.209 Interestingly, I also observe a broad, poorly resolved peak adjacent to 
the substrate peptide peak at a lower m/z value for both peptides. These peaks could also 
be due to the formation of metastable ions post-source as the breakdown of ions after 
acceleration and is sometimes referred to as meta-stable decay.210 This would in turn lead 
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to the formation of ions that possess a shift in kinetic energy to the original ions and 
therefore a partitioning of their energies and different flight times. This could explain the 
mass difference that is observed in this case, as well as the poorer resolution as these 
ions may exhibit a broader range of kinetic energies compared with the parent ions.210 In 
addition, for both phosphorylated and unphosphorylated CHKtide I observed a peak of 
+15.98 Da, which corresponds to single oxidation. Interestingly, this oxidation is not seen 
to the same extent with NUAK peptide. This could be due to CHKtide possessing a 
methionine residue within its sequence whereas NUAK peptide does not as methionine is 
known to be readily oxidised and its derivatives can be readily detected by MALDI-TOF-
MS.211  
Figure 3-4. Representative spectra of SIK mediated phosphorylation of peptide 
substrates. The serine phosphorylation reaction with (A) NUAK peptide and (B) CHKtide 
by SIKs. 
The CHKtide substrate could be efficiently phosphorylated by SIK2 and SIK3 with SIK2 
proving to be the more active enzyme. However, there was little to no activity observed 
with SIK1 only obtaining a maximal % phosphorylation of ~6% with CHKtide (Figure 3-
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3.C). More concentrated reactions of SIK1 were tested up to 50 ng/µL, however enzyme 
activity did not improve and salt / glycerol concentrations from the SIK enzyme storage 
buffer become MALDI intolerable, therefore I proceeded with SIK2 and SIK3 for further 
assay development. 
3.3.2 Characterisation of enzyme reaction kinetics of the MALDI-TOF-MS assay  
To truly compare the MALDI-TOF-MS assay with the fluorescent ADP Hunter assay we 
performed experiments that would characterise the kinetics of the reaction with both assay 
types. All experiments that used the ADP Hunter assay method were performed by Lesley-
Anne Pearson, a biologist of the University of Dundee drug discovery unit. The ADP 
Hunter technology (DiscoverX, UK) is an enzyme coupled assay that detects the 
abundance of the resorufin fluorophore at ex 550 nm; em 595 nm as a downstream 
consequence of the conversion of ATP to ADP. This readout method is generic for a high- 
throughput biochemical assay that measures kinase activity. The SIK ADP Hunter assay 
was performed using the same CHKtide as a substrate peptide but used ADP as a 
measure of SIK activity rather than the direct phosphorylation of CHKtide that is measured 
with the MALDI-TOF-MS assay.212 As the ADP Hunter assay buffer contains high levels 
of salt that would be incompatible with MALDI-TOF-MS, we utilised a comparable buffer 
containing the same concentrations of magnesium chloride and a tolerable Tris/HCl 
concentration for both assays to maintain as much similarity as possible. We chose to use 
Michaelis-Menten kinetics to describe the rate of the enzymatic reaction in both assays 
with the following equation:213 






Here, v is equal to reaction rate and [S] equates to substrate concentration. The two 
quantities of interest Vmax and KM can be calculated for the substrates based on the 
hyperbolic relationship between reaction rate and the substrate concentration. In the case 
of the SIK reaction, these entities would be the CHKtide peptide and ATP. The Vmax for a 
given reaction is the maximum rate of reaction under enzyme-substrate saturated 
conditions whereas KM is the Michaelis constant equates to half Vmax. This parameter 
represents the dissociation constant for the ES complex in this case was the most 
important parameter for assessing the differences between the ADP Hunter and MALDI-
TOF-MS assay for both ATP and CHKtide consumption. This in turn enabled us to 
determine whether the rate of formation of the product was affected by the availability of 
substrate, which for kinases is particularly important to determine for ATP. A high KM value 
indicates that the reaction is significantly dependent on the availability of a substrate, 
whereas a low KM indicates independence. Therefore, it was important to determine KM 
for both assays as it enabled us to determine whether both assays were performing under 
similar physiological conditions. 
For this, substrates were titrated from very high concentrations to very low to determine 
dependence of the reaction rate on the substrate availability. For determining ATP KM this 
was relatively straight forward (Figure 3-5.C), where values of 23.0 and 40.0 for MALDI-
TOF-MS and ADP Hunter were calculated respectively (Table 3-1.) This indicates that the 
rate of consumption of ATP under physiological conditions is very similar, and therefore 




Figure 3-5. Michaelis-Menten kinetics of the SIK2 reaction. (A) Reaction rate SIK2 
phosphorylation of CHKtide over one hour showing linear correlation up to 75% 
phosphorylation with error bars representing the ± SD from the mean average of three 
technical replicates. (B) CHKtide concentration versus reaction velocity curve for 
determining Km for CHKtide in the MALDI-TOF-MS assay. (C) ATP concentration versus 
reaction velocity curve for determining KM for ATP in the MALDI-TOF-MS assay. 
However, for CHKtide, the calculation of KM was more difficult with the MALDI-TOF-MS 
assay as calculation of the rate of reaction is dependent on the substrate concentration. 
At very high concentrations the rate of reaction was no longer well represented by the 
relative peak areas of the substrate and product as the peak area of CHKtide substrate 
suppresses the phosphorylated product in the spectrum. This in turn resulted in highly 
underrepresented reactions rates where the reaction rate appeared to decline with 
increasing CHKtide concentration. Therefore, there was a limited window for determining 
CHKtide KM (Figure 3-5.B) where the reaction rate was accurate, which may account for 
the discrepancies in KM between the MALDI-TOF-MS and ADP Hunter assays. Here, the 
KM value for MALDI-TOF-MS was significantly lower than the ADP Hunter assay, which 
may imply there are some subtle differences in enzyme activity. However, it is more likely 
that the inability to perform the kinetic experiment at high concentrations causes an 
underestimation of KM and the reaction rate is similar for both reactions. 
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Table 3-1. KM values for ATP and CHKtide with the MALDI-TOF-MS and ADP Hunter 
assays. 
KM ATP [µM] MALDI-TOF-MS ADP Hunter 
SIK2 22.0 ± 1.3 40 ± 6 
KM CHKtide [µM] MALDI-TOF-MS ADP Hunter 
SIK2 7.7 ± 0.5 93 ± 10 
 
The problem with calculating KM for the direct substrate by MALDI-TOF-MS is likely to 
only occur when there is relative quantitation between the substrate and product peak 
areas. This in turn could be solved utilising a method that does not consider substrate 
concentration to calculate reaction rate such as using an internal standard.  
3.3.3 Determining IC50 values for known compounds and compare correlation 
between MALDI-TOF MS and ADP Hunter assay and validation in cells 
The final step of validating the MALDI-TOF-MS assay for screening was to test the 
potency of known SIK inhibitors by calculating IC50 values and to compare with the ADP 
Hunter assay. Five kinase inhibitors with reported activity in SIKs were chosen for this 
study: staurosporine, HG-9-91-01, MRT199665, MRT67307 and KIN112 (Figure 3-
6).184,214 Staurosporine is a potent and broad kinase inhibitor, where as KIN112 and the 
more potent analogue HG-9-91-01 target the ATP binding site of kinases. MRT199665 
inhibits the vast majority of AMPK-related kinases, but unlike MRT67307 it does not inhibit 




Figure 3-6. Chemical structures of the five inhibitors of SIKs. (A) Staurosporine, (B) 
HG-9-91-01, (C) MRT67307, (D) MRT199665, (E) KIN112. 
IC50 curves spanning 1000 – 0.03 nM were generated for each compound against SIK2 
(Figure 3-7.A). I was able to fit good R2 values >0.95 for all compounds using a four-
parameter variable slope algorithm, thus validating MALDI-TOF-MS as a readout for 
potential hit compound titrations. Staurosporine was the most potent inhibitor for both 
assays exhibiting an IC50 below 1 nM (Figure 3-7) and also had the poorest slope fit. This 
poor fitting could suggest that other factors such as tight-binding could be causing 
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uncertainty in the potency of staurosporine.215 Tight binding results in an IC50 value being 
near or below the SIK2 concentration in the assay as there is depletion of the free inhibitor 
by binding to the target enzyme, which in turn would underrepresent the true potency of 
the inhibitor. The other four compounds behaved similarly for both assays, with HG-9-91-
01 also exhibiting ~1 nM inhibitory concentration for both SIKs. MRT199665, MRT67307 
and KIN112 MALDI-TOF-MS IC50 values were more potent than those previously 
described by Clark et al., but do follow the same trend where all compounds were stated 
as being more specific for SIK2 rather than SIK3.184 Comparing the data against the 
fluorescent ADP Hunter assay for SIK2 generated a correlation plot with a good R2 of 
0.81, however there was a five-fold difference between KIN112 IC50s generated by 
MALDI-TOF-MS and ADP Hunter assay. Moreover, the low measured IC50 of <1 nM for 
staurosporine suggests that either the concentration of active SIK2 enzyme, which was 
provided by the Drug Discovery Unit, was likely substantially lower than 15 nM, or the 




Figure 3-7. Evaluation of known SIK inhibitors by MALDI-TOF-MS. (A) & (B) MALDI-
TOF-MS IC50 curves for Staurosporine, HG-9-91-01, MRT199665, MRT67307 and 
KIN112 for SIK2. Compounds were titrated from 1000 – 0.06 nM (SIK3) and 125 - 0.06 
nM (SIK2) in a twofold dilution curve. (C) Correlation plot of MALDI-TOF-MS and ADP 
Hunter assay IC50 values for the 5 compounds generating an R2 value of 0.81. All error 
bars are given as ± SD from the mean average of three individual well replicates.  
Finally, Katherine Reyskens (Postdoctoral researcher, Division of Cell Signalling and 
Immunology, University of Dundee 2017) validated all five compounds by a fluorescent-
based assay that was built on the fact that CRTC3 translocates into the nucleus when SIK 
kinases are inactivated. This is driven by dephosphorylation of four serine residues that 
are targeted by SIKs. This nuclear translocation is essential for activating the 
transcriptional program for IL-10 production and polarization toward regulatory-like, anti-
inflammatory macrophages.205  
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Human U2OS cells were treated for 1 hr with inhibitors, cells were fixed, and nuclear 
CRTC3 translocation was analysed by fluorescence-labelled antibody staining on a high-
throughput fluorescence imaging platform (PerkinElmer Operetta). The cellular assay 
showed that nuclear translocation of CRTC3 is enhanced by SIK inhibition. Comparable 
with our in vitro data, CRTC3 translocation correlated with the potency of the inhibitors. 
Staurosporine and HG 9-91-01 were the most potent of the inhibitors compared to DMSO, 
showing a very dense nuclear localization of CRTC3. Kin112 was not as potent, and 
although MRT67307 does induce localization, this was with much greater variation versus 
the other compounds. MRT199665 was the least potent of all the inhibitors tested. These 
data show that this is a useful platform to differentiate screening hits efficacy for SIK 





Figure 3-8.  Performed by Katherine Reyskens. Nuclear localization of CRTC3 with 
small-molecule salt-inducible kinase (SIK) inhibitors. U2OS cells were treated for 1 h 
with 0.1% DMSO or small-molecule inhibitors serially diluted. (A) Representative 
microscopic images at 20x magnification from the high-throughput system at 10 µM 
inhibitor with CRTC3 (Alexa 488, green) and nucleus (DAPI, blue) shown. Scale bar = 50 
µm. (B) Inhibition of SIK kinases induces strong nuclear translocation of CRTC3. Mean 
fluorescent intensity of nuclear CRTC3 calculated with data represented as mean ± SD. 
The p values versus 0.1% DMSO are as follows: staurosporine, p = 1.31 × 10−19; HG 9-
91-01, p = 4.45 × 10−14; Kin112, p = 2.95 × 10−6; MRT67307, p = 0.0061; MRT199665, p = 
0.533. *p < 0.01, **p < 0.001 vs 0.1% DMSO. 
Overall, the IC50 values were all in the low nanomolar range and about 0.5 to 1 order of 
magnitude higher potency than published biochemical assays, suggesting a specific trend 
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in the MS-based assay. However, this is not unexpected as previous IC50 values were 
determined by less direct measurements, such as IL-10 messenger RNA (mRNA) 
induction or cell-based methods. In cells, a higher ATP concentration and the presence 
of other potential targets such as AMPKs and a number of protein tyrosine kinases, 
cellular penetration of the compound, and inclusion of high concentrations of proteins that 
may bind to compound could contribute to differences seen for the inhibitor potencies. 
3.3.4 High-throughput screen of an ATP mimic library set of 2648 compounds with 
both the MALDI-TOF-MS and ADP Hunter assays. 
To test the potential of the SIK2 MALDI-TOF-MS assay for compound screening, I 
performed a single-concentration screen of 2648 commercially available ATP mimetics 
that describe a diverse region of kinase pharmacophore space and compared the data 
with the ADP Hunter assay. Lesley Pearson (Biologist, Drug discovery unit (DDU), 
University of Dundee 2017) performed the corresponding ADP Hunter assay with the 
same set of compounds. In brief, the final MALDI-TOF-MS assay conditions were as 
follows. Compounds were transferred into 384 HiBase non-binding assay plates using an 
Echo 550 acoustic dispenser to give a final concentration of 30 µM in-assay with 
staurosporine included as a positive control at 10µM. Assay buffer (3 µL) and SIK enzyme 
master mix (1 µL) were added and the reaction was incubated for 30 minutes at 30°C prior 
to addition of substrate master mix (1 µL) that initiated the reaction. Plates were then 
incubated for 30 minutes at 30°C before subsequent addition of TFA to final concentration 




Figure 3-9. Graphical representation of the compound library screening workflow. 
Description of how both the (A) MALDI-TOF-MS Assay and (B) ADP Hunter assay identify 
hits in a high throughput screening set up. 
The output of both screens for SIK2, expressed as percentage effect for the MALDI-TOF-
MS and ADP Hunter assays exhibited a normal distribution (Figure 3-10.A), which gives 
confidence in the data set quality and hit identification. I calculated mean percentage 
effects of 2.3 (MALDI-TOF-MS) and 7.6 (ADP Hunter) for SIK2 and standard deviations 
of the whole screening data set were comparable with 20.6% and 14.6% for MALDI-TOF-
MS and ADP Hunter respectively. To further evaluate assay quality, I performed Z’ 
analysis on both data sets and measured the statistical effect size. This is calculated by 
the following equation where (µ), (σ), (p) and (n) equate to the mean and standard 
deviations of the positive and negative controls respectively.216 
𝑍𝑍′ = 1 − �
3(𝜎𝜎𝑝𝑝 + 𝜎𝜎𝑟𝑟
|𝜇𝜇𝑝𝑝 − 𝜇𝜇𝑟𝑟| � 
A good Z’ of >0.5 was generated for both assays (Table 3-2), which was also observed 
for robust Z’ analysis. Robust Z’ substitutes the outlier-insensitive median and median 
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absolute deviation (MAD) for the mean and standard deviation respectively in the Z’ 
equation.217 This Z’ calculation is less sensitive to extreme outliers and both assays were 
demonstrated to be robust methods for screening (Table 3-2). 
Table 3-2. Robustness of SIK2 screening assays 
SIK2 Assay Z’ Robust Z’ 
MALDI-TOF-MS 0.53 0.50 
ADP Hunter 0.95 0.90 
 
To identify hit compounds for both screens a statistically significant effect was defined as 
a percentage effect (PE) of greater than or equal to mean effect ± 3 SD of the whole 
screening data set. In addition, the number of compounds producing percentage effect 
greater than 40% was also determined for each assay and the number of hits for each 
definition is shown in Table 3-3 for both assays. 
Table 3-3. Number of hit compounds for both assays 
SIK2 Assay PE ≥ Mean ± 3 SD PE ≥ 40% 
Unique hits: 
PE ≥ Mean ± 3 SD 
Unique hits: 
PE ≥ 40% 
MALDI-TOF-MS 45 107 14 45 
ADP Hunter 59 79 26 16 
  
As expected for single-shot, single concentration screens, the number of hits for both of 
the assays was not identical for the two screens, but they did correlate (R2 = 0.44) 
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between the percentage effects measured for compounds producing greater than 40% 
effect in the two assays (Figure 3-10.D). With further replicates and I would expect a 
tighter correlation between the hits of the two assays. 
 
Figure 3-10. Comparison between biochemical and matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF-MS) salt-inducible kinase 2 (SIK2) 
assay. (A) Data distribution of the MALDI-TOF-MS SIK2 kinase assay shows a normal 
distribution. (B) Blot showing significant hits (>40% inhibition, in red) of the MALDI-TOF-
MS assay. Data also show some apparent activators (<–50% effect). (C) Comparison of 
percentage inhibition for all compounds tested between the biochemical ADP Hunter 
assay and the MALDI-TOF-MS assay. (D) Comparison of “hits” (>40% inhibition) from 
both biochemical ADP Hunter assay and MALDI-TOF-MS SIK2 assay showing high 
correlation between the two assays. 
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Eighty percent of the ADP Hunter assay hits (PE >40%; 59 compounds) were identified in 
both screens (28 with PE >3 SD). There were also 16 hits that were only identified in the 
ADP Hunter assay and a significant number of hits (45) that were only present in the 
MALDI-TOF-MS assay suggesting that direct analysis of the peptide product might 
produce additional hits compared to the indirect ADP assay. Interestingly, when looking 
at the total correlation plot of hits between the MALDI-TOF-MS assay and the ADP Hunter 
assay, nine compounds appeared to increase the kinase reaction rate that were not 
identified in the ADP Hunter assay (Figure 3-11.A). When looking at the spectra, which 
were spotted in technical duplicate, these hits appeared to be genuinely increasing the 
product formation when compared with a no compound control on the same assay plate. 
To validate these findings, I took two of the hit compounds (DDD00853763 & 
DDD01510849) and two of the activating compounds (DDD00041312 & DDD01010801) 
and repeated the screening assay conditions. Both the hit compounds significantly 
inhibited SIK2 activity, whereas DDD01010801 exhibited significant activating potential 




Figure 3-11. Identification of SIK activating compounds by MALDI-TOF-MS. (A) Full 
scale axis correlation plot of ADP Hunter vs MALDI-TOF-MS assay showing the potential 
activating compounds. (B) Validation of two of the activating compounds (DDD0101801 & 
DDD000041312) and hit compounds (DDD00853763 & DDD01510849) by repetition of 
the screening conditions. Error bars represent ± standard deviation from the mean. (C) 
MALDI-TOF-MS spectra for three activating compounds and no compound control 




Mass spectrometry-based assays are on the rise in the drug discovery field, with MALDI-
TOF-MS proving particularly successful for the high-throughput screening of compounds. 
Salt inducible kinases regulate the production of the anti-inflammatory cytokine IL-10 by 
phosphorylating the cofactor CRTC3. This phosphorylation sequesters CRTC3 to the 
cytoplasm and prevents transcription of IL-10. SIKs can often become activated after the 
initiation of an inflammatory response as they enable to propagation and systemic spread 
of inflammation by dampening any IL-10 production that would reverse the response. 
Under normal circumstances, cytokine production is well balanced by homeostasis and 
enables efficient clearance of invading pathogens and protection of the host, but when 
dysregulated this systemic and severe inflammation can cause significant pathogenesis. 
This is particularly prevalent in auto-immune diseases such as Crohn’s and rheumatoid 
arthritis. By inhibiting SIK activity during acute inflammation, IL-10 production should rise 
and dampen the inflammatory response, thus there should be an improvement in patient 
health. Current assays for screening against SIKs are often biochemical assays like the 
ADP Hunter assay, a secondary assay that measures ADP production by incorporation of 
the fluorophore resorufin. Although fast and relatively simple, these biochemical based 
assays are not label free, do not directly measure substrate phosphorylation and can be 
prone to false positives/negatives arising from auto-fluorescent interactions of test 
compounds. Therefore, in this chapter I aimed to develop and characterise a robust 
MADLI-TOF-MS assay for monitoring SIK phosphorylation activity and compare it with the 
already established biochemical ADP Hunter assay. 
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3.4.1 MALDI-TOF-MS is a viable readout for phosphorylation activity of SIK2 and 
SIK3 
I first demonstrated the differences in SIK isoform activity by performing an in vitro reaction 
of each enzyme with two substrate candidates: NUAK peptide and CHKtide derived from 
NUAK2 and CRTC3, respectively. It became clear that our recombinant SIK1 was inactive 
with both these substrates as there was negligible phosphorylated substrate detected. 
This was not necessarily unexpected, as SIK1 expression is reported to be more regulated 
by external stimulus compared with SIK2/3 that are more ubiquitously expressed in tissues 
at a given time.218 However, both SIK2/3 had measurable activity with both substrates, 
with CRTC3 derived CHKtide proving to be more preferable. This combined with its higher 
MALDI-TOF-MS ionisation efficiency made it the peptide substrate of choice for further 
assay development. 
Characterisation of assay kinetics is key to developing a robust assay and subsequent 
compound screening. We were able to demonstrate how the MALDI-TOF-MS assay 
behaved linearly for the SIK2 assay over one hour at an enzyme concentration of 30 nM. 
By using the Michaelis-Menten model I could show how the cofactor ATP exhibits similar 
KM values of 23 µM and 40 µM for MALDI-TOF-MS and ADP Hunter respectively. This 
calculation for the CHKtide substrate was significantly more challenging with the MALDI-
TOF-MS assay as the rate of product formation is calculated from the substrate and 
product peak areas. At saturated concentrations of CHKtide, this caused significant under-
representation of the reaction rate as the substrate peptide was suppressing the 
phosphorylated product peak and in turn a reduced reaction rate. Therefore, it was not 
possible to exceed concentrations of 50 µM of CHKtide. Using these modified conditions, 
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I was able to determine a KM of 7.7 µM of CHKtide, which was significantly lower than 93 
µM determined for the ADP Hunter assay. However, it is likely that the physiological 
constraints of calculating the reaction rates with relative MALDI-TOF-MS quantitation led 
to this underestimation, and it may be important in future work to include an internal 
standard to avoid this problem. 
A compound’s potency is often measured by determining the half maximal inhibitory 
concentration over a compound titration, thus giving an IC50 value. Four compounds that 
have been shown previously to have activity against SIKs as well as the non-specific 
kinase inhibitor staurosporine were chosen to validate the MALDI-TOF-MS assay and 
compare with the ADP Hunter assay.184 Generation of IC50 curves showed very good fits 
for both SIK2 and SIK3. However, for staurosporine it is likely that its potency may be 
underestimated due to tight-binding kinetics. This is due to the IC50 value being dependent 
on enzyme concentration, and therefore tight-binding kinetics occurs with inhibitors when 
the inhibitor constant Ki approaches the enzyme concentration or tight-binding limit. 
Correlation of the determined IC50 values between the MALDI-TOF-MS and ADP Hunter 
assays showed good correlation, thus suggesting that the reaction kinetics and behaviour 
of both assays is similar. Interestingly, in both assays the compounds were significantly 
more potent than previously reported by Clark et al. We hypothesised that this was due 
to our assays being a single enzyme/substrate reaction, whereas previous studies 
measured mRNA transcription as a readout in cells where multiple other kinases are 
present. As many of these compounds are ATP mimetics, it is likely that SIK inhibition 
potency would be underestimated under cellular conditions due to off-target competition. 
We did, however, validate all five inhibitors in cells with CRTC3 translocation to the 
nucleus with a fluorescent cellular assay. 
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3.4.2 A 2648 compound screen demonstrates assay compatibility and highlights 
potential novel findings in MALDI-TOF-MS assay 
A selected library of 2648 ATP mimetics was screened with both the MALDI-TOF-MS and 
ADP Hunter assays. Both assays were determined to be very robust with Z’ and robust Z’ 
values exceeding >0.5. We were able to identify 80% of the ADP Hunter assay hits with 
the MALDI-TOF-MS assay that generated a percentage effect correlation of 0.44.  These 
data suggest that for the majority of hit identification both assays are comparable. We 
were able to identify unique hits from the library for both assays, with the MALDI-TOF-MS 
assay identifying significantly more. This suggests that by directly measuring the peptide 
phosphorylation rather than ADP formation we were able to identify hits that may be false 
negatives in a biochemical assay. It is also important to note that there were 16 unique 
hits to the ADP Hunter assay, and it would be interesting in future work if these could be 
determined as genuine hits or false negatives using other assay types such as the cellular 
fluorescent assay. Finally, we noted that with the MALDI-TOF-MS assay that 9 
compounds appeared to accelerate the phosphorylation reaction rather than inhibit it, an 
observation that was missed with the biochemical assay. This is due to the larger dynamic 
range of the MALDI-TOF-MS assay which allows measurements of percentage effect to 
exceed 100%. These results were validated by spectral interrogation and further repetition 
of the assay conditions with two of the compounds that showed genuine reaction 
enhancing potential. 
Collectively, these data confirm that the developed label-free MALDI-TOF-MS peptide 
substrate assay correlates with current biochemical approaches for screening inhibitors 
against SIKs. Moreover, we could show that both techniques generate comparable 
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IC50 data for known inhibitors of SIK kinases and reported significantly more potent 
findings than previously shown. We took these inhibitors further into a fluorescence-based 
cellular assay using the SIK activity-dependent translocation of CRTC3 into the nucleus, 
thereby providing a complete assay pipeline for the identification of SIK kinase inhibitors 
in vitro and in cells. Our data demonstrate that MALDI-TOF mass spectrometry is fully 
applicable to high-throughput kinase screening by way of a 2648 compound screen that 
when compared with the biochemical assay show considerable similarities in hit 
identification. These data also highlight interesting and novel aspects of a MALDI-TOF-
MS assay, such as hits that may be falsely identified in biochemical assays, as well as 
potential SIK activators. The biological activity of these compounds would be of a 
significant interest and further work in this area would be required. Ultimately, this work 
confirms that MALDI-TOF-MS is robust for kinase screening and now ready to be scaled 




Chapter 4. Optimising a sample preparation method for 
phenotyping of whole mammalian cells by MALDI-TOF-MS 
4.1 Introduction 
Ascertaining a mammalian cell’s state or phenotype prior to functional studies is key for 
understanding their biological processes and is often deduced through biochemical 
assays. This is particularly important for primary cells, as these cultures are typically 
isolated from animals or living tissues and they often exist as a heterogeneous population 
of different cell types. Biochemical assays and measurement of cellular biomarkers are 
two common techniques for cellular phenotyping and utilise flow cytometry219,220, qPCR221 
or cell biology techniques such as western blotting. However, all these methods typically 
require long sample preparation methods and incorporate the use of a fluorescently 
labelled antibody or primer to quantify expression and identify cell phenotypes. Flow 
cytometry and cell sorting is currently the gold standard in the field for characterising, 
quantifying and separating heterogeneous cell preparations by analysing both physical 
and fluorescent properties. This technology has been shown to be particularly powerful 
for discriminating different immune cells and those undergoing phenotypic shifts.222,223 
However, this method is costly in time and reagents and involves complex data analysis. 
Moreover, some biomarkers of certain cell states are cytoplasmic, thus requiring cells to 
be lysed and stained prior to analysis, which can be detrimental for further functional 
assays.  
There is a growing need for label-free and rapid techniques for whole mammalian cell 
analysis and phenotyping that are less costly compared with conventional methodologies. 
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Mechanical approaches show promise here as they take advantage of cell deformability 
and morphology to discriminate positive and negative single cells.224–226 By utilising a 
micro-fluidic device, Gossett et al. described how a cell can be hydrodynamically stretched 
and manipulated in a high-throughput manner. The resulting data can then be used to 
assess changes in cytoskeleton and nuclear structure, thus giving rise to various different 
cellular phenotypes.227  
In contrast, mammalian whole cell phenotyping by mass spectrometry approaches are 
often lower throughput, with mass cytometry228,229 or MALDI imaging230,231 being 
commonly used to classify cell or tissue types. A well-established application of cellular 
MALDI-TOF-MS is the phenotypic profiling and characterisation of micro-organisms, also 
known as biotyping.22,232 Profiling of protein biomarkers specific to a bacterial taxonomy 
by MALDI-TOF-MS was first performed by Claydon et al. and enabled reproducible and 
robust identification of gram-positive and gram-negative species.111 Since then, bacterial 
genera have been identified through various approaches from spectral mass 
fingerprinting, to more complex approaches that involve matching peaks identified in 
MALDI spectra to predictive masses from proteomic and genomic data sets.114,233 This in 
turn enabled the generation of reference protein databases that list biomarkers specific to 
different bacterial species.116 Combined with automated spectral acquisition and novel 
algorithms to tackle data analysis, biotyping has become a powerful, high-throughput tool 
for rapidly profiling bacterial genera in both academic and clinical settings.117 However, 
inter-lab studies revealed surprising discrepancies in E. coli fingerprints as experimental 
variables such as sample preparation and instrument parameters can affect spectral 
quality and reproducibility.234,235 Several studies have therefore scrutinised sample 
preparation methods for bacterial biotyping, looking at solvent extraction or direct analysis, 
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sample handling and also matrix choice affects spectra quality with the aim of developing 
a standardised method to enable universal identification of micro-organisms.236–238  
Whilst bacterial biotyping has been very successful and has become a standard tool in 
the clinic, profiling of mammalian cells by MALDI-TOF-MS has not yet reached this level. 
Characterising the protein and peptide signatures of mammalian cells by MALDI-MS is 
less common when compared with lipid analysis, however it has been used successfully 
for phenotypic screening of human cancer cell lines124, identification of cells within a co-
culture7 or tissues231 and detection of transient changes within a specific cell type, such 
as immune cells240. However, many of these studies list dramatically different 
experimental procedures with several being adapted from existing biotyping protocols. 
This huge range of experimental parameters could therefore be problematic for translation 
of published assays into the pharmaceutical industry or further research. Therefore, it 
would be of interest to develop a universal sample preparation workflow that can be 
utilised for multiple cellular analyses and is ultimately compatible with a high-throughput 
screening platform. 
4.2 Aims 
The aim of this chapter was to address the variation in experimental workflows for 
preparing mammalian cells for whole cell MALDI-TOF-MS analysis (Figure 4-1). 
Therefore, I systematically tested different conditions at key steps in the preparation and 
have validated a robust and sensitive sample preparation workflow suitable for high-




Heap, R. et al. Profiling embryonic stem cell differentiation by MALDI TOF mass 
spectrometry: development of a reproducible and robust sample preparation workflow. 
Analyst, (2019)241 
4.2.1 Sub-chapters  
1. Optimising of on-target concentration for protein and peptide mass fingerprinting. 
2. Systematic characterisation and evaluation of the efficacy of different sample 
preparation techniques. 
3. Identifying matrix suitability for whole mammalian cell analysis and liquid handling 
compatibility 
4. Profiling stages of embryonic stem cell differentiation by MALDI-TOF-MS 
4.3 Results 
My workflow for optimising a whole cell MALDI-TOF-MS preparation is depicted in Figure 
4-1, where I will explore different preparation steps in order to gain maximum cellular 
information and speed as well robust technical analysis. From previous studies, methods 
describing protein signatures in the m/z range 2000 – 20,000 have utilised several 
different parameters to discriminate cell phenotypes. These typically include common 
masses, features that differ in intensity, unique features or a shift between two peaks that 
are not baseline resolved that could indicate post-translational modification.126,127,129,242 
The developed method must be able to identify these types of distinguishing features 
clearly and I will use multivariate and statistical analyses to determine the features that 





Figure 4-1. Concept of a mammalian whole cell analysis workflow by MALDI-TOF-
MS highlighting missing information under sample preparation. 
4.3.1. Optimising of on-target concentration for protein and peptide mass 
fingerprinting. 
In order to optimise the sample preparation for whole cell MALDI-TOF-MS, I chose to work 
initially with four different human cell lines (U2OS, MCF7, THP1 and HEK293) (Figure 4-
2.A). These were chosen as they vary in morphology and biological function, but are all 
derived from human tissues, thus I hypothesised that there would be no species clustering 
bias. As a starting point, I initially followed the protocol described by Munteanu et al., who 
alongside other published studies report PBS washing to remove culture medium 
contaminants such as high levels of FBS and salts from the culture medium that could 
affect MALDI-TOF-MS ionization.240 The number of PBS washes used has varied from 
one to three depending on the authors’ experimental design, but my data indicated that a 
single initial PBS wash was sufficient to remove contaminants. This also significantly 
reduced sample preparation time. As the cell lines all vary significantly in size (Table 4-1), 
I sought to determine an optimal cell concentration, therefore a titration of 25 to 20,000 
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cells for each line was spotted on target. Unsurprisingly, the ionisation efficiency varied 
between the cell lines (Figure 4-2.B), and by taking the total spectral intensity, it was 
possible to identify an optimal on-target concentration from each cell line (Figure 4-2.B, 
C) (Table 4-1). This data shows that good signal and spectral intensity can be obtained 
from each cell line at a significantly lower number of cells than previously reported. We 
did also observe a narrow window where good spectra could be acquired, with large 
numbers of cells on-target proving to be detrimental to ionization. 
 
Table 4-1. Mean cell diameter measurements and optimal on-target cell number for 
MALDI-TOF-MS for each of the four cell lines with ± standard deviation. 
Cell line U2OS MCF7 THP1 HEK293 
Cell diameter (μm) 21.6 ± 1.4 18.1 ± 0.75 8.0 ± 0.25 16.9 ± 0.63 
Optimal cell number 250 500 1000 500 
 
To further understand the relationship between cell lines and their individual optimal 
concentration the total protein concentration was determined by a standard BCA assay. 
The relationship between number of cells and total protein concentration correlated well, 
validating our previous observation with cell number (Figure 4.2.D). Therefore, I 
determined the in-solution diameter of all four cells lines by bright-field light microscopy 
and when plotted against the optimal cell number these generated a linear relationship 
with a very good correlation of R2 = 0.99 (Figure 4.2.C). Taken together, these data show 
that to obtain optimal and reproducible spectra from mammalian cells by MALDI-TOF-MS, 
cell numbers on target need to be optimised and that this number is dependent on cell 
size / total protein concentration. This concentration can now easily be obtained by initially 
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measuring a cell populations diameter and calculating the on-target concentration with the 
equation described in Figure 4-2.C. 
 
Figure 4-2. Differences in MALDI-TOF-MS ionisation efficiency for each of the four 
cell lines. (A) Bright-field microscopy images of the four cell lines U2OS, MCF7, THP1 
and HEK293. (B) Ionisation profiles of the four cell numbers generated from spectral 
intensity at 25 – 20,000 cells on target. (C) Correlation plot of optimal cell number on-
target derived from (B) and each cell line’s in-solution diameter measurement where error 
bars represent ± standard deviation from the mean. (D) Correlation plot of total protein 




4.3.2. Systematic characterisation and evaluation of the efficacy of different sample 
preparation techniques. 
I next determined whether lysis of cells enhanced the occurrence of unique mass features 
over intact cells. Employing harsh acidic lysing conditions resulted in spectra that were 
less distinguishable, which has also been observed by lysing with increasing acidity.242 As 
well as this, strong lysing conditions such as mechanical disruption often resulted in a 
viscous solutions from the cellular DNA that was difficult to handle and would not be 
compatible with liquid handling robots. It was previously shown for bacterial culture 
analysis that mild lysis by freeze-thawing of cell pellets prior to MALDI-TOF-MS analysis 
was beneficial with respect to the number of features identified and overall spectral 
intensity.235,238 I therefore decided to test whether a freeze/thaw cycle improved MALDI-
TOF-MS analysis of mammalian cell lines and whether freezing before or after the initial 





Figure 4-3. Comparison of three freeze/thaw techniques for MALDI-TOF-MS 
analysis of mammalian cells. (A) Graphical representation of the three freeze/thaw 
strategies employed to test efficacy of this sample preparation method. (B) Number of 
features identified for each cell line with each strategy described in (A) and a S/N >4. (C) 
Trypan blue staining with each strategy described in (A) to determine the percentage cell 
membrane permeability for each cell in. In all cases error bars represent ± standard 
deviation from the mean over six technical replicates. 
Both strategies of freeze/thawing permeated the cell membrane of about 50-80% of the 
cells (Figure 4-3.C). This led to a significant increase in the number of peaks detected 
compared to “intact” cell samples within the m/z range of 2 – 20 kDa (Figure 4-3.B). As 
well as this, software analysis did not result in a significant difference between cells frozen 
before or after further treatment and manual inspection of spectra resulted in the same 
conclusion. Therefore, it was concluded to include a freeze/thaw cycle within the sample 
preparation method. However, the specific order in which this step was performed, did not 
affect the final readout. 
Many protocols for both bacterial and mammalian cell analysis by MALDI-TOF-MS utilise 
specific solvents to extract and analyse biomolecules of interest.243,244 This work has been 
particularly successful for lipid analysis, where solvent extraction can efficiently isolate 
lipids from cells.245 However, for our particular study, where I aimed to look at peptide and 
protein features, these methods were unsuitable. I therefore I applied two cell and tissue 
fixing techniques and evaluated their efficacy for preparation of mammalian cells for 
MALDI-TOF-MS analysis. Initially, I employed formaldehyde and methanol fixing 
methods, as they have been used previously in MALDI imaging workflows.246,247 In brief, 
cells pellets were thawed and resuspended in ice cold methanol or 4% PFA at 4°C for 
fixation before subsequent preparation steps. The resulting mass spectra revealed that 
samples treated with 4% PFA generated spectra were 5 – 10x less intense than other 
127 
 
methods and was therefore excluded from further work. Consequently, I systematically 
evaluated how both methanol fixing and PBS washing performed with respect to the 
number of identified peaks, quality of the acquired spectra, as well as technical 
reproducibility when analysed by MALDI-TOF-MS (Figure 4-4). 
Each of the four cell lines could be distinguished by both manual spectra interrogation and 
principle component analysis (PCA) of mass spectra intensities after methanol and PBS 
washing steps (Figure 4-4. A-F). Each method was able to generate a unique set of peaks 
for each of the four cell lines, thus allowing classification of the different populations. 
Phenotype distinguishing peaks were often not the most intense or abundant peaks and 
were identified with a lower S/N and intensity than the base peak, thus were less likely to 
be quantified accurately. Therefore, I plotted the relative intensity distribution of the top 10 
most intense peaks for each cell line (Figure 4-4. G&H). Both PBS washing and methanol 
fixation showed a generally even intensity distribution for each cell line. Finally, and 
arguably most importantly, I tested how reproducible peak detection was over six technical 
replicates (Figures 4-4. I&J). Methanol was the most consistent, with the majority of all 
peaks being detected in all six spectra, whereas PBS was slightly more variable. Taken 
together, this data suggests that methanol fixation is comparable to PBS washing for 





Figure 4-4. Technical reproducibility of MALDI-TOF-MS sample preparation 
methods. (A & B) Number of detected unique features for any of the four cells after 
methanol fixation (A) and PBS washes (B). (C & D) PCA plots showing how multivariate 
analysis can distinguish each of the four cell lines after methanol fixation (C) and PBS 
washes (D). (E & F) Number of peaks detected for each cell line over six technical 
replicates where error bars represent ± standard deviation from the mean. (G & H) 
Relative intensity distribution of the top 10 peaks detected over six technical replicates for 
each cell line. (I & J) Pie charts displaying the % of peaks detected within each of the six 
replicates per cell line. 
4.3.3. Identifying matrix suitability for whole mammalian cell analysis and liquid 
handling compatibility 
Next, I evaluated which type of matrix allows for the best MALDI-TOF-MS analysis of 
mammalian cells.  Each cell line sample was prepared with one of the three most common 
peptide and protein matrices: saturated sinapinic acid (SA), α-cyano-4-hydroxycinnamic 




Figure 4-5. Classification of mammalian cell lines by MALDI-TOF-MS multivariate 
analysis. (A) PCA plots showing unique groupings for each of the matrix conditions and 
(B) Venn diagrams showing unique and common peaks detected for each of the four cell 
lines (U2OS, MCF7, THP1, HEK293) over six technical replicates. 
Significantly different mass profiles of the same cell line were observed. Using DHB matrix 
resulted in more variable spectra over technical replicates, with the PCA analysis showing 
wider distances (Figure 4-5. A). Moreover, unique peaks could be assigned to each of the 
matrices, which indicates that different biomolecules are being ionised and mammalian 





Figure 4-6. Impact of matrix choice on MALDI-TOF-MS ionisation of whole 
mammalian cells. (A) Dependence of matrix concentration from 2.5 – 30 mg/mL 
(saturated) on number of peaks detected for each of the four human cell lines and three 
matrices. (B) Laser power dependence of each of the three matrices for each of the four 
cell lines. Non-linear regressions were fitted with a sigmoidal, 4PL curve with good fits of 
R2 >0.85 – 0.99. All error bars are given as ± SD over six technical replicates. 
I then evaluated how each matrix performs with respect to concentration and increasing 
laser power. In all four cell lines, CHCA performed significantly better with respect to both 
parameters (Figure 4-6). Following this, I observed that CHCA matrix was also able to 
ionise cellular biomolecules at much a lower laser power than DHB and SA. I was able to 
fit non-linear curves to these data, thereby identifying optimal minimal laser power and 
approximate saturation points of each matrix (Figure 4-6. A). From these values, the fold 
change in laser power necessary to achieve an optimal sample acquisition could be 
determined between each matrix. A laser power of 60% corresponded to a laser energy 
fold change of 1.74x and 2.30x for 80% (DHB) and 90% (SA), respectively when 
compared to CHCA.  
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I pursued this study further to understand the dynamics of matrix behaviour with fixed cells 
in a mock screen MALDI plate and evaluate performance across a 1536 target. THP-1 
cells were then mixed with each matrix using a Mosquito HTS and spotted in 200 nL 
aliquots. Each target was then analysed at the approximate saturation points described 
previously. From manual inspection as well as a positive MALDI response in which peaks 
could be detected at a S/N >3. A spotting accuracy of >96% could be achieved for each 
target and matrix using the Mosquito HTS spotting robot (Figure 4-7. A). This infers that 
methanol-fixed whole-cell samples are compatible with current liquid handling 
technologies, as well as MALDI TOF-MS.  
 
Figure 4-7. Mock screening plate demonstrates that CHCA is the preferable choice 
for MALDI-TOF-MS analysis of mammalian cells. (A) Mosquito spotting accuracy 
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determined by achieving a spectra where peaks could be detected with a S/N >3 in 
addition to manual inspection for each of the matrices. Percentage of 1536 spots. (B) 
Percentage peak detection of the top 5 most intense peaks over a 1536 target for each of 
the three matrices. (C) Frequency distribution of the top 5 most intense peak intensities of 
a 1536 target for each of the three matrices bin width = 0.1. (D) Violin plots showing 
distribution of the signal-to-noise of the top 5 most intense peaks over a 1536 target for 
each of the three matrices. Solid lines indicate median values and dotted lines the upper 
and lower quartiles. 
Using the top five most intense features for each matrix preparation I was able to show 
that these were detected in >98% of spots for CHCA and SA, thus showing robustness 
for screening. Samples spotted with DHB matrix were much more variable and therefore 
had poorer repeat peak detection (Figure 4-7. B). Overall spectral intensity based on the 
top five peaks as well as signal to noise varied significantly between the three matrix 
conditions (Figure 4-7. C&D). Samples spotted with CHCA exhibited much greater 
spectral intensity compared to SA, and an almost 10-fold increase when compared with 
DHB (Figure 4-7. C), as well as significantly better S/N for these top 5 features (Figure 4-
7. D). Interestingly, we observed different lens contamination patterns for each of the three 
matrices after accumulation of 3072 individual spectra with each matrix, although this did 
not negatively impact analysis. From this data, I concluded that CHCA would be the matrix 
of choice for whole cell analysis at a small and large scale due to its superiority across the 
parameters discussed above. Together, these results show how phenotyping cells by 
MALDI-TOF MS using the final optimised method (Figure 4-8) can be scaled up to a high-




Figure 4-8. Final optimised workflow for mammalian whole cell analysis by MALDI-
TOF-MS. In brief, cells in culture are first harvested, washed once with PBS and snap 
frozen. Pellets are then thawed and either fixed with methanol or washed 1x with PBS. 
Cells are then resuspended in 0.1% TFA to the desired concentration and spotted with 
CHCA matrix either manually or with liquid handling instruments. Described fully in 2.2.3.4. 
4.3.4 Profiling stages of embryonic stem cell differentiation by MALDI-TOF-MS 
To validate the complete workflow the sample preparation method was applied to profile 
cells in a physiologically relevant system that is employed in drug screening and toxicity 
testing and that has been used as a drug discovery model.248,249 Murine embryonic stem 
cells (mESC) were utilised as they can be maintained in a naïve ground state pluripotency 
using the 2i kinase inhibitor system (PD0325901 and CHIR99021), which inhibit the 
kinases ERK1/2 and GSK3, respectively (Figure 4-9. A).250,251 Efficient exit from this naïve 
ground state pluripotency towards differentiation upon 2i release is achieved by removal 
of the kinase inhibitors from culture resulting in distinct morphology differences (Figure 4-
9.C). This results in two populations derived from a single mouse. These cells were 
prepared by Anna Segarra-Fas (University of Dundee) who also confirmed the 2i release 




Figure 4-9. Performed by Anna Segarra-Fas Classification of mESC populations. (A) 
Schematic showing the differentiation of naïve mESCs upon removal of the two kinase 
inhibitors (2i). (B)  qPCR data showing changes in key mESC pluripotency and 
differentiation genes. (C) Light microscopy image showing the morphological change in 
naïve mESCs upon 2i release after 1 and 2 days. Error bars represent standard deviation 
of 2 technical replicates from 3 biological replicates. *** and **** represent p<0.001 and 
p<0.0001, respectively, student’s t-test.  
 
Using MALDI-TOF-MS, I could robustly identify unique features to each population, as 
well as quantify changes in common peaks. For all spectra, the base peak was identified 
at m/z 4875, which made subsequent analysis simpler, as the raw spectral intensity can 




Figure 4-10. Representative MALDI TOF spectra of each of the three individual 
biological replicates for 2i and 2i release cell populations. 
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It was possible to use the relative intensity of each peak in the spectra as the base 
peak was identical in all spectra at m/z 4875, which I used for normalisation. A 
heatmap was generated using Z-score averaging (Figure 4-11A) where the averaging 
was performed by row and involved the mean value of each row being subtracted 
from the individual value. This value is then divided by the standard deviation of each 
row to generate a normalised expression matrix and a normal distribution for the 
population. Each Z-score value represents how many standard deviations a given 
value is away from the mean relative intensity for that particular m/z value. This 
enabled us to look at more subtle changes within the total data set and identify 
features that differentiate masses of the two phenotypes, whose relative intensity 




Figure 4-11. MALDI-TOF-MS analysis of naïve and pluripotent mESC 
populations. (A) Z-score heat map showing how each normalised peak intensity 
changes with respect to 2i and 2i release condition over three biological and five 
technical replicates. (B) Selected examples of mass spectral regions that showed 
changes between mESCs cultured in 2i and 2i release conditions where the base 
peak (m/z 4875) is of identical intensity, thus allowing relative intensity comparison. 
For robustness, data were first filtered to include features that were identified in at 
least 30% of all technical replicates. The hierarchical clustering approach allowed us 
to look at the unique and common features combined across all independent 
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biological and technical replicates. The three biological replicates clustered well 
together and 2i and 2i release conditions were separated efficiently and two discrete 
row clusters emerged – peaks that were up-regulated and those that were down-
regulated upon release from PD0325901 and CHIR99021 inhibitors. This was 
determined to be significant by a hierarchical dendrogram using bootstrapping 
(performed by Alasdair Blain, Newcastle University). This generated scores >95 for 
the two conditions, thus considered significant separation.  
Finally, using multivariate analysis, 2i and 2i release conditions could be well 
differentiated as two populations by PCA (Figure 4-12.A & B) and we observed good 
grouping of biological replicates. A similar distribution was identified when using a 
jackknife method performed by Alasdair Blaine which is a resampling technique that 
estimates variance and bias within a dataset (Figure 4-12.C).  
 
Figure 4-12. Multivariate analysis of mESCs analysed by MALDI-TOF-MS. (A) 
PCA plot of the biological and technical replicates of 2i vs 2i release filtered MALDI-
TOF-MS data showing separation of the two phenotypes. (B) loadings plot 
corresponding to (A) showing the m/z values that contribute most to the separation of 
the two cellular phenotypes. (C) Performed by Alasdair Blair: Jackknife statistical 
analysis of the MALDI-TOF-MS enables distinct clustering of the two phenotypes 
similar to that shown in (A).  
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Analysing the loading plot of the PCA clustering identified the same features shown 
in Figure 4-11.B. to be driving the majority of the separation.  
Taken together, in this data set several peaks were identified that changed 
significantly in intensity between the conditions by manual inspection, Z-score 
averaging and PCA analysis. These mass features can now be used as features of 
phenotypic screening of mESC differentiation. The analysis workflow was validated 
by Alasdair Blain, who performed independent statistical analysis to recreate the 
heatmap and PCA showing very similar data. Consequently, this confirms that the 
optimised MALDI-TOF-MS sample preparation method described in this chapter is 
suitable for phenotypic screening of different cell types. 
4.4 Discussion 
Due to its speed and relative simplicity, MALDI-TOF-MS has become increasingly 
popular for bacterial biotyping in clinic. Classification of cellular phenotypes by protein 
and peptide fingerprinting using MALDI-TOF-MS has been well described for 
discriminating prokaryote genera, however these methods have never truly been 
translated into mammalian cell phenotyping. Several applications for discriminating 
mammalian cell cultures by analysing their protein and peptide mass fingerprints have 
been reported such as discriminating cancer cell lines124, profiling of immune cells240 
and identifying cells in a co-culture.127 However, the methods presented are 
significantly different with some using protein extraction over direct analysis, and all 
utilising very different matrix compositions and preparations. Furthermore, some of 
the methods described would not be suitable for more automated analysis and 
therefore more throughput screening applications would not be possible. 
Consequently, there is a need for a universal method for sample preparation of whole 
mammalian cell samples for MALDI-TOF-MS analysis that enables robust, sensitive 
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and reproducible classification of cell phenotypes. In this study, I have used four 
human cell lines to systematically test various sample preparation techniques, thereby 
determining which ones are most technically robust and yield maximum information. 
Further to this, I validated the final optimised method with established liquid handling 
techniques to ensure compatibility for screening and finally applied the method to 
profile mESC differentiation. 
4.4.1. Optimisation of a robust and sensitive MALDI-TOF-MS sample 
preparation method for whole mammalian cell analysis  
By utilising the four human cell lines U2OS, MCF7, THP1 and HEK293, I was able to 
test several different sample preparation strategies to assess grouping of cell 
phenotype without species bias. Firstly, by titrating the cells from a very high number 
to a low number of cells, I could identify that each of the four cell lines had an optimal 
number of cells on target for MALD-TOF-MS analysis as well as their individual limits 
of detection. This was determined over six technical replicates utilising total spectral 
intensity and, unexpectedly, there was a significant drop in signal intensity at high cell 
numbers. This could be explained by the matrix: cell ratio resulting in inefficient 
ionisation, poor spot crystallisation or the total intracellular salt content of the cells.  
A good linear relationship between total protein content and overall spectral intensity 
was observed and indicates that protein concentration could be used to calculate an 
optimal on-target cell concentration of an unknown cell population. However, as this 
approach is indirect and requires a significant number of cells it adds time and extra 
sample loss to the workflow which isn’t favourable for screening assay development. 
Therefore, I aimed to develop a simple and fast method to determine this important 
parameter and evaluated cell diameter as an alternative measurement that can be 
performed without sample loss. Plotting the in-solution diameter against optimal 
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concentration a linear correlation was generated with very good R2 >0.99, thus the 
equation derived from the linear regression could be used to estimate on-target 
MALDI-TOF-MS cell concentration based on the cellular diameter.  
I then established that the use of a mild lysis method by freeze/thawing of cell pellets 
significantly increased the number of features detected by MALDI-TOF-MS for all cell 
lines. This is likely due to the permeabilization of the cell membrane enabling intra-
cellular biomolecules to be more available for ionisation. I found that this lysing 
method was preferable to harsher lysing conditions such as sonication or use of 
detergents and salt buffers, as this often leads to viscous sample solutions due to 
release of nuclear DNA. It has also been reported that high concentrations of acids 
such as TFA results in spectra that are indistinguishable and an individual cell 
populations phenotype is lost.242 These harsh lysis conditions likely result in the 
exposure of cellular components that are very abundant in most cell types, such as 
actin or histones, which in turn dominate the spectra and supress signals that may 
discriminate phenotypes. A freeze/thaw step was evaluated as a mild lysis step at two 
stages of the sample preparation workflow and there was no significant difference in 
ionisation or number of features identified. This was important to establish as it could 
be possible that distinguishing features of cell phenotype may be lost by washing of 
permeabilised cells. However, these data show that there is no loss of characteristic 
biomolecules and can therefore be used interchangeably depending on the specific 
application. For example, it is particularly important to preserve cell populations where 
transient and subtle phenotypes may be lost during sample preparation. Therefore, in 




Inclusion of an extraction step or solvent wash has been described for bacterial 
biotyping as well as analysis of lipids isolated from mammalian cells. However, for 
acquisition in the protein/peptide region for our analyses extraction was not suitable. 
For example, chloroform-methanol precipitation from cellular samples resulted in a 
large protein pellet, but subsequent mass spectrometry analysis resulted in little to no 
information in the mass region of interest. Therefore, I took inspiration from cellular 
fixing techniques to test whether this would preserve a cellular phenotype and extract 
some metabolites and/or lipids to reduce the complexity of the sample and improve 
MALDI-TOF-MS signal. Fixing with PFA resulted in significantly lower signal intensity 
compared to PBS washes, which is not necessarily surprising as there is some 
controversy about its use in MALDI imaging studies.252 However, evaluation of cellular 
phenotype and technical reproducibility showed that methanol fixation was a 
comparable sample preparation alternative to PBS washing if not superior in some 
respects.  
Finally, I evaluated the three most common matrices for protein and peptide analysis 
for whole mammalian cell analysis as the origin of the biomolecules being ionised is 
often unknown. As hypothesised, the choice of matrix had a significant influence on 
the resulting mass spectrum. Each matrix generated a different spectral fingerprint 
with unique peaks for each of the four cell lines that could be separated by distinct 
PCA clustering. Samples spotted with DHB showed the most heterogeneity, where in 
some cases such as MCF7 multivariate analysis distances between technical 
replicates were too wide to enable efficient grouping. This is somewhat expected as 
DHB crystallises into long, needle-like structures that produce a heterogeneous 
surface that causes significant spot to spot variation. As well as this, there was a 
matrix dependent effect with respect to increasing laser power and concentration. 
Each matrix performed optimally at a saturated concentration, however CHCA was 
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able to yield much more informative spectra and identified more features at a third of 
the concentration of DHB and SA. This was also the case with increasing laser power, 
where a two-fold lower minimum laser input was required to reach the same number 
of features with versus DHB. This observation was somewhat expected for detecting 
ions by UV MALDI-TOF-MS as it has been shown by the performance of a matrix is 
dependent on its optical absorbance coefficient (α).253 Allwood et al. demonstrated 
that CHCA has a particularly high α in the UV wavelength region of 300-400 nm 
compared to DHB and SA.253 These results have since been elaborated where a 
quantitative solid state study of matrices including CHCA and DHB further highlight 
the discrepancies in the optical absorption and optical cross section of different 
matrices with respect to variable laser fluences and wavelength.254 Here, CHCA was 
also shown to have a significantly greater optical absorbance and cross section 
compared with DHB in their chosen UV absorbance range (200-500 nm). As the 
RapifleX employs an Nd:YAG laser that operates at a 355 nm wavelength, the matrix 
optical properties likely explain the discrepancies I observed with the minimum laser 
energy requirements of CHCA, DHB and SA. Taken together, this indicates that the 
features observed in the mass spectra are likely to be peptidic or small proteins, as 
they ionise more efficiently with either CHCA or SA. However, it is important that for 
masses greater than >10,000 Da, peak resolution is significantly improved by using 
SA and therefore may have a role to play in studies that identify significant features 
in this mass range.  
Compatibility of the workflow for screening was validated with current liquid handling 
robots and performance of a mock-assay MALDI target with all three matrices. This 
data confirmed the previous observations that CHCA is most suitable for screening 




4.4.2 Differentiating embryonic stem cell phenotypes by MALDI-TOF-MS 
This method has shown to be successful for phenotypic profiling of diverse cell lines, 
however it was necessary to assess its potential for distinguishing subtle phenotypes. 
Therefore, the optimised sample preparation was used to phenotype the naïve and 
pluripotent stages of differentiation of mESCs. The transition from naïve to 
differentiated is tightly controlled by removal of kinase inhibitors from the naïve culture 
and Anna Segarra-Fas provided validation data for the two cellular phenotypes with 
a standard qPCR approach. Using MALDI-TOF-MS, over 100 features were identified 
for both cell states and after filtering for reproducibility 66 were utilised for 
phenotyping. Interestingly, from multivariate analysis the loading plot indicates that 
most of the loading values lie closer to the 2i release grouping, thus indicating a 
noticeable shift from the naïve state to the pluripotent. Furthermore, a number of 
features were identified that significantly influence the separation of these two stem 
cell populations that was then validated by independent statistical analysis. 
Consequently, this demonstrates the suitability of MALDI-TOF-MS for studying subtle 
phenotypes that is highly consistent with genomic analysis. 
Ultimately the work presented in this chapter describes a systematic study that 
explores initial sample handling, matrix choice and suitability of methanol fixing with 
whole cell MALDI-TOF-MS analysis. All three steps were found to have a profound 
impact on the resulting mass spectra and were evaluated by not only spectral quality 
and observable changes but also technical performance over replicate spots. This 
has resulted in a technically robust and reproducible workflow that is suitable for liquid 
handling with commercially available automated systems. This is due to the inclusion 
of mild lysis and extraction or fixing steps that ensures a non-viscous sample solution 
which is suitable for pipetting small volumes and is compatible with multiple matrices. 
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For application to high throughput screening assay, the assay could be miniaturised 
as automated centrifuges and cell culture systems could be used as only a small 
number of cells are required. However, the inclusion of the freeze/thaw step could 
prove problematic for automated studies as this is not routinely employed in a high 
throughput workflow and would require specialised input. 
This method has multiple potential applications for biological studies and determining 
cell phenotype.  For example, qualifying cell line validity is incredibly important as it 
has been shown previously that there has been use of misidentified or cross 
contaminated cell lines across multiple institutes that could compromise biological 
studies.255 Typically, this analysis is performed by genome sequencing and is time 
consuming and expensive, therefore MALDI-TOF-MS analysis could be a viable 
alternative for qualifying cell phenotype against a validated spectral fingerprint. 
Furthermore, as this method is sensitive to transient phenotypic shifts there could be 
application to monitoring cell viability over multiple passages to ensure that studies 
are performed with cells of the same phenotype. As well as this, the basic premise of 
this method could prove versatile for future applications to lipids or metabolites for a 
specific cellular phenotype which could then be extended to MALDI imaging studies 
to identify cells in tissue. Taken as a whole, this novel sample preparation method is 
more sensitive to cell number than previously described methods and that enables 
robust, reproducible and rapid profiling of mammalian cells and is suitable for a wide 




Chapter 5. A cell-based MALDI-TOF-MS assay for 
identifying inhibitors of inflammation 
5.1 Introduction 
Cell-based assays make up one of the corner stones of drug discovery and have long 
been used throughout the development pipeline to characterise compounds.256,257 
Cellular assays have been shown to be more reliable at predicting in-vivo effects of 
compounds over biochemical assays at early stage drug discovery as the small 
molecule inhibitors often exhibit different activity in a cellular context.258 Further to 
this, recent studies have been able to distinguish small molecule target interaction 
and differentiate between agonists, antagonists and allosteric inhibitors.259–261 This 
information was previously limited to biochemical reactions that can deduce a 
compound’s regulatory action through kinetic measurement of protein-compound 
interactions. A strength of cellular assays is that they provide more biologically 
relevant information on a cell’s overall physiology and state. The most common 
readouts are compound toxicity, cell morphology, cell surface marker expression, 
proliferation and gene transcription. One of the appealing qualities of these types of 
assays for pharmaceutical industries is that more than one of these readouts can be 
acquired in a single cellular screen, such as cell viability and protein activity.262 This 
simultaneous acquisition of information is known as multiplexing and is desirable in 
cellular assays as it significantly increases the efficiency of compound library 
screening.  
Most cellular assays utilise either second messenger, reporter genes or 
proliferation/cytotoxicity assays as readouts for cell state and characterising drug 
characteristics.258 However, there are significant pitfalls with these approaches as 
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frequently assay readouts are based on downstream effects of initial signal-
transduction and the target protein. This is as often the case with reporter gene 
expression, as mRNA levels do not always correlate linearly with protein expression 
levels, and vice versa.263 Methods for quantifying cellular activity are numerous, with 
the majority either exploiting mechanical and physical properties of cells, quantifying 
bioluminescence or integrating a fluorescent probe at a region of interest. For 
example, luciferase activity and subsequent bioluminescence is a common biosensor 
readout for secondary messenger assays,264 whereas incorporation of fluorescent 
probes like GFP are popular for cellular FRET assays that assess protein-protein 
interactions.265 Despite success in the HTS field, these reporter-based assays can be 
prone to formation of artefacts, non-native protein interactions and activity due to 
genetic engineering, which in turn compromises cell physiology.256 Consequently, 
there is a growing desire for label-free cellular assays. However, despite these 
approaches showing potential they yet lack specificity and require further exploration 
before being implemented in drug discovery workflows.266  
Inflammation is a core host response that is typically triggered by invading pathogens 
or endogenous host signals arising from cell damage or pathology that activates the 
innate immune response. This has led various new avenues of drug research, such 
as combined therapies targeting both unregulated host inflammation and tumour 
growth267 and potent suppressors of dysregulated inflammation in sepsis.268. Cellular 
assays for identifying inhibitors of inflammation have been reported269–271, but are yet 
to rise to the forefront of drug discovery. This could be due to the complexity of the 
specific signalling pathways and mechanisms that drive a pro-inflammatory 
phenotype. New connections and molecular cross talk between inflammation and 
existing diseases such as cancer, diabetes and autoimmune diseases are on the rise, 
thus making assay design complicated for even conventional cellular assays. Despite 
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the complexity of inflammatory signalling, the overall pro-inflammatory phenotype of 
macrophages is well described and could be used to assay the anti-inflammatory 
potential of compound collections. This concept would allow the development of a 
label-free cellular based assay that does not measure a specific drug-target 
engagement, but rather measures a cellular phenotype. This could be performed in 
response to drugs and various pro-inflammatory stimuli and could be complimentary 
to well established biochemical assays.178  
Monocytes and macrophages are key players in the innate immune response and 
often form the first line of defence against invading pathogens. These myeloid cells 
are highly plastic and their function is closely related to their tissue localisation and 
surroundings that can induce an active pro-inflammatory phenotype and are therefore 
very attractive candidates for cellular assays.167,272 Pathogen-associated molecular 
patterns (PAMPs) such as bacterial ligands and viral DNA can be sensed by 
membrane receptors such as Toll-like Receptors (TLRs) and initiate the production of 
pro-inflammatory cytokines such as TNF-α, IL-6, IL-1, IL-12 and type one 
interferons.151 Tumour necrosis factor alpha (TNF-α) is a particularly potent cytokine 
primarily secreted during acute phase inflammation and is considered a central player 
in pro-inflammatory signalling.273 Its primary role is to regulate immune cells through 
TNFR1 and TNFR2 signalling that induces a variety of cell responses ranging from 
proliferation, differentiation, pro-inflammatory activation and apoptosis or necrosis 274. 
Despite being key for maintaining normal homeostatic mechanisms in the face of 
pathogenic invasion, acute or sustained overexpression of TNF-α can lead to 
significant dysregulation of the host immune response.275 Acute TNF-α secretion has 
now been closely linked to fatal septic shock, as well as one of the principal causes 
of the pathogenesis observed in autoimmune diseases such as Crohn’s disease, 
inflammatory bowel disease (IBD) and rheumatoid arthritis.276–278 Several successful 
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treatments have been developed such as antibody based therapies279,280, however 
the discovery and design of new small molecule compounds for inhibiting cellular 
TNF-α secretion or an inflammatory phenotype are typically limited by the high 
throughput methods currently available. Therefore, there is a growing need in the field 
of suppressing dangerous levels of inflammation to develop assays that can be high 
throughput and accelerate the discovery of inhibitors that tackle acute TNF-a 
secretion and pathogenesis.281,282  
5.2 Aims 
In this thesis thus far, I have demonstrated how MALDI-TOF-MS can be utilised for 
screening for anti-inflammatory compounds and cellular phenotypes. Therefore, in 
this study I combined these two concepts to develop a MALDI-TOF-MS assay that 
can quantify a pro-inflammatory phenotype and is capable of screening for anti-
inflammatory compounds. Finally, I validated this assay by ELISA quantification of 
TNF-α secretion where the data showed striking similarities and correlation to the 
MALDI-TOF-MS assay. 
5.2.1 Sub-chapters 
1. Quantifying and determining specificity of a pro-inflammatory THP-1 phenotype by 
MALDI-TOF-MS. 
2. Reversing the pro-inflammatory phenotype with known inhibitors. 
3. Identifying inhibitors of inflammation with a 78 compound screen against LPS 




5.3.1 Quantifying and determining specificity of a pro-inflammatory phenotype 
by MALDI-TOF-MS. 
My first aim of this study was to determine whether it was possible to distinguish a 
pro-inflammatory phenotype in THP-1 monocytes by whole cell MALDI-TOF-MS. For 
the initial assay, I proceeded by stimulation of THP-1 monocytes with 
lipopolysaccharide (LPS) derived from Salmonella. After 24 hrs of incubation with 1 
µg/mL of LPS, cells were then processed in following with an adapted method from 




Figure 5-1. Workflow of whole cell MALDI-TOF-MS sample preparation of THP-
1 monocytes. Distinguishing a pro-inflammatory phenotype from resting or inhibitor 
treated cells (2.2.3.5). 
In brief, LPS-treated or untreated THP1 cells were harvested by scraping, pelleted 
and then snap frozen to perturbate the cell membrane and stored at -80°C until 
required for analysis. Thawed pellets were then washed once in an aqueous Tris 
buffer at 4°C to remove residual contaminants and background signals before 
resuspension in Tris buffer at a final concentration of 5000 cells/µL. 2500 cells were 
spotted on target with α-cyano-4-hydroxycinnamic acid (CHCA) matrix in either 
sandwich or dried droplet method onto a 384 or 1536 AnchorChip target depending 
on manual or automated analysis respectively. This workflow (Figure 5-1) enabled 
disruption of the cellular membrane and release of intracellular biomolecules for 
greater feature detection without full cell lysis that can result in release of DNA and a 
viscous sample solution that is problematic when handling small sample volumes. 
Spots were then analysed by MALDI-TOF-MS in positive ion linear mode in the m/z 
range 2000 – 20000 and data was acquired at approximately 2 seconds per spot and 
acquiring 10,000 laser shots per spot with typical spectra for untreated and LPS 
treated monocytes shown in Figure 5-2.A. From initial inspection of individual spectra, 
I observed differences in peak intensity between the two conditions and when the 
biological and technical replicates were combined in a relative peak intensity 
heatmap, it was possible to visualise and distinguish intensity-based differences 
between the two phenotypes. Both the untreated and LPS treated conditions 
separated into two distinct populations across three biological replicates. There was 
some difference from LPS1 to 2 and 3, but the trends in protein intensity remained 
similar. Furthermore, the reproducibility between technical replicates was very good, 
thus demonstrating that the sample preparation method is robust and reproducible. 
152 
 
From this data set I identified three features at m/z 4632, 4964 and 6891 that altered 
significantly in their abundance between untreated and LPS treated (Figure 5-2.C).  
 
Figure 5-2. Analysis of pro-inflammatory stimulated and resting THP-1 
monocytes by MALDI-TOF-MS. (A) Representative spectra of untreated controls 
(UT) and LPS treated THP-1 monocytes. (B) Relative intensity heat map of three 
biological and four technical replicates of untreated and LPS treated monocytes 
showing significant separation of the two phenotypes. (C) Box plots of significantly 
changing intensities between untreated and LPS-treated monocytes identified at m/z 
4632, 4964 and 6891. (D) Representative spectra of untreated and LPS-treated 
monocytes in the m/z range 4500 - 5000 and relative quantitation between the two 
features normalised to LPS treated conditions. Error bars represent standard 
deviation of 3 biological replicates that were each mean averaged from three technical 




The relative intensity of these features alone was enough to distinguish resting and 
pro-inflammatory monocytes, but I aimed to develop an intra-spectral method to 
quantitatively measure the pro-inflammatory response to avoid any spot-to-spot or 
shot-to shot variation. I therefore sought to combine the intensity change in the two 
significant features at m/z 4964 and 4632 as biomarkers of the two phenotypes. Both 
these features were identified in all spectra, and their signal-to-noise and resolution 
was above the 75% percentile, thus they were robust features for classifying the two 
phenotypes. I chose to develop a ratiometric quantification approach using the two 
peak areas that was then normalised to the positive control as a read out as described 
in the equation below (Figure 5-2.D). Using this method, the phenotypic shift could be 
measured robustly when applied to LPS and untreated cells and it was possible to 
quantify a phenotypic shift in the assay with a significant p-value <0.0001. This 
method of intra-spectra quantification was robust over ten cell passages, where I was 
able to quantify the pro-inflammatory MALDI-TOF-MS response with a Z’ >0.5 and a 
p-value <0.001.  
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To determine assay specificity and further understand the biology underpinning the 
pro-inflammatory response I tested a variety of different pro-inflammatory stimuli that 
cover a broad range of pro-inflammatory signalling receptors such as TLRs and 
interferon receptors (Figure 5-3). Each of these stimuli are derived from either 




Figure 5-3. Determining MALDI-TOF-MS assay stimuli specificity. The five stimuli 
used to treat THP-1 monocytes and their relative receptor proteins that initiate either 
the pro-inflammatory or type-1 interferon response. 
THP-1 monocytes were therefore incubated with the stimuli to yield six different 
experimental conditions: Pam2CSK4, Pam3CSK4, LPS, interferon gamma (IFN-γ) 
and the viral ligand Poly(I:C) with and without prior incubation of the dsRNA with the 
transfection reagent Fugene to form artificial liposomes that can cross the plasma 
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membrane (Figure 5-3). From initial spectral analysis Pam2CSK4 and Pam3CSK4 
were more similar in peak intensity distribution to LPS treated monocytes over the 
untreated condition (Figure 5-4.A). Conversely, IFN-γ treatment resulted in spectra 
that more closely resembled untreated monocytes (Figure 5-4.A). Surprisingly, 
Poly(I:C) did not result in a pro-inflammatory phenotype by MALDI-TOF-MS with or 
without transfection, which was unexpected as it is reported to initiate both signalling 
pathways once it has crossed the plasma membrane (Figure 5-3). Visualisation of the 
data by a relative intensity heat map (Figure 5-4.B) and Euclidian clustering enabled 
clear separation of the bacterial ligand treated samples and the IFN-γ and untreated 
conditions within the column dendrogram over three biological repeats. Taken 
together, this data infers that the measured MALDI-TOF-MS response is due to 
specific engagement and activation of plasma membrane TLRs, which in this case 






Figure 5-4. MALDI-TOF-MS assay phenotype is induced by bacterial ligand 
stimulation. (A) Representative MALDI-TOF-MS spectra of untreated (UT) and IFN-
γ, LPS, Pam2CSK4, Pam3CSK4 treated THP-1 monocytes. (B) Relative intensity 
heatmap of three biological replicates of LPS, IFN-γ, Pam2CSK4 and Pam3CSK4 
treated THP-1 monocytes showing significant separation of bacterial ligand treated 
monocytes compared to IFN-γ and untreated monocytes. Each biological replicate is 
a mean averaged value of three technical replicates. 
Using the equation described previously, the relative peak area of m/z 4632/4964 
enabled quantitation of the pro-inflammatory response for each stimulus condition. 
Here, LPS appears to be a more potent instigator of the pro-inflammatory response 
over Pam2CSK4 and Pam3CSK4, who generated a readout of 75% and 80% 
respectively compared with 100% for LPS. Both IFN-γ and Poly(I:C) conditions were 
not significant, apart from prior incubation of dsRNA with Fugene that resulted in a 
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lower quantification than the untreated control. These trends were reflected in a dose-
dependent manner for the bacterial ligands and IFN-γ (Figure 5-5.D) with a 
concentration of 1 µg/mL being optimal. 
 
Figure 5-5. Quantifying the pro-inflammatory phenotype by MALDI-TOF-MS in 
response to the five stimuli. (A) Relative quantitation of peak areas (4964/4632) of 
LPS, Pam2CSK3, Pam2CSK4, IFN-γ and Poly(I:C) ± Fugene treated macrophages 
compared to untreated THP-1 monocytes normalised to LPS positive control. (B) PCA 
plot of LPS, Pam2CSK4, Pam3CSK4 and IFN-γ treated THP-1 monocytes showing 
distinctly grouping of bacterial ligand-treated cells and resting/IFN-γ treated 
monocytes. (C)  Loadings plot derived from PCA plot (B) showing that m/z 4964, 4632, 
6891 and 7002 contribute the most to the separation of the two clusters in PC1 and 
PC2. (D) Titration of LPS, Pam2CSK4, Pam3CSK4 and IFN-γ treated monocytes from 
10 µg – 100 pg/mL of stimulus. Error bars represent standard deviation of 3 biological 
replicates that were each mean averaged from three technical replicates. n.s, *, *** 
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and **** represent non-significant, p<0.05, p<0.001 and p<0.0001, respectively, 
student’s t-test. 
Multivariate analysis generated a 2D PCA plot with two distinct clusters (Figure 5-
5.B). This grouped together all of the bacterial ligand data, which in turn localised 
separately from no treatment and IFN-γ stimulation. Furthermore, the corresponding 
loadings plot generated in Figure 5-5.C shows that features identified as m/z 4964, 
4632 6891 and 7002 contribute most to the PCA clustering in both component 1 and 
component 2.   
5.3.2 Reversing the pro-inflammatory phenotype with known inhibitors. 
With the established analytical workflow and phenotype specificity I then aimed to use 
known inhibitors of pro-inflammatory signalling pathways to evaluate the potential of 
the assay to discriminate positive and negative hits. Initially, I chose three 
compounds; NG-25283, BI2536284 and MRT67303184, which inhibited the pro-
inflammatory response at different stages of inflammatory signalling pathways (Figure 
5-6). These compounds cover a broad range of anti-inflammatory targets and inhibit 
the conventional pro-inflammatory signalling via NF-κB pathway and results in 
production of tumour necrosis factor alpha (TNF-α), as well as the interferon signalling 




Figure 5-6. Inhibiting the pro-inflammatory phenotype by use of known 
inhibitors. Targets of NG-25, BI2536, MRT67307 and staurosporine compounds that 
inhibit the NF-κB pro-inflammatory signalling pathway, pro-inflammatory gene 
transcription, type-1 interferon signalling and induce cell death, respectively. 
 
Compounds were incubated with THP-1 monocytes at 5 µM for one hour to allow 
equilibration in culture before subsequent addition of LPS for 24 hours. Interestingly, 
from manual inspection of the spectra (Figure 5-7) it was clear that NG-25 and BI2536 
were able to reverse the pro-inflammatory phenotype with spectra resembling that of 




Figure 5-7. MALDI-TOF-MS spectra of positive and negative controls as well as 
THP-1 monocytes treated with NG-25, BI2536 and MRT67307 prior to LPS 
treatment. 
 
The specific position of each compound’s target proteins within their respective 
signalling cascades let me identify upstream and downstream inhibitors of the pro-
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inflammatory response that were able to reverse the MALDI-TOF-MS phenotype, 
whereas inhibition of early type 1 interferon signalling had showed no effect (Figure 
5-8. A). The inhibitor action was validated by qPCR kindly performed by Joseph Innes 
(PhD student, Prof. Trost Lab, 2019) and Dr. Anetta Härtlova (Post-doctoral assistant, 
Prof. Trost Lab, 2018), where all IFN-β transcription was down-regulated with the 
three inhibitors, but only NG-25 and BI2536 were able to suppress transcription of 
TNF-α mRNA. The secretion of TNF-α was quantified by ELISA (Figure 5-8.E), which 
showed statistically significant differences between the compound treatments and 




Figure 5-8. Induction of the classical pro-inflammatory signalling a pathway 
induces the MALDI-TOF-MS pro-inflammatory phenotype. (A) Signalling 
pathways inhibited by MRT6307, NG-25 and BI2536. (B) qPCR analysis of known 
compounds measuring transcription levels of TNF-α mRNA and (C) IFN-β mRNA 
levels relative to TBP performed by Joseph Innes (PhD student, Prof. Trost Lab, 2019) 
& Dr. Anetta Härtlova (Post-doctoral assistant, Prof. Trost Lab, 2018). (D) Relative 
quantitation of untreated, LPS and inhibitor treated THP-1 monocytes derived from 
MALDI-TOF-MS whole cell spectra. (E) Measurement of TNF-α secretion by ELISA 
of untreated, LPS and inhibitor treated THP-1 monocytes. (F) 3D PCA plot of 
untreated, LPS, staurosporine and inhibitor treated monocytes showing separation of 
resting, apoptotic and pro-inflammatory treated monocytes along the PC1, PC2 and 
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PC3 axis. (G) MALDI-TOF-MS IC50 curves of BI2536 and NG-25 treated monocytes. 
Error bars represent standard deviation of 3 biological replicates that were each mean 
averaged from three technical replicates. n.s, *, *** and **** represent non-significant, 
p<0.05, p<0.001 and p<0.0001, respectively, student’s t-test. 
Some anti-inflammatory compounds are known to induce mild to severe apoptosis as 
a side effect285,286, therefore I sought to discriminate pro-inflammatory and apoptotic 
monocytes. THP-1 monocytes were incubated with 1 µM staurosporine, a broad 
kinase inhibitor (Figure 5-6), which induces cell death. Quantification of the MALDI-
TOF-MS spectra did not result in a pro-inflammatory phenotype, but instead 
resembled a false positive hit using the dual biomarker quantification. However, when 
analysed by 3D PCA apoptotic cells clustered separately to both pro-inflammatory 
and resting phenotypes (Figure 5-8.F). As well as this, when inhibitor treated 
conditions were added these also clustered closer to either the positive or negative 
controls (LPS/untreated) depending on their efficacy, thus validating the previous 
MALDI-TOF-MS quantification. This 3D PCA plot now effectively allows evaluation of 
three distinct cell phenotypes; resting, apoptotic and pro-inflammatory along each of 
the component axes. 
Finally, I evaluated the MALDI-TOF-MS method for generating IC50 data for both NG-
25 and BI2536. Compounds were titrated from 30 – 0.001 µM over 11 concentration 
points and achieved an excellent four parameter sigmoidal fit of >0.98 for both BI2536 
and NG25 (Figure 5-8.G). For BI2536 and NG-25, I obtained IC50 values of 64.4 and 
8.35 nM, respectively, thus demonstrating the sensitivity of the assay and highlighting 
the difference in potency of the two inhibitors.  
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5.3.3 Identifying inhibitors of inflammation with a blind 78 compound screen 
against LPS treated THP-1 monocytes. 
As a proof of concept, a set of 78 potential anti-inflammatory compounds provided by 
LifeArc were screened blindly with the MALDI-TOF-MS assay. I also included 
MRT63707 and NG-25 as control compounds. The experiment was performed in 
technical triplicates over three independent weeks. Compounds were staggered into 
8 subsets of 10 compounds, each with positive and negative controls to enable 
manual handling of the assay. Across the three biological replicates a good Z’ score 
was obtained for all assays (Figure 5-9.A) with an average of 0.8 ± 0.1 across all three 
screens.  
 
Figure 5-9. Proof of concept 78 compound screen. (A) Z’ scores of biological 
replicates 1, 2 and 3 from the 78 compound screen across the 8 staggered sets. Violin 
plot dashed and dotted lines represent the mean average and interquartile ranges 
respectively. (B) Correlation plots of biological replicates 1, 2 and 3 showing good 
correlation R2 > 0.80. (C) Compound hit map of the averaged 3 biological replicates 
with 40% effectiveness cut off showing Nilotinib and NG-25 as positive hits. 
Good linear correlation between the three technical replicates was obtained for each 
screen (Figure 5-10) as well as between the biological triplicates with an R2 >0.8 in 
all cases (Figure 5-9.B), thus confirming that the assay is robust and conforms to 





Figure 5-10. Technical reproducibility correlation plots between the three 
technical replicates from each biological replicate screen showing good 
correlation of R2 >0.8 
From the mean averaged data of the three screens I applied a percentage effect cut 
off of 40%, meaning that compounds must reduce the MALDI-TOF-MS quantification 
by 60% to be considered. From this, the control compound NG-25 was identified as 
a positive hit, as well as nilotinib, a second generation BCR-ABL inhibitor used in the 
treatment of chronic myeloid leukaemia (CML) (Figure 5-9.C) 287. Interestingly, the 
first generation BCR-ABL inhibitor imatinib was also included in the assay panel, but 
was not identified as a positive hit. The spectra from each of the three biological 
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repeats of the screening were very similar (Figure 5-11), thus demonstrating the 
robustness of the sample preparation method as well as the behaviour of both 
compounds is reproducible.  
Figure 5-11. A representative spectrum of imatinib and nilotinib treated 
monocytes from each of biological replicates of the 78 compound screen. 
 
Both compounds share a similar backbone structure (Figure 5-12) and, therefore, I 
further investigated the pro-inflammatory effect of these two compounds by MALDI-






Figure 5-12. Chemical structures of imatinib (orange) and nilotinib (blue). 
5.3.4 Validating Nilotinib as an anti-inflammatory compound and exploring its off-
target effect 
Firstly, qPCR analysis was performed by Joseph Innes and José Luis Marin Rubio to 
investigate the activity of nilotinib and imatinib on the transcription levels of TNF-α 
and IFN-β. Similarly to hit compounds NG25 and BI2536, Nilotinib was able to supress 
the transcription of both cytokines, whereas imatinib did not prevent transcription of 
TNF- α. Using the ratiometric pro-inflammatory quantitation by MALDI-TOF-MS the 
activity of nilotinib and imatinib was validated over three biological replicates (Figure 
5-13.C) and when compared with the amount of secreted TNF-α the trends were 
almost identical (Figure 5-13.D). As well as this, IC50 curves could be generated for 
nilotinib using both readouts and a good R2 of >0.95 was achieved as well as an IC50 
value of 205.3 and 208.7 nM for MALDI-TOF-MS and TNF-α secretion, respectively. 
These data demonstrate that both readouts yield almost identical information and that 
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a nilotinib is a genuine inhibitor of the pro-inflammatory signalling pathway that 
induces TNF-α secretion with good potency.  
Figure 5-13. Validating the anti-inflammatory properties of nilotinib. qPCR 
analysis of TNF-α (A) and IFN-β (B) mRNA expression relative to TBP performed by 
Joseph Innes (PhD Student, Prof. Trost Lab, 2019) & Dr. José Luis Marin Rubio (Post-
doctoral researcher, Prof. Trost Lab, 2019). (C) Relative quantitation of untreated, 
LPS, Nilotinib and Imatinib THP-1 monocytes derived from MALDI-TOF-MS whole 
cell spectra from the 78 compound screen over three biological replicates. (D) 
Measurement of TNF-α secretion by ELISA of untreated, LPS Nilotinib and Imatinib 
treated THP-1 monocytes. (E) MALDI-TOF-MS IC50 curve of hit compound Nilotinib 
(F) ELISA TNF-α IC50 curve of hit compound Nilotinib. Each value represents a 
biological replicate averaged from three technical wells or MALDI spots. Error bars 
represent standard. n.s, *, **, *** and **** represent non-significant, p<0.05, p<0.01, 




Finally, to assess how both nilotinib and imatinib affected cells, global changes in cell 
proteomes were analysed. Over 7000 proteins were identified across all conditions 
with 5790 proteins quantified with >2 unique razor peptides. Multivariate analysis of 
the four conditions showed that imatinib treated monocytes clustered closely with the 
pro-inflammatory phenotype, whereas nilotinib localised between untreated and LPS 
treated, thus validating that nilotinib displays anti-inflammatory properties, but does 
not revert cellular physiology completely back to a resting state (Figure 5-14.B).  
 
Figure 5-14. Proteomic profiling of nilotinib and imatinib treatment in THP-1 
monocytes. (A) Volcano plot of t-test data of nilotinib vs imatinib with statistical cut 
off at >1.5 fold change and >1.3 -Log10(p-value) and annotated significantly 
differential proteins. (B) PCA plot of the four conditions showing Imatinib clustering 
with LPS, thus not affecting cellular inflammatory responses. (C) GO term analysis of 
biological processes upregulated by imatinib or nilotinib treatment. 
Data were filtered to leave only proteins that were identified in 3/6 replicates for each 
group. T-test statistical analyses with FDR correction between nilotinib and imatinib 
treated samples identified 29 upregulated proteins by nilotinib compared to 65 that 
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were upregulated by imatinib with a fold-change >1.5 and p-value <0.05. This 
generated a volcano plot shown in Figure 5-14.A, where proteins in the inflammatory 
signalling pathway were significantly upregulated in imatinib treatment over nilotinib, 
thus indicating more inflammatory signalling occurs with imatinib treatment. Further 
to this, 75 and 67 unique proteins were identified to nilotinib and imatinib treatment, 
respectively. GO term biological process analysis was performed with these proteins 
combined (Figure 5-14.C) 
 
Figure 5-15. Autophosphorylation of p38 (MKK3) is inhibited by nilotinib. 
Performed by José L Marín-Rubio (Post-doctoral researcher, Prof. Trost Lab, 2019). 
Immunoblot analysis (IB) showing the inhibition of p38 (MKK3) activation loop 
phosphorylation by nilotinib over 1 hour, while imatinib does not lead to p38 inhibition. 
p38 protein abundance is unchanged. Also shows that nilotinib has no impact on IKBα 
and IKKα phosphorylation or degradation 
Further to this, José Marín-Rubio performed immunoblot analysis to identify off-target 
effects of nilotinib in the NF-κB pathway (Figure 5-15). Here, these data show 
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specificity of nilotinib inhibiting the activation loop phosphorylation of the MAP kinase 
p38 (MKK3) over imatinib, which may explain why there is a reduction in TNF-α 
secretion and nilotinib was identified as a positive hit. More work is being undertaken 
to evaluate nilotinib influence on the NF-κB signalling pathway. 
Taken together, this data validates that nilotinib unlike imatinib has anti-inflammatory 
properties. Preliminary data indicates that nilotinib inhibits to phosphorylation of p38 
mitogen-activated protein kinase MKK3, which in turn could result in a dampened pro-
inflammatory response. However, further work is required to characterise the off-
target effect of nilotinib that reverses a pro-inflammatory phenotype.  
5.4 Discussion 
5.4.1 MALDI-TOF-MS is a viable label-free readout for phenotypic screening of 
anti-inflammatory compounds 
Inflammation is fundamental biological response to injury or infection that coordinates 
multiple immune cell types and complex signalling pathways to protect the host and 
eliminate invading pathogens. Under normal homeostatic conditions, the levels of 
inflammation at any one time are tightly regulated, however, perturbation of this 
system can result in chronic or acute inflammation that can in turn lead to 
pathogenesis and tissue damage. In recent years, dysregulated inflammation is more 
and more frequently associated with debilitating conditions such as cancer, 
neurodegeneration and autoimmune diseases, therefore there has been a surge to 
study how these disorders interlink and often lead to a worse prognosis. Quantifying 
levels of inflammation is typically achieved by measuring the secretion pro-
inflammatory cytokines by immune cells such as TNF-α, IL6 and IL-1b. Tumour 
necrosis factor alpha is a particularly potent cytokine and a well-established hallmark 
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of dangerous levels of acute inflammation in diseases such as sepsis and IBD, thus 
its secretion in vitro would be a valuable readout for compound screening. However, 
current methods for measuring TNF-α are expensive, often utilise labelled antibodies 
and lack throughput. Mass spectrometric techniques have been on the rise in the drug 
discovery and characterisation process, however despite being used to decipher the 
subtleties of TNF-α signalling, they have yet to be extended to screening for 
compounds that inhibit TNF-α secretion.288 In this chapter, I have described the 
development of a MALDI-TOF-MS assay that quantifies the pro-inflammatory state of 
THP-1 monocytes in response to bacterial ligands and can be used to identify 
inhibitors of inflammation. Furthermore, I have shown that the MALDI-TOF-MS assay 
readout correlates very closely to TNF-α secretion with respect to differentiating 
nilotinib and imatinib as well as IC50 values, thus this assay is a viable alternative to 
ELISA-based screening.  
As a model, the THP-1 cell line was chosen for assay development. This human 
leukaemia monocytic cell line has been used widely to study the role of inflammatory 
cytokine signalling in monocytes as well differentiated macrophages by phorbol 
ester.289,290 As well as this, previous studies have used THP-1 monocytes to develop 
screening assays for measuring TNF-α in response to bacterial ligands.291,292 Both 
methanol fixing and aqueous washing techniques described in Chapter 4 were tested 
to optimise a sample preparation method suitable for detecting a phenotypic shift in 
THP-1 cells, and in this case aqueous washing was more robust. It was also observed 
that washing and resuspension in a neutral pH buffer was beneficial for this study, 
with acidic buffers being less consistent when discriminating between pro-
inflammatory and untreated THP-1 cells. This observation is similar to that reported 
by Munteanu et al. and discussed in Chapter 4 of this thesis, therefore I proceeded 
with a mild Tris buffer to maintain cellular integrity, as water alone sometimes caused 
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a strong osmotic effect and inconsistent sample prepartion.242 THP-1 cells were first 
stimulated with LPS, the major cell wall component of Gram-negative bacteria, which 
consists of three different moieties, a core oligosaccharide, lipid A and the O-antigen 
that is particularly endotoxic for macrophages and monocytes and promotes secretion 
of pro-inflammatory cytokines. No unique features were robustly detected for either 
LPS or untreated monocytes, but there were significant shifts in common peak 
intensity that lead to significant separation of the two phenotypes, as well as formation 
of two defined clusters by PCA multivariate analysis. By taking the two features that 
induced the strongest polarisation for a pro-inflammatory and resting phenotype, m/z 
4964 and 4632, respectively, I could generate a method that enabled ratiometric 
quantification of the pro-inflammatory response. A similar approach of intra-cellular 
dual-biomarker quantification approach has previously been described to successfully 
identify cell lines in a co-culture.129 Interestingly, the feature detected at m/z 4964 has 
been described previously in several studies that have used MALDI-TOF-MS to study 
macrophages.230,293 This feature has been identified as thymosin beta 4 (Tb4), a small 
molecular weight protein involved in binding and promoting actin polymerisation. 
Thymosin beta 4 itself is a highly abundant protein in cells and has also been 
described as having potential anti-inflammatory properties.294,295 Using the dual 
biomarker approach provided a robust and reproducible analysis over biological and 
technical repeats with a consistently significant t-test difference p<0.001 and Z’ >0.5, 
thus meeting the necessary assay screening qualities.  
A significant pro-inflammatory MALDI-TOF-MS phenotype was quantifiable with three 
bacterial ligands that engage TLRs anchored in the cell membrane and induce pro-
inflammatory signalling via the NF-κB pathway. Interestingly, other stimuli such as 
viral dsRNA and pro-inflammatory cytokines were ineffective in this assay. This 
suggests that the MALDI-TOF-MS phenotype is induced by the pro-inflammatory 
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signalling pathway and not the type I interferon pathway as IFN-γ treated THP1 cells 
separated with the untreated population. Further to this, it was surprising that 
induction of endosomal TLR3 signalling by poly(I:C) did not present a pro-
inflammatory phenotype, as it has previously been shown to activate the NF-kB 
pathway.296 However, the mechanism by which this occurs is different to membrane 
expressed TLRs (1,2,4,6) that require the adapter protein Myd88 to induce NF-kB, 
whereas TLR3 does not and directly recruits the TRAF6/TAK1/TAB1/TAB2 
complex.297 This alternate signalling could be an explanation for why there is no 
observable MALDI-TOF-MS pro-inflammatory phenotype with poly(I:C), but much 
more study would be required to conclude this confidently.   
Having established the specificity of the MALDI-TOF-MS assay for bacterial ligand 
stimulation of TLRs and robust quantitation, I then proceeded to determine whether 
this LPS induced phenotype could be reversed with known inhibitors of pro-
inflammatory and interferon signalling. Firstly, NG-25 was chosen as an upstream 
regulator as it is a widely unspecific TAK1 inhibitor that primarily inhibits pro-
inflammatory cytokine signalling via NF-kB but also the type one interferon 
response.283,298 The BET inhibitor BI25636 is a potent inhibitor of Plk1, 2 and 3, and 
has been implicated in the downregulation of pro-inflammatory cytokine transcription, 
thus down stream of NG-25.299,300 Finally, the compound MRT67307 was previously 
been shown to be potent inhibitor in the SIK in-vitro assay but is also reported to be  
a specific inhibitor of TBK1. This compound was therefore a useful control TBK1 for 
discriminating the inflammatory pathways as TBK1 initiates upstream interferon 
signalling but does not inhibit NF-κB signalling transduction. Both NG-25 and BI2536 
were able to inhibit the pro-inflammatory response, with MALDI-TOF-MS 
quantification similar to that of resting conditions, whereas treatment with MRT67307 
still exhibited a pro-inflammatory phenotype. Compound efficacy validation by TNF-α 
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ELISA, where the results were almost identical. Interestingly, secretion of TNF-α was 
quantifiable in BI2536 treated conditions, which implies that there is activation of the 
NF-κB pathway and release of the cellular TNF-α reservoir, but further transcription 
of the pro-inflammatory cytokines is blocked. This could be a useful indicator of 
whether an unknown compounds mode of action is up- or downstream of initial NF-
κB activation. Taken together, these three compounds were able to probe the specific 
signalling pathways involved in the pro-inflammatory response and reinforce previous 
conclusion the MALDI-TOF-MS phenotype is induced by activation of the pro-
inflammatory signalling pathways. Furthermore, NG-25 and MRT67307 could now be 
utilised as positive and negative compound controls.  
5.4.2 Characterising the anti-inflammatory properties of hit compound Nilotinib 
Induction of apoptosis by staurosporine demonstrated that the MALDI-TOF-MS assay 
was capable of multiplexing readouts, a desirable outcome for cellular screening 
assays. By way of a 3D PCA plot, the three distinct cellular phenotypes apoptotic, 
resting and pro-inflammatory could be defined along one of the axes and therefore  
compound cytotoxicity could be characterised as well as their anti-inflammatory 
properties. This combined with determination of low nanomolar IC50 values for NG-25 
and BI2536 confirmed assay suitability for screening, therefore I proceeded with a 
blind 78 compound screen, which generated excellent Z’ scores and good 
reproducibility between biological repeats. Here, nilotinib, a second generation 
leukaemia drug, was reproducibly identified as hit compound that reduced the pro-
inflammatory response back to resting levels. Surprisingly, imatinib, the first 
generation counterpart, was also included in the screen and did not show any anti-
inflammatory effects. Both nilotinib and imatinib are structurally similar and potent 
inhibitors of BCR-ABL tyrosine kinase that are used as first line treatments for CML.301 
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Interestingly, both compounds have been previously suggested to have potential anti-
inflammatory effects, particularly in autoimmune diseases such as rheumatoid 
arthritis.302 These findings also extend to another second generation BCR-ABL 
tyrosine kinase dastanib, which was not included in this particular screen, but has 
been shown to reduce TNF-α secretion.303 Despite nilotinib being structurally related 
to imatinib, the integration of a 3-methylimidazole group and trifluoromethyl groups 
enables it to make unique interactions within the Abl kinase domain.304 This in turn 
means that once bound, the shape and conformation of nilotinib is very different to 
imatinib, which may account for differences in off-target protein effects. Interestingly, 
BI2536 has been shown to synergise with imatinib to prevent CML proliferation.305 By 
inhibiting Plk1 an anti-inflammatory phenotype is induced that enables better imatinib 
efficacy, which may in turn account for why nilotinib is a more effective therapy. 
Quantification of TNF-α secretion validated the MALDI-TOF-MS screening data as 
nilotinib was able to dramatically reduce TNF-α secretion compared with imatinib that 
only mildly reduced TNF-α levels. Further to this, using both TNF-α secretion and 
MALDI-TOF-MS as a readout IC50 curves for nilotinib generated with almost identical 
IC50 values of ~200 nM, thus validating the MALDI-TOF-MS assay as an alternative 
strategy to conventional ELISA assays for screening of anti-inflammatory compounds.  
Finally, total proteome analysis of nilotinib and imatinib treatments enabled the 
significant changes in protein expression that are associated with inflammatory 
signalling. These included CD14 that is involved in the sensing of LPS alongside 
TLR4, as well as IRF7, TRAF1, and RelA/C, all of which are involved in the interferon 
or NF-κB signalling induced by activation of plasma membrane TLRs. Multivariate 
analysis indicates that nilotinib does prevent complete activation of inflammatory 
signalling as it does not cluster directly with untreated samples. This may explain why 
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certain proteins such as IRAK3, IRAK4 and TRAF2, were found to be upregulated in 
with nilotinib treatment. These proteins are associated with inflammatory signalling, 
with IRAK4 transducing a positive TLR response immune and TRAF2, which 
regulates activation of the NF-κB and JNK response and modulates cell survival.306,307 
Interestingly, IRAK3 is associated with negative regulation of TLR signalling by 
inhibiting dissociation of IRAK1 and IRAK4 from TLRs by preventing their 
phosphorylation.308 Overall, this data infers that nilotinib has an off-target effect within 
the inflammatory signalling cascades that, although does not prevent signal-
transduction, does disrupt the production of the cytokine TNF-α. Further work will be 
needed to identify the off-target involved with inflammatory signalling such as 
identifying phosphosites that are unoccupied with nilotinib treatment, as well as 





Chapter 6. The L929 secretome – a study to understand the 
subtleties in bone marrow-derived macrophage 
differentiation 
6.1 Introduction 
Mouse models are key for studying inflammation and the innate immune response in 
vivo to decipher the complex signalling pathways that result in tissue pathogenesis 
and disease. These models have been important for the study of various diseases 
such as rheumatoid arthritis and inflammatory bowel disease, where research in mice 
has enhanced knowledge about how these diseases progress in humans.309 Further 
to this, genetic engineering has advanced significantly in recent years to establish 
knock-out, knock-in or transgenic mice to further explore how specific genetic 
modifications influence physiological responses.310 This has been particularly 
successful for the development of histone deacetylase inhibitors to target 
inflammatory diseases with dysregulated cytokine production.311 However, these in 
vivo experiments do not always yield specific information about the behaviour of 
specific cells during infection or treatment, thus it is often necessary to perform in vitro 
experiments to understand specific cellular responses. There are numerous 
immortalised cell lines available as models for murine macrophages that have been 
used widely to study effects of stressors on the innate immune response and decipher 
signalling pathways. Combined with the development of advanced genetic 
engineering technologies such as CRISPR-Cas9 these lines have become a powerful 
tool for studying signalling cascades as it is relatively simple and fast to genetically 
engineer immortalised cell lines compared with mice.312 These studies have 
advanced our knowledge of how macrophages interact specifically with bacterial 
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infections, their phagocytic behaviour and also their ability to switch between an M1 
and M2 phenotype.313 However, despite their advantages, there are studies that have 
highlighted the differences between these cell lines in response to infection or 
stressors.314 It has been shown that the stability of some RAW264.7 macrophages 
can become compromised after 30 passages, as well as the fact that J774 
macrophages exhibit a different response to Mycobacterium tuberculosis infection 
compared with primary cells. Consequently, the utmost care must be taken when 
selecting a model for a particular experiment as it is likely to affect the biological 
outcome.315,316  
Primary macrophages are the ideal source of cells for in vitro experiments as they 
provide more biologically relevant models. These cells cannot be passaged but can 
be isolated from a variety of organs such as liver, spleen, peritoneum and bone 
marrow.317,318 Importantly, any genetic modification incurred at the mouse genome 
level is translated into in vitro experiments and therefore results can be verified in the 
original in vivo model. The most common source of primary murine macrophages are 
derived from bone marrow, where stem cells are first isolated and then they undergo 
differentiation in vitro in the presence of macrophage colony stimulating factor 1; M-
CSF or CSF-1 as described in Figure 6-1. This method was first described by 
Tushinski et al. and Guilbert et al. in 1982 and 1986, respectively, and generates a 
pool of bone marrow-derived macrophages (BMDMs).319,320 Both these studies 
highlight the importance of M-CSF in the production of a highly homogenous 
population of mononuclear phagocytes. M-CSF is a secreted cytokine and growth 
factor that induces differentiation of hematopoietic stem cells into macrophages and 
stimulates phagocytic behaviour. It is closely related to granulocyte-macrophage 
colony stimulating factor (GM-CSF), a glycoprotein that has numerous 
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immunomodulatory functions in vivo, but can induce dendritic cell differentiation from 
stem cells.321,322    
 
Figure 6-1. Differentiation culture method of bone marrow-derived 
macrophages from stem cells under the influence of either M-CSF or L929 
supplemented media. 
It has since been described how GM-CSF and M-CSF are highly expressed and 
secreted by the L929 murine cell line, an immortalised fibroblast cell line derived from 
connective tissue.323,324 Consequently, this has led to the development of protocols 
that prefer to use L929 conditioned medium for BMDM differentiation over the addition 
of recombinant M-CSF as it is cheaper and simple to produce in house.325 Moreover, 
substantially more BMDMs can be obtained from bone marrow differentiated in L929 
supernatant compared to recombinant M-CSF.  However, there remains scepticism 
in the field over BMDM production utilising L929 supplemented media. This is partially 
driven by the utilisation of different protocols, with L929 supplementation of media 
ranging from 10-30% and secretion collection from L929 cultures described from as 
early as 7 days up to 14 days with different seeding densities.326–328 These different 
experimental procedures will likely influence resultant BMDM properties, as it has 
already been shown that cellular density during differentiation can alter the resulting 
macrophage phenotype.329 Furthermore, early studies described how L929 medium 
could induce an interferon stimulated phenotype in BMDMs, which may then affect 
results due to the macrophage polarisation.330,331 Despite this heterogeneity in culture 
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conditions, BMDMs differentiated under L929 conditioned media have been utilised 
widely for the study of macrophage behaviour such as regulation of antigen 
presentation by treatment with IL-4, as well as deciphering cell signalling pathways in 
response LPS treatment.332–334 
The classification and phenotype of M-CSF derived macrophages has been well 
described in detail with respect to their adhesion and cell surface marker expression, 
however, this has not been compared with alternative differentiation 
methodologies.318,335 Therefore, there is a need to characterise BMDM phenotypes 
under the different culture conditions to determine whether there are significant 
differences in biological function. Furthermore, despite the characterisation of M-CSF 
as a significant component of L929 secretion, the identification of total protein content 
has not yet been described. Consequently, there is a need to define the secretion 
profile of L929 to identify any factors that my influence resultant BMDM phenotype. 
6.2 Aims 
In this thesis thus far, I have explored different models that can be utilised for drug 
discovery from in vitro enzymatic reactions to immortalised cell lines. A well-
established source of primary macrophage are BMDMs that have been used as 
models for drug discovery. However, their differentiation protocol is controversial, 
therefore, within this study I undertook proteomic profiling of the L929 secretome 
protein content. This identified M-CSF as a major component of the secretion along 
with macrophage inhibitory factor (MIF). Finally, I characterised the differences 
between BMDMs differentiated under three different culture conditions by total 





1. Proteomic profiling of the kinetic L929 secretome over a two-week time course 
2. Characterising BMDM differentiation under different culture conditions 
6.3 Results 
6.3.1 Proteomic profiling of the kinetic L929 secretome over a two-week time 
course 
The collection of L929 supernatant is typically performed at 7 or 14 days, with some 
protocols combining both time points to generate potent differentiation media. This is 
because L929 supernatant collection follows a unique protocol where cells are initially 
seeded and not passaged from then on. Therefore, my first aim was to design a study 
that characterised the secretion profile of L929 fibroblasts over the two week time 
period by sampling at 3, 7, 10 and 14 days. For secretomic studies standard cell 
culture medium is incompatible due to the very high concentrations of fetal bovine 
serum (FBS) that skews the dynamic range for mass spectrometry analysis. 
Therefore, a reduced sera medium, named Opti-MEM, has been developed that 
enables biologically similar culture conditions without that addition of FBS, thus 
suitable for proteomic experiments. L929 fibroblasts were seeded in six well plates 
and grown in accordance with standard L929 supernatant collection (Figure 6-2.A). 
From this analysis, bright field light microscopy visualised the progression of cell 
confluency at days 3, 7, 10 and 14 (Figure 6-2.B), showing increasing confluency and 
morphology changes over time. Cells were well adhered with long protrusions at day 
3, however cell size reduced significantly as confluency grew. At day 14, it was 
possible to visualise multiple layers of small, round cells that are dramatically different 
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in morphology compared with day 3. For the secretome, cells were washed prior to 
addition of Opti-MEM media for 3 hours to accumulate secreted proteins. 
Consequently, this approach measures the rate of protein secretion without 
compromising cellular biology throughout the growth period. Incubation with sera free 
media was limited to three hours as the absence of nutrients from FBS could impact 
cellular biology and may in turn induce stress and apoptosis. From a previous study, 
I was able to verify that under basal conditions in sera free media it was possible to 
collect cellular secretion for up to three hours without inducing PARP1 cleavage, 




Figure 6-2. Proteomic profiling of the L929 secretome. (A) Graphical 
representation of the collection of L929 supernatant over 14 days and the 
corresponding secretome collections for proteomic analysis. (B) Brightfield light 
microscopy images of L929 fibroblasts at the secretome time points showing 
significant changes in morphology with increasing confluency. 
This study identified 2877 proteins to define the L929 secretome, with 2198 being 
robustly identified with 2 or more razor + unique peptides. The top three proteins 
identified from the secretome based on overall intensity comprised of fibronectin, actin 
and collagen alpha-type-2, which is unsurprising for fibroblast cells as they are known 
to secrete high levels of these extracellular matrix proteins.336,337 Using iBAQ ranking, 
a top twenty list of proteins that could influence subsequent BMDM phenotype was 
generated (Table 6.1). The iBAQ ranking enables quantitation of a protein’s 
abundance relative to its molecular weight. Here, the sum of intensities for all the 
identified tryptic peptides for a given protein is divided by the number of theoretically 
observable peptides for that protein to yield an IBAQ intensity. This is particularly 
important when looking at smaller molecular weight proteins as there are much fewer 
potential tryptic peptide, thus they will often yield a lower intensity than larger proteins 
without IBAQ correction.338 





names Protein names 
1 P60710 Actb Actin 1 (Beta-actin) 
2 P11276 Fn1 Fibronectin  
3 P21460 Cst3 Cystatin-C 
4 P16045 Lgals1 Galectin-1  
5 Q9DD06 Rarres2 Retinoic acid receptor responder protein 2 
6 P01887 B2m Beta-2-microglobulin 
7 P34884 Mif Macrophage migration inhibitory factor (MIF) 
8 P47879 Igfbp4  Insulin-like growth factor-binding protein 4  
9 P07091 S100a4 Protein S100-A4 (Metastasin)  
10 P10923 Spp1  Osteopontin  
11 Q61398 Pcolce Procollagen C-endopeptidase enhancer 1  
14 P06151 Ldha  L-lactate dehydrogenase A chain 
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16 P05064 Aldoa Fructose-bisphosphate aldolase A  
27 O09164 Sod3 Extracellular superoxide dismutase  
39 P35700 Prdx1 
Peroxiredoxin-1 Macrophage 23 kDa stress 
protein) 
41 P14069 S100a6  Protein S100-A6 (Calcyclin) 
49 Q03366 Ccl7 C-C motif chemokine 7  
50 P50543 S100a11  Protein S100-A11 (Calgizzarin)  
60 P07141 Csf1  Macrophage colony-stimulating factor 1  
64 P10148 Ccl2  C-C motif chemokine 2 
 
Taking the data set as a whole, gene ontology (GO) enrichment was performed for 
the cellular component subset. I observed significant enrichment of extracellular 
exosomal proteins with-log10(p-value) of 300 using a Benjamini-Hochberg FDR 
correction as well as enrichment in cytosolic protein groups (Figure 6-3.A). Using 
iBAQ ranking and cumulative protein intensity that ranks proteins in terms of their 
percentage contribution to the overall intensity, I was able to identify M-CSF and MIF 
as significant components of the L929 secretome (Figure 6-3.B&C). Both of these 
proteins are secreted cytokines that have reported function in the modulation of 
macrophage differentiation and function.339,340 Taking the normalised Log2 intensity 
of the proteins their expression rates were plotted against the day of secretion for both 
MIF and M-CSF (Figure 6-3.D). This data showed that the rate of M-CSF secretion is 
generally consistent throughout the two week L929 secretion time period. Conversely, 
the rate of MIF expression correlated with depletion of nutrients within the media, as 
rates decreased two fold after addition of fresh media. This could imply that MIF is 




Figure 6-3. Proteomic profiling of L929 secretome identifies M-CSF and MIF as 
significant components. (A) GO enrichment of L929 secretome cellular component 
showing enrichment of extracellular exosome. (B) Log10 iBAQ ranking of proteins 
from the L929 secretome showing positions of MIF and M-CSF. (C) Cumulative 
protein intensity ranking, i.e. not normalised, showing positions of MIF and M-CSF. 
(D) Log2 intensities of M-CSF and MIF showing expression rates over the two week 
time course. Error bars represent the mean average ± SD over three biological 
replicates. 
Prior to further analysis, the data set was filtered for protein groups that had values in 
two out of three biological replicates for each sampling day. To analyse for variance 
over multiple groups, I applied Benjamini-Hochberg FDR corrected ANOVA that 
identified 1128 significant protein groups. Using Z’ score averaging and Euclidean 
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clustering, a group averaged heat map was drawn as shown in Figure 6-4 that 
exhibited distinct patterns in protein secretion rates over time.  
 
Figure 6-4. Global analysis of the L929 secretome kinetic. (A) Z’ heat map of 
ANOVA significant proteins across the sampling days. (B) Six distinct cluster profiles 
that show different secretion patterns over time with purple dots indicating down and 
orange dots up regulation. (C) Associated molecular function and biological process 
GO terms for the six cluster profiles. 
From this, six distinct clusters could be defined (Figure 6-4.B) that exhibited different 
rates of protein secretion over time. Interestingly, it appears that for the majority of 
proteins secretion rate decreases over time, which is inconsistent with an increase in 
cell confluency over the two week period. Analysis of the normalised Log2 intensity 
histograms for each secretome sample showed an even distribution for all sampling 
days, thus this trend is not due to variation in injection volume or sample quantity. As 
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well as this, there are notable changes in protein secretion that may be induced by 
the presence or absence of nutrients over the time period. The associated GO 
enrichment plots for each cluster describe the enrichment in both the biological 
process and molecular function of each cluster subset, thus allowing insight into cell 
state at the different time points (Figure 6-4.C) 
Taken together, these data provide a comprehensive list of proteins that are secreted 
by L929 fibroblasts over a two week time period. Within this data set, M-CSF was 
expectedly identified as being highly secreted, however, MIF was also identified as a 
highly expressed protein and may influence subsequent differentiation.  
6.3.2. Characterising BMDM differentiation under different culture conditions 
The original aim of this study was to identify the major protein components of L929 
supernatant and subsequently characterise BMDM differentiation under either M-CSF 
or L929 supplemented media. However, as MIF was identified as a highly secreted 
protein by L929 fibroblasts and is known to play a role in regulating macrophage 
function it was deemed necessary to explore whether MIF impacts BMDM 
differentiation. Therefore, three culture conditions were defined: 10 ng/mL of M-CSF, 
10 ng/mL of MIF + 10 ng/mL of M-CSF and 20% L929 supplemented media (Figure 
6-5.A). The concentration of 10 ng/mL was chosen for M-CSF as this is the most 
widely reported differentiation concentration.341,342 Furthermore, the L929 secretome 
data indicated that MIF (12 kDa) was about 5 times more abundant than M-CSF (60 
kDa), thus indicating similar total amounts of both proteins in the L929 supplement. 
For L929 supplemented media the secretion collection was performed in tandem to 
the secretome proteomic analysis, thus the protein composition described is an 
accurate representation of the differentiation media. 
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Three female wild type C57BL/6 mice of the same age were taken for this experiment. 
After red blood cell lysis, the haemopoietic stem cells from each mouse were pooled 
into culture media excluding any differentiation agents to prevent cross contamination 
of different culture conditions. One millilitre of the mixture was added to three tissue 
culture plates containing the individual culture conditions 1, 2 and 3 to allow adhesion 
of contaminant cells such as leukocytes and osteoblasts before transfer into petri 
dishes for differentiation over seven days (Figure 6-5.A). 
For proteomic analysis, the three biological replicates of each culture condition were 
first digested and then labelled with 9 out of 10 of the labels of a TMT10 plex reagent 
kit. This enabled pooling of all samples and offline-HPLC HPRP peptide separation 
to enable deeper proteome analysis as peptides are orthogonally separated. TMT 
labels consist of four parts: a reporter ion, mass normaliser, a reactive amine group 
and a cleavable linker. Samples are incubated with a specific tag that initiates a 
reaction between the ester-activated-amine group of a TMT tag and N-terminus of 
peptides, thus allowing conjugation. However, it is also possible for TMT tags to react 
with the amine group of lysine residues in a TMT label: peptide ratio dependent 
manner.343 The mass normaliser balances the isotopic mass difference induced in the 
mass reporter. In turn, this allows peptides in the MS1 scan to be identified at the 
same m/z, but in the MS2 scan when selected peptides are fragmented the cleavable 
linker is broken and the reporter ion released that enables quantification (Figure 6-
5.C).64 As TMT labelled samples were processed on an on Orbitrap Fusion Lumos 
Tribrid mass spectrometer quantification can be performed at either the MS2 and MS3 
level. Here, the relative quantification is either performed at the first fragmentation 
step of the peptides (MS2), or there is a further fragmentation step (MS3) that enables 
complete cleavage of the reporter ion by using higher energy CID known as HCD 
fragmentation.344,345 This step is performed on the isolated precursor peptides 
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independently of the MS2 scan and results in almost complete fragmentation of the 
reporter ion, thus more accurate quantification. The introduction of MS3 fragmentation 
was particularly important for studies that required highly accurate and precise 
quantification, as it has been described previously for isobaric labelling strategies that 
there is often contamination from near-isobaric ions that are fragmented with the 
same precursor ion.346–348 Consequently, this can lead to over- or under- estimation 
of peptide and protein intensities in the different channels and in extreme cases lead 
to identification of knock-out proteins in knock-out channels. This has led to the 
development of strategies to diagnose ion interference such as a two-proteome model 
for TMT-6plex labelling systems, and a triple knockout standard for TMT-10plex 
systems.345,349 For this particular study, MS2 quantification was chosen as it enables 
a greater number of IDs. This was important to enable generation of the deepest 




Figure 6-5. Proteomic profiling of the three BMDM populations by TMT 
quantitation. (A) Experimental design of the three BMDM differentiation conditions 
coupled with TMT labelling and LC-MS/MS analysis. (B) Structure of the TMT label 
with reporter, mass normaliser, reactive group and cleavage point. (C) Schematic of 
LC-MS/MS fragmentation strategies for TMT quantification. 
Labelling efficiency was first determined prior to quenching of the reaction with a small 
pool that reported >98% labelling of peptides, thus the experiment was progressed to 
HPRP fractionation into 12 fractions and analysed by LC-MS/MS. Here, 6724 protein 
groups were identified with 5607 quantified with 2 razor + unique peptides. The LFQ 
data set was subjected to T-test statistics with Benjamini-Hochberg FDR correction 
between the three BMDM populations that generated the volcano plots shown in 
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Figure 6-6.A. Interestingly, there were no significant differences in protein expression 
between BMDMs cultured with M-CSF +/- MIF, thus implying that there is little impact 
of MIF on M-CSF induced differentiation. Conversely, over 100 differential proteins 
were identified between L929 differentiated BMDMs and the two other culture 
conditions (Figure 6-6.A).  
 
 Figure 6-6. BMDM’s differentiated with L929 supplementation exhibit 
significantly different proteomes over M-CSF/MIF differentiation. (A) Volcano 
plots of the three culture conditions compared showing differential proteins with 
respect to BMDM populations. (B) Molecular function GO enrichment of proteins that 
up or down regulated in BMDMs with respect to M-CSF and MIF. 
Taking these differential protein lists GO terms showed significant enrichment with 
respect to molecular function (Figure 6-6.B). Interestingly, these data indicate that 
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BMDMs grown in L929 supplemented media have a heightened interferon and innate 
immune response compared with M-CSF/MIF cultured BMDMs. Conversely, BMDMs 
grown in L929 supernatant show down-regulation of cell division and mitotic 
machinery. These differential proteins were plotted using Log2 fold change of the 
protein LFQ intensities and Euclidean clustering between L929 and M-CSF + MIF 
culture conditions showing good clustering of up and down-regulated proteins that 
were highly consistent over three biological replicates. These data also show the 
protein Dcaf11/DDB1, which was the only protein that was identified as up-regulated 
by inclusion of MIF showing similar protein expression levels to L929 cultured 




Figure 6-7. Significantly regulated proteins with respect to L929 supernatant 
BMDM differentiation. Log2 fold change heatmap of differential proteins identified by 





To validate biological function the three BMDM populations were subjugated to further 
characterisation using cell biology techniques. Firstly, cell surface protein biomarker 
expression was evaluated using flow cytometry. Three markers were chosen: F4/80, 
a widely used murine marker of macrophage populations, CD11b that recognises the 
antigen ITGAM that is highly expressed by macrophages and CD11c, a marker that 
is used to differentiate macrophage and dendritic cell populations.158,350,351 
Interestingly, there were significant differences between L929 cultured BMDMs and 
the M-CSF and MIF conditions. 
 
Figure 6-8. Flow-cytometry analysis of the three BMDM populations. Percentage 
expression of cell surface markers F4/80, CD11b and CD11c measured by flow 
cytometry for the three BMDM populations. Error bars represent ± SD from the mean 
average of three biological replicates. n.s, *, **, *** represent non-significant, p<0.05, 
p<0.01 and p<0.001 respectively, student’s t-test.  
It was surprising to observe that L929 cells did not express F4/80 ubiquitously, as this 
suggests that they lack macrophage-like functions. However, it has been shown that 
F4/80 is not required for the development and distribution of murine tissue 
macrophages.352 CD11b was expressed by all detected cells in the three BMDM 
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conditions, which indicates a highly homogenous population of macrophages. 
However, measurement of CD11c showed that there was a four-fold higher 
expression on cells cultured with M-CSF with or without MIF. This in turn suggests 
that M-CSF induces a more dendritic like than BMDMs grown in L929 supernatant. 
As the proteomic data showed a difference in innate immune response and interferon 
phenotype, I sought to assess the differences in pro-inflammatory cytokine secretion 
with and without pro-inflammatory stimulation by LPS. Here, I measured the secretion 
of TNF-α, IL-6 and IFN-β. Without stimulation, all three populations displayed either 
non-detectable levels of the pro-inflammatory cytokines TNF-α and IL6 or non-
significant levels of the type one interferon IFN-β.  
 
Figure 6-9. ELISA quantification of secreted cytokines TNF-α, IL6 and IFN-β 
under basal conditions and treatment with 100 ng/mL of LPS. 
Upon treatment with 100 ng/mL of LPS for six hours BMDMs cultured with L929 
supplement presented a much stronger pro-inflammatory and interferon response 
over M-CSF ± MIF differentiated conditions, thus correlating with the total proteome 
data presented in Figures 6-6 & 6-7. Error bars represent ± SD from the mean average 
of three biological replicates. n.d, n.s, **, *** and **** represent not detected, non-
significant, p<0.01, p<0.001 and p<0.0001, respectively, student’s t-test. 
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Taken together, these data show that different BMDM phenotypes result from the 
differentiating agent used with respect to total proteome and biological function. 
Therefore, it is important to consider the biological ramifications that result from the 
different BMDM differentiation strategies and resultant in vitro biological outcome. 
6.4 Discussion 
6.4.1 The L929 secretome protein composition is highly diverse  
Bone marrow-derived macrophages are primary cells derived from the isolation of 
haemopoietic stem cells from mammalian femurs and tibia and differentiated in vitro. 
These macrophages are particularly important for the understanding of biological 
function and complex signalling cascades involved in the immune response as they 
provide the best models for in vitro experiments. Consequently, this had led to the 
development of high content screening assays against primary macrophages with the 
aim of reducing subsequent drug failures and generating more predictive in vivo 
results. This has been particularly successful in the development of anti-leishmanial 
drugs, where interaction with the entire parasite is necessary for effective ex vivo drug 
screening.353,354 This can sometimes be compromised with the use of immortalised 
cell lines that do not necessarily exhibit native macrophage behaviour.  
Initially, macrophage colony stimulating factor (M-CSF) was identified as the main 
driver of primary macrophage differentiation and was introduced in vitro as an active 
differentiation agent. However, in more recent years the supplementation of 
differentiation media with the secretion of L929 fibroblasts has become more 
favourable as it cheaper and relatively simple to produce in-house. L929 fibroblasts 
were isolated from connective tissue have been shown to produce and secrete large 
volumes of M-CSF. This may be physiologically relevant to the cell type, as fibroblasts 
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are a major component of connective tissue and play a critical role in wound healing 
and recruitment macrophages.355 Further to this, fibroblasts secrete cytokines and 
chemokines to modulate macrophage behaviour and the inflammatory response, 
therefore the production of M-CSF is necessary for the initial recruitment of 
macrophages to site of injury.356 However, the secretion of fibroblasts is much more 
complex than purely M-CSF, but this has never been truly characterised with respect 
to BMDM differentiation. Therefore, the primary aim of this study was to describe the 
protein composition of the L929 supernatant across the collection time period. Here, 
2198 proteins were robustly identified over the two week time course with different 
expression rates. Interestingly, the top 100 proteins ranked by iBAQ contributed 
towards more than 60% of the total protein content with M-CSF and MIF being highly 
expressed. With respect to cumulative protein intensity, both M-CSF and MIF exist in 
similar proportions within the L929 secretion. However, I observe MIF to be ranked 
higher than M-CSF with respect to the IBAQ ranking as MIF is approximately five 
times smaller in size than M-CSF. This therefore suggests that MIF is produced and 
secreted in greater amounts by L929 fibroblasts with respect to protein count. In 
addition to MIF, many other cytokines were also identified alongside stress proteins 
such as peroxiredoxin-1 and two chemokines Ccl7 and Ccl2. This may indicate that 
the L929 supernatant may induce a pro-inflammatory activation state during the 
differentiation on BMDMs. However, secretion of both IFN-γ and IFN-β were 
measured by ELISA for all four sampling conditions and neither of the two interferons 
were detectable, thus disputing previous studies that reports the production of type 1 
interferons by L929 fibroblasts during the supernatant collection period.330 As well as 
this, three members of the S100 protein family were identified and multifunctional low 
molecular weight calcium binding proteins.357 They are known to exist extracellularly 
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and modulate the immune response, however the two known members S100-8 and 
S100-9 that act as pro-inflammatory cytokines were not detected.358  
Looking at the secretome as a whole, it was possible to identify protein expression 
rates that appeared to be regulated by nutrients and cell cycle. Initiation of translation 
and cell-cell adhesion was most highly upregulated immediately after initial seeding 
at three days, which supports rapid proliferation into available surface area. 
Conversely, as cell number increases, there is a significant increase in secretion of 
glycolytic and metabolic proteins. Interestingly, there is an increase in catabolic 
processes at day 7 and 14, which suggests that anabolic metabolism is occurring 
versus aerobic, which is likely due to depletion of nutrients within the media. At day 
14, where cell confluency is at its highest, there is significant increase in protein 
folding, oxidative processes that are indicative of stress responses. This is important 
to note, as the secretion of stress proteins or induction of apoptosis due to confluency 
or lack of nutrients could impact the resultant BMDM phenotype. Therefore, it could 
be beneficial to collect L929 supernatant at earlier time points and test the potency in 
BMDM differentiation. 
Overall, more than 2000 proteins were identified in the L929 secretome as well as 
high levels of M-CSF, the driving component of haemopoietic stem cell differentiation 
into bone marrow-derived macrophages. Unexpectedly, in this data set macrophage 
inhibitory factor MIF was highly abundant has been indicated in regulation of 
macrophage function. The protein composition of the L929 secretome provides a 
valuable resource to the community as it is a comprehensive list of protein secretion 
rates across a two week time period. This list is particularly beneficial for those who 
perform in vitro differentiation of BMDMs with knock-out or point mutation mice, as 
the endogenous protein may re-introduced into the system. Consequently, this could 
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compromise studies that aim to understand particular protein functions. In these 
cases, it would be more advantageous to use M-CSF as a differentiating agent so as 
to prevent contamination.  
6.4.2 Culture conditions influence the resultant BMDM population phenotype 
Utilising cell biology techniques and total proteome analysis I was able to assess the 
phenotypic differences between the three BMDM populations. Isolated stem cells 
were incubated with three different differentiation media compositions: M-CSF and 
MIF, pure M-CSF and L929 supplemented media. Relative quantification of protein 
expression was enabled by using TMT labelling. Here, MS2 quantification allowed the 
robust quantification of 5607 proteins across the three biological replicates. There 
was no significant difference in total protein expression between BMDMs cultured with 
or without the presence of MIF, which was interesting as it has previously been 
described as a mediator of host defence. This implies that MIF cannot solely influence 
macrophage phenotype and is likely to act in tandem with other cytokines that are 
released during injury or infection to coordinate a pro-inflammatory response. The 
only protein that appeared to be up-regulated in response to MIF was Dcaf11 as 
shown in the fold changes in Figure 6-7. This is somewhat ambiguous, as Dcaf11, or 
DDB1, is poorly described in the literature but has been implicated as a substrate 
receptor for the CUL4-DDB1 E3 ligase complex that modifies proteins by addition of 
ubiquitin. One substrate of this complex is thought to be involved in the control of cell 
cycle progression359, however more exploration would be necessary to identify 
whether there is an interaction between MIF and DDB1. 
The total proteome of BMDMs differentiated under L929 supplementation had a 
clearly distinct phenotype compared with pure M-CSF or M-CSF with MIF. Here, there 
were 109 differential proteins that GO term enrichment classified as either involved in 
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cell cycle/mitosis or the innate immune response. These cells showed much higher 
expression of proteins involved in the interferon and immune response such as 
interferon induced proteins IFIT1, IFIT3, IFITM2, IFITM3 and ISG15. As well as this, 
L929 differentiated BMDMs show decreased protein expression of cell division and 
cell cycle proteins such as cyclin-A2, spindle and centromere proteins SPDLY and 
INCE compared to pure M-CSF differentiation. Consequently, this implies that using 
M-CSF and MIF for differentiation does not halt the progression of cell cycle, whereas 
factors in the L929 supplement may cause cell cycle arrest, perhaps through faster 
differentiation. Several cell division control proteins were identified in the L929 
secretome such as CARP-1 as well as multiple cyclin-dependent kinases (1, 2, 4 and 
6), but neither of these have been implicated in cell cycle arrest. Therefore, this 
implies that differentiation with L929 supplement generates a population of 
macrophages that are more mature than those differentiated purely with M-CSF. 
Following this, flow cytometry analysis of surface expressed markers correlated with 
proteomic data. Here, marker CD11c was highly enriched on macrophages 
differentiated with either M-CSF or MIF over L929 supernatant. This indicates that 
these macrophages are more dendritic-like, which may in turn justify why these 
BMDMs are less mature. Due to its close relationship with GM-CSF, the dendritic cell 
differentiating agent, it is unsurprising that these cells are more dendritic like, however 
inclusion of MIF does not reduce the expression of CD11c, thus it is unlikely to play 
an important role in the differentiation process. However, it was surprising to observe 
that the murine macrophage marker F4/80 was less expressed on the surface of 
macrophages differentiated with L929 supernatant over pure M-CSF/MIF. This 
implies that these cells are less macrophage-like, however previous data has 
suggested that F4/80 is not necessarily important for development of murine tissue 
macrophages.352 Therefore, it would be important in further studies to evaluate 
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macrophage functions such as phagocytosis and both the M1 and M2 phenotype to 
fully characterise L929 differentiated BMDM phenotypes. 
To assess the pro-inflammatory response of the three BMDM populations the 
secretion of pro-inflammatory cytokines was measured after stimulation with LPS. It 
was necessary to use LPS over IFN-γ stimulation so as to prevent bias with the 
interferon response as it was previously indicated that BMDMs under L929 culture 
may be interferon stimulated.330 Three cytokines were measured in response to LPS: 
TNF-α, IL-6 and IFN-β, which cover the classical NF-κB pro-inflammatory and type 
one interferon response. At basal levels, with no treatment, there were undetectable 
levels of TNF-α and IL6, thus implying that all BMDM populations are not pro-
inflammatory stimulated throughout the differentiation. There were detectable, but 
very low levels of IFN-β secretion under basal conditions. However, these were not 
significant between the three populations. This in turn shows that despite the variety 
of proteins present in the L929 supernatant, including MIF, they do not induce a pro-
inflammatory activation state in BMDMs. Upon stimulation, BMDMs that were 
differentiated by L929 supplemented media showed significantly increased pro-
inflammatory response across the three cytokines. This was particularly pronounced 
with IFN-β, where levels were elevated five-fold in response to LPS. These data 
correlate with the previously described proteomic data where GO enrichment showed 
an enhanced innate immune response and response to type one interferons (Figure 
6-6.B).  
Inclusion of MIF as a differentiation agent resulted in a negligible difference in cellular 
phenotype with respect to total proteome, cytokine secretion and protein marker 
expression. Overall, the combined cellular biology and proteomic data shows that 
differentiation with L929 supplemented media generates a population of cells that are 
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more macrophage-like than M-CSF or MIF alone. From a biological perspective this 
makes sense, as in vivo induction of macrophage differentiation would likely be 
initiated by cellular secretion of multiple factors in response to injury or pathogenic 
infection. Fibroblasts play a significant role in the recruitment of macrophages and 
their migration towards the site of infection. Therefore, differentiation under L929 
fibroblast supernatant supplementation results in a macrophage population that is 
more relevant in vitro. Taken together, it is possible to conclude that M-CSF is a 
driving component of BMDM differentiation, but other factors secreted by L929 
fibroblasts influences the resulting cellular phenotype. Further exploration of these 
factors would be necessary to understand the subtleties in BMDM differentiation and 




Chapter 7. Perspective  
Within this thesis I have explored how mass spectrometry techniques can be utilised 
to enhance the drug discovery process as well as develop better models of innate 
immunity for compound screening purposes. Here, my efforts have focussed on 
applying MALDI-TOF-MS as a screening tool for inhibitors of inflammation that can 
compete with current existing assays. This work demonstrated the potential of a 
MALDI-TOF-MS kinase peptide based assay for SIKs that avoids the use of a stable 
isotopically labelled (SIL) internal standard for compound screening. For the first time, 
we compared the developed MALDI-TOF-MS peptide based assay with an 
established fluorescent biochemical assay by performing an ATP mimetic compound 
screen. From this, we demonstrated a good correlation of hit compounds between 
both assay types, and also identified a subset of unique hits with the MALDI-TOF-
MS assay. Furthermore, it was surprising yet promising to observe that the larger 
dynamic range of the MALDI-TOF-MS assay allowed activating compounds to be 
identified. The potential of a MALDI-TOF-MS assay to identify both activators and 
inhibitors within a single screen could be particularly interesting for future assay 
development. In addition, an assay that can ascertain whether a compound acts as 
an activator rather than a negative hit could help broaden the understanding of a 
particular chemotype as well as target engagement.  
However, despite the advantages highlighted within this thesis, MALDI-TOF-MS for 
drug discovery does lack some of the benefits of traditional biochemical assays. For 
example, it would be difficult to fully resolve most full-length proteins and their post 
translationally modified product by MALDI-TOF-MS. Therefore, assays would 
realistically rely on truncated substrates, such as peptides, so that the shift in 
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molecular weight could be resolved and measured accurately. This may in turn not 
truly reflect the activity of an enzyme with its substrate in vivo. Further to this, it has 
been discussed in this thesis, as well as by Chandler et al.,83 that MALDI-TOF-MS 
assays are intolerant to certain buffer conditions such as detergent, high salt 
concentrations and glycerol, all of which can help maintain protein conformation and 
activity. Finally, it was originally hypothesised that relative quantitation between the 
measured substrate and product rather than using a SIL would enable faster and 
cheaper development of assays for screening purposes. However, this work has 
highlighted that perhaps this may not be the most suitable approach for future assays. 
Characterising some enzyme kinetics, such as KM, that were dependent on substrate 
concentration became challenging with the relative substrate to product ratio method. 
In the presence of excess substrate, the quantitation of enzyme activity from product 
formation relative to the unmodified substrate was no longer representative of 
enzyme turnover, thus a narrower concentration window must be used. In addition, it 
was also observed that it was more challenging to achieve a good Z’ value with this 
approach as the dynamic range between positive and negative controls was narrow. 
The use of an internal standard such as a SIL product derivative to quantitate enzyme 
activity would avoid both these problems. Therefore, it is unsurprising to observe that 
in the past decade this approach has been favoured by industrial companies, despite 
the extra cost. Taken together, this thesis work presents a positive and promising 
perspective of MALDI-TOF-MS as a readout for future enzymatic HTS assays, but 
also outlines some of its limitations that may reduce its applicability to certain targets 
or assay types.  
Cellular assays often provide better in vitro models for drug discovery; thus, I 
explored the potential of MALDI-TOF-MS as a readout for cell based assays. This 
approach was inherently more difficult than an enzymatic product monitoring reaction 
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as the MS spectra is more complex and the biomolecules were typically unknown. 
Current literature surrounding this phenotyping approach varied significantly in their 
methodologies, therefore I performed rigorous method development to a 
fingerprinting approach of proteins in mammalian cells. Here, I demonstrated the 
compatibility of the optimised sample preparation method with MALDI-TOF-MS, as 
well as current automated liquid handling robotics. This protein fingerprinting 
approach was sensitive for phenotyping transient changes within mESC 
differentiation as well as compliant with robust and independent statistical analysis. 
This approach was then applied to an inflammatory model with the aim to develop a 
MALDI-TOF-MS cellular assay for identifying inhibitors of inflammation. Initial work 
identified a unique spectral phenotypes, or fingerprints, that corresponded to pro-
inflammatory and resting monocytes. It was promising to observe the biological 
specificity that could be achieved with this approach as the pro-inflammatory spectral 
phenotype was induced specifically in response to bacterial ligands. It was also 
possible distinguish between IFN and NF-κB pro-inflammatory signalling inhibitors. A 
proof of concept screen revealed nilotinib as a hit compound with anti-inflammatory 
properties that was then validated by cellular biology and proteomic approaches. This 
study was promising and demonstrates the power of MALDI-TOF-MS to identify novel 
effects of compounds, which may in turn have the potential for drug repurposing.  
However, this protein fingerprinting approach was not without limits. For the THP-1 
assay, it wasn’t possible to identify the differential features that influenced the pro-
inflammatory phenotype, thus no target could be derived from this work. In addition, 
the poorer resolution of linear MALDI-TOF-MS resulted in protein features that drifted 
in m/z value due to base peak width. This variability increased with larger molecular 
weight biomolecules and may prove problematic for downstream analysis and 
confident peak assignment. Spectral alignment tools in combination with an internal 
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standard for normalisation could be useful to address this problem in future work. An 
interesting take on this work could be to focus on analysing different biomolecules 
such as metabolites, lipids and oligonucleotides directly from cells by MALDI-TOF-
MS. These molecules tend to occupy the lower mass region; thus, it would be more 
favourable to use a reflectron mode where it is possible to perform MS/MS analysis 
and identify the differential features. There could also be potential to generate 
multiplexed assays, where multiple readouts could be monitored by utilising the 
properties of different matrices to identify different biomolecules from the same 
population or treatment.  
In conclusion, the work in this thesis demonstrates the power of MALDI-TOF-MS as 
a future drug discovery screening tool. This technique is particularly applicable to the 
enzymatic assay screening field, where applications of MALDI-TOF-MS technology 
have grown year on year. A promising application that has arisen from this body of 
work could be MALDI-TOF-MS cell-based drug discovery assays. A cells phenotypic 
response or a particular biomolecule of interest could be rapidly screened in response 
to a treatment. This combined with the potential to identify multiple biomolecules and 
readouts from single assay could allow better drug characterisation at an early stage 
of the drug discovery process. When combined with complimentary mass 
spectrometry approaches, MALDI-TOF-MS phenotypic screening of a compounds 
effect in cell could reveal novel drug interactions as well as accelerate the lead 
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